

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number  
WO 01/60992 A2

- (51) International Patent Classification<sup>7</sup>: C12N 9/14, C07K 16/40, G01N 33/50, C12Q 1/42, C12N 5/10, 15/55, C12Q 1/68
- (21) International Application Number: PCT/US01/04432
- (22) International Filing Date: 12 February 2001 (12.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/182,194 14 February 2000 (14.02.2000) US  
09/685,853 11 October 2000 (11.10.2000) US
- (71) Applicant: PE CORPORATION (NY) [US/US]; Millman, Robert, A., 761 Main Avenue, Norwalk, CT 06859 (US).
- (72) Inventors: WEI, Ming-Hui; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). KETCHUM, Karen, A.; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). BEASLEY, Ellen, M.; Celera, 45 West Gude Drive, Rockville, MD 20850 (US).
- (74) Agent: MILLMAN, Robert, A.; Celera Genomics Corp., 45 West Gude Drive C2-4, Rockville, MD 20850 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: ISOLATED HUMAN PHOSPHATASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS, AND USES THEREOF

1 MEDVLEFFPS LPOCKEDAEZ WTYPWRAHQ ELPLGLGP TSSMGEKLP  
51 VLQKNGITHI ICINQNTIEM FIKPWQOLF RYLVLEJAN PVETIIRFP  
101 MYKEFIDGSL QMGCKVLVNG WAGISRSAAV VIAYIMETFG KYRDATATV  
151 QKATCINFM AGFVHOLGEI EATYLAETI QMSPLQER SLVSSGTTG  
201 SLATREED DFTGHWATA QMG

## FEATURES:

Functional domains and key regions:

(1) P00C30005 P500005 PKC\_PHOSPHO\_SITE  
Protein kinase C phosphorylation site  
201-203 SLK

(2) P00C00005 P500004 CK2\_PHOSPHO\_SITE  
Casein kinase II phosphorylation site  
205-208 THEE

(3) P00C00007 P500007 TYR\_PHOSPHO\_SITE  
Tyrosine kinase phosphorylation site  
Number of matches: 2 1 15-23 KEDAKETI 2 142-149 KYRDATATV

(4) P00C00008 P500008 MYRISTYL  
N-myristoylation site  
Number of matches: 2 1 123-128 GISRSA 2 197-202 GTTGSL

## Membrane spanning structure and domains:

Helix	Begin	End	Score	Certainty
1	123	143	0.626	Predictive

## BLAST Alignment to Top Hit:

gq12137696 ipat11149365 protein tyrosine phosphatase - mouse  
gq11063426 igb1AA87037.11 (U34973) protein tyrosine  
phosphatase-like [Mus musculus]  
Length = 223

Score = 444 bits (1131), Expect = e-124  
Identities = 214/223 (95%), Positives = 221/223 (98%)

Query: 1 MEDVLEFFPS LPOCKEDAEZ WTYPWRAHQ ELPLGLGP TSSMGEKLP VLQKNGITHI 60  
MEDVLEFFPS LPOCKEDAEZ WTYPWRAHQ ELPLGLGP TSSMGEKLP VLQKNGITHI 60  
Subject: 1 MEDVLEFFPS LPOCKEDAEZ WTYPWRAHQ ELPLGLGP TSSMGEKLP VLQKNGITHI 60

Query: 61 ICINQNTIEM FIKPWQOLF RYLVLEJAN PVETIIRFP MYKEFIDGSL QMGCKVLVNG 120  
ICINQNTIEM FIKPWQOLF RYLVLEJAN PVETIIRFP MYKEFIDGSL QMGCKVLVNG 120  
Subject: 61 ICINQNTIEM FIKPWQOLF RYLVLEJAN PVETIIRFP MYKEFIDGSL QMGCKVLVNG 120

Query: 121 WAGISRSAAV VIAYIMETFG KYRDATATV QKATCINFM AGFVHOLGEI EATYLAETI 180  
WAGISRSAAV VIAYIMETFG KYRDATATV QKATCINFM AGFVHOLGEI EATYLAETI 180  
Subject: 121 WAGISRSAAV VIAYIMETFG KYRDATATV QKATCINFM AGFVHOLGEI EATYLAETI 180

Query: 181 QMSPLQER SLVSSGTTG SLATREED DFTGHWATA QMG 223  
QMSPLQER SLVSSGTTG SLATREED DFTGHWATA QMG 223  
Subject: 181 QMSPLQER SLVSSGTTG SLATREED DFTGHWATA QMG 223

## Rover search results (Pfam):

Scores for sequence family classification (score includes all domains):

Model	Description	Score	E-value	N
PF00782	Dual specificity phosphatase, catalytic doma	221.5	1.2e-62	1

(57) Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the phosphatase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogues of the phosphatase peptides, and methods of identifying modulators of the phosphatase peptides.



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

## ISOLATED HUMAN PHOSPHATASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS, AND USES THEREOF

### RELATED APPLICATIONS

- 5       The present application claims priority to provisional application U.S. Serial No. 60/182,194, filed February 14, 2000 (Atty. Docket CL000259-PROV) and U.S. Serial No. 09/685,853, filed October 11, 2000 (Atty. Docket CL000871).

### FIELD OF THE INVENTION

- 10       The present invention is in the field of phosphatase proteins that are related to the protein tyrosine phosphatase subfamily, recombinant DNA molecules and protein production. The present invention specifically provides novel protein tyrosine phosphatase peptides and proteins and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and  
15       methods.

### BACKGROUND OF THE INVENTION

- Phosphatase proteins, especially the member of protein tyrosine phosphatase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of  
20       pharmaceutical development to identify and characterize previously unknown members protein tyrosine phosphatase subfamily. The present invention advances the state of the art by providing a previously unidentified human phosphatase proteins that have homology to members of the protein tyrosine phosphatase subfamily.

#### Protein Phosphatase

- 25       Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. The biochemical pathways through which signals are transmitted within cells comprise a circuitry of directly or functionally connected interactive proteins. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of certain residues on proteins.  
30       The phosphorylation state of a protein may affect its conformation and/or enzymic activity as

well as its cellular location. The phosphorylation state of a protein is modified through the reciprocal actions of protein kinases (PKs) and protein phosphatases (PPs) at various specific amino acid residues.

Protein phosphorylation is the ubiquitous strategy used to control the activities of eukaryotic cells. It is estimated that 10% of the proteins active in a typical mammalian cell are phosphorylated. The high-energy phosphate that confers activation and is transferred from adenosine triphosphate molecules to protein-by-protein phosphatases is subsequently removed from the protein-by-protein phosphatases. In this way, the phosphatases control most cellular signaling events that regulate cell growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis.

The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic cells to control cellular activities. It is estimated that more than 10% of the active proteins in a typical mammalian cell are phosphorylated. During protein phosphorylation/dephosphorylation, phosphate groups are transferred from adenosine triphosphate molecules to protein-by-protein phosphatases and are removed from the protein-by-protein phosphatases.

Protein phosphatases function in cellular signaling events that regulate cell growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis. Three protein phosphatase families have been identified as evolutionarily distinct. These include the serine/threonine phosphatases, the protein tyrosine phosphatases, and the acid/alkaline phosphatases (Carboneau H. and Tonks N. K. (1992) *Annu. Rev. Cell Biol.* 8:463-93).

The serine/threonine phosphatases are either cytosolic or associated with a receptor. On the basis of their sensitivity to two thermostable proteins, inhibitors 1 and 2, and their divalent cation requirements, the serine/threonine phosphatases can be separated into four distinct groups, PP-I, PP-IIA, PP-IIB, and PP-IIC.

PP-I dephosphorylates many of the proteins phosphorylated by cyclic AMP-dependent protein phosphatase and is therefore an important regulator of many cyclic AMP mediated, hormone responses in cells. PP-IIA has broad specificity for control of cell cycle, growth and proliferation, and DNA replication and is the main phosphatase responsible for reversing the phosphorylations of serine/threonine phosphatases. PP-IIB, or calcineurin (Cn), is a  $\text{Ca}^{2+}$ -activated phosphatase; it is involved in the regulation of such diverse cellular functions as ion channel regulation, neuronal transmission, gene transcription, muscle glycogen metabolism, and lymphocyte activation.



PP-IIC is a Mg.sup.++ -dependent phosphatase which participates in a wide variety of functions including regulating cyclic AMP-activated protein-phosphatase activity, Ca.sup.++-dependent signal transduction, tRNA splicing, and signal transmission related to heat shock responses. PP-IIC is a monomeric protein with a molecular mass of about 40-45 kDa. One .alpha. and several .beta. isoforms of PP-IIC have been identified (Wenk, J. et al. (1992) 5 FEBS Lett. 297: 135-138; Terasawa, T. et al. (1993) Arch. Biochem. Biophys. 307: 342-349; and Kato, S. et al. (1995) Arch. Biochem. Biophys. 318: 387-393).

The levels of protein phosphorylation required for normal cell growth and differentiation at any time are achieved through the coordinated action of PKs and PPS. 10 Depending on the cellular context, these two types of enzymes may either antagonize or cooperate with each other during signal transduction. An imbalance between these enzymes may impair normal cell functions leading to metabolic disorders and cellular transformation.

For example, insulin binding to the insulin receptor, which is a PTK, triggers a variety of metabolic and growth promoting effects such as glucose transport, biosynthesis of 15 glycogen and fats, DNA synthesis, cell division and differentiation. Diabetes mellitus, which is characterized by insufficient or a lack of insulin signal transduction, can be caused by any abnormality at any step along the insulin signaling pathway. (Olefsky, 1988, in "Cecil Textbook of Medicine," 18th Ed., 2:1360-81).

It is also well known, for example, that the overexpression of PTKs, such as HER2, 20 can play a decisive role in the development of cancer (Slamon et al., 1987, Science 235:77-82) and that antibodies capable of blocking the activity of this enzyme can abrogate tumor growth (Drebin et al., 1988, Oncogene 2:387-394). Blocking the signal transduction capability of tyrosine phosphatases such as Flk-1 and the PDGF receptor have been shown to block tumor growth in animal models (Millauer et al., 1994, Nature 367:577; Ueno et al., 25 Science, 252:844-848).

Relatively less is known with respect to the direct role of phosphatases in signal transduction; PPs may play a role in human diseases. For example, ectopic expression of RPTP.alpha. produces a transformed phenotype in embryonic fibroblasts (Zheng et al., Nature 359:336-339), and overexpression of RPTP.alpha. in embryonal carcinoma cells 30 causes the cells to differentiate into a cell type with neuronal phenotype (den Hertog et al., EMBO J 12:3789-3798). The gene for human RPTP.gamma. has been localized to chromosome 3p21 which is a segment frequently altered in renal and small lung carcinoma. Mutations may occur in the extracellular segment of RPTP.gamma. which renders a RPTP that no longer respond to external signals (LaForgia et al., Wary et al., 1993, Cancer Res

52:478-482). Mutations in the gene encoding PTP1C (also known as HCP, SHP) are the cause of the moth-eaten phenotype in mice that suffer severe immunodeficiency, and systemic autoimmune disease accompanied by hyperproliferation of macrophages (Schultz et al., 1993, *Cell* 73:1445-1454). PTP1D (also known as Syp or PTP2C) has been shown to bind  
5 through SH2 domains to sites of phosphorylation in PDGFR, EGFR and insulin receptor substrate 1 (IRS-1). Reducing the activity of PTP1D by microinjection of anti-PTP1D antibody has been shown to block insulin or EGF-induced mitogenesis (Xiao et al., 1994, *J Biol Chem* 269:21244-21248).

The discovery of a new human protein phosphatase and the polynucleotides encoding  
10 it satisfies a need in the art by providing new compositions that are useful in the diagnosis, prevention and treatment of biological processes associated with abnormal or unwanted protein phosphorylation.

The phosphatase gene of the present invention can be expressed in yeast to identify possible interactors and substrates; this can be done by means of a complementation assay or  
15 a two-hybrid experiment. Artificially synthesized enzyme as well as derived peptides can be used to activate or inhibit cellular processes modulated by this phosphatase. Immunoassay or PCR may be used to measure the concentration of this protein and detect abnormally developing tissue or cancerous growth.

For a review of the phosphatase associated with the present invention see Wishart *et al.*, *J Biol Chem* 1995 Nov 10;270(45):26782-5, Bjorge *et al.*, *J Biol Chem* 2000 Sep 27;  
20 Harroch *et al.*, *Mol Cell Biol* 2000 Oct;20(20):7706-15, Beghini *et al.*, *Hum Mol Genet* 2000 Sep 22;9(15):2297-2304, Waddleton *et al.*, *Anal Biochem* 2000 Oct 1;285(1):58-63.

## SUMMARY OF THE INVENTION

25 The present invention is based in part on the identification of amino acid sequences of human phosphatase peptides and proteins that are related to the protein tyrosine phosphatase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of  
30 therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate phosphatase activity in cells and tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as

well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

## DESCRIPTION OF THE FIGURE SHEETS

5       FIGURE 1 provides the nucleotide sequence of a cDNA molecule or transcript sequence that encodes the phosphatase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates  
10       expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

      FIGURE 2 provides the predicted amino acid sequence of the phosphatase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as  
15       protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

      FIGURE 3 provides genomic sequences that span the gene encoding the phosphatase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where  
20       available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in Figure 3, known SNP variations include G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G, C39269G, -20999T, -4004A, and G20988-.

25

## DETAILED DESCRIPTION OF THE INVENTION

### General Description

      The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information  
30       revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a phosphatase protein or part of a phosphatase protein

and are related to the protein tyrosine phosphatase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human phosphatase peptides and proteins that are related to the protein tyrosine phosphatase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these phosphatase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the phosphatase of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known phosphatase proteins of the protein tyrosine phosphatase subfamily and the expression pattern observed. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known phosphatase family or subfamily of phosphatase proteins.

## Specific Embodiments

### Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the phosphatase family of proteins and are related to the protein tyrosine phosphatase subfamily (protein sequences are provided in Figure 2, transcript/cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the

information in Figure 3, will be referred herein as the phosphatase peptides of the present invention, phosphatase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the phosphatase peptides disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1,  
5 transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially  
10 free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

15 In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein  
20 preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the phosphatase peptide having  
25 less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated phosphatase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using  
30 known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. For example, a nucleic acid molecule encoding the phosphatase peptide is cloned into an expression vector, the

In some uses, the fusion protein does not affect the activity of the phosphatase peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant phosphatase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.

Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A phosphatase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the phosphatase peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the phosphatase peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for

optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M.; and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (*CABIOS*, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the

NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST  
5 program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

10 Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the phosphatase peptides of the present invention as well as being encoded by the same genetic locus as the phosphatase peptide provided herein. As indicated by the data presented in Figure 3, the map position was determined to be on  
15 chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

Allelic variants of a phosphatase peptide can readily be identified as being a human  
20 protein having a high degree (significant) of sequence homology/identity to at least a portion of the phosphatase peptide as well as being encoded by the same genetic locus as the phosphatase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. As indicated by the data presented in Figure 3, the map position was determined to be on  
25 chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and  
30 more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a phosphatase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.



Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Paralogs of a phosphatase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the phosphatase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a phosphatase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a phosphatase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the phosphatase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a phosphatase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the phosphatase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the phosphatase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a phosphatase peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which

amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant phosphatase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to dephosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as phosphatase activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the phosphatase peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a phosphatase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the phosphatase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the phosphatase peptide, e.g., active site, a transmembrane domain or a

substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The

5 results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art.

10 Common modifications that occur naturally in phosphatase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

30 Accordingly, the phosphatase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature phosphatase peptide is fused with another compound, such as a compound to increase the half-life of the phosphatase

peptide, or in which the additional amino acids are fused to the mature phosphatase peptide, such as a leader or secretory sequence or a sequence for purification of the mature phosphatase peptide or a pro-protein sequence.

5        Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological  
10 fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a phosphatase-effector protein interaction or phosphatase-ligand interaction), the protein can be used to identify the binding partner/ligand  
15 so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual",  
20 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, phosphatases  
25 isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the phosphatase. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a  
30 virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid. A large percentage of

pharmaceutical agents are being developed that modulate the activity of phosphatase proteins, particularly members of the protein tyrosine phosphatase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1.

Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to phosphatases that are related to members of the protein tyrosine phosphatase subfamily. Such assays involve any of the known phosphatase functions or activities or properties useful for diagnosis and treatment of phosphatase-related conditions that are specific for the subfamily of protein tyrosine phosphatases that the one of the present invention belongs to, particularly in cells and tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the phosphatase, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the phosphatase protein.

The polypeptides can be used to identify compounds that modulate phosphatase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the phosphatase. Both the phosphatases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds

for the ability to bind to the phosphatase. These compounds can be further screened against a functional phosphatase to determine the effect of the compound on the phosphatase activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate

5 (antagonist) the phosphatase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the phosphatase protein and a molecule that normally interacts with the phosphatase protein, e.g. a substrate or a component of the signal pathway that the phosphatase protein normally interacts (for example, another phosphatase).

10 Such assays typically include the steps of combining the phosphatase protein with a candidate compound under conditions that allow the phosphatase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the phosphatase protein and the target, such as any of the associated effects of signal transduction such as protein  
15 phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2)  
20 phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')<sub>2</sub>, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural  
25 product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant phosphatases or appropriate fragments containing mutations that affect phosphatase function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a  
30 fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) phosphatase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate phosphatase activity. Thus, the dephosphorylation of a substrate, activation of a protein, a change in the expression of genes that

are up- or down-regulated in response to the phosphatase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the phosphatase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the phosphatase can be assayed.

Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

Binding and/or activating compounds can also be screened by using chimeric phosphatase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized by the native phosphatase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the phosphatase is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the phosphatase (e.g. binding partners and/or ligands). Thus, a compound is exposed to a phosphatase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble phosphatase polypeptide is also added to the mixture. If the test compound interacts with the soluble phosphatase polypeptide, it decreases the amount of complex formed or activity from the phosphatase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the phosphatase. Thus, the soluble polypeptide that competes with the target phosphatase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the phosphatase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

- 5           Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., <sup>35</sup>S-labeled)
- 10          and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of phosphatase-
- 15          binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein
- 20          trapped in the wells by antibody conjugation. Preparations of a phosphatase-binding protein and a candidate compound are incubated in the phosphatase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the phosphatase protein target
- 25          molecule, or which are reactive with phosphatase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

- Agents that modulate one of the phosphatases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use
- 30          a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

          Modulators of phosphatase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating



cells or tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. These methods of treatment include the steps of administering a modulator of phosphatase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the phosphatase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the phosphatase and are involved in phosphatase activity. Such phosphatase-binding proteins are also likely to be involved in the propagation of signals by the phosphatase proteins or phosphatase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such phosphatase-binding proteins are likely to be phosphatase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a phosphatase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a phosphatase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the phosphatase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent

identified as described herein (e.g., a phosphatase-modulating agent, an antisense phosphatase nucleic acid molecule, a phosphatase-specific antibody, or a phosphatase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described  
5 herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The phosphatase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the  
10 invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The method  
15 involves contacting a biological sample with a compound capable of interacting with the phosphatase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from  
20 a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for  
25 the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered phosphatase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino  
30 acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

*In vitro* techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a

detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound.

Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the phosphatase protein in which one or more of the phosphatase functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and phosphatase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human

brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Accordingly, methods for treatment include the use of the phosphatase protein or fragments.

### Antibodies

5       The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially  
10 homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an  
15 antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')<sub>2</sub>, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press,  
20 (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of  
25 sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the phosphatase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity  
30 and/or phosphatase/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

#### Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal

expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the phosphatase peptide to a binding partner such as a substrate. These uses can also

be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

#### Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a phosphatase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the phosphatase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by

recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated.

5 Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

10 Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

15 The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in  
20 the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the  
25 nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief  
30 description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain



genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the phosphatase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the phosphatase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis

techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

5       The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be  
10 identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers.

15 Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or  
20 oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence  
25 encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by  
30 genetic locus of the encoding gene. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

#### Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As illustrated in Figure 3, known SNP variations include G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G, C39269G, -20999T, -4004A, and G20988-.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such  
5 vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically  
10 introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. As indicated  
15 by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

The nucleic acid molecules are also useful in making vectors containing the gene  
20 regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

25 The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the  
30 presence, level, form and distribution of nucleic acid expression. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain,

human brain, human heart, human liver, human lung, human placenta, and human thyroid.

Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides  
5 described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in phosphatase protein expression relative to normal results.

*In vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.  
10

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a phosphatase protein, such as by measuring a level of a phosphatase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a phosphatase gene has been mutated. Experimental data as provided in Figure 1 indicates that  
15 phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

20 Nucleic acid expression assays are useful for drug screening to identify compounds that modulate phosphatase nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the phosphatase gene, particularly biological and pathological processes that are mediated by the phosphatase in cells and tissues  
25 that express it. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The method typically includes assaying the ability of the compound to modulate the expression of the phosphatase nucleic acid and thus  
30 identifying a compound that can be used to treat a disorder characterized by undesired phosphatase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the phosphatase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for phosphatase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the phosphatase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these  
5 genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of phosphatase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of phosphatase mRNA in the presence of the candidate compound is compared to the level of expression of phosphatase mRNA in the absence of the candidate  
10 compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is  
15 statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate phosphatase nucleic acid expression in cells and tissues that express the phosphatase.  
20 Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung,  
25 human placenta, and human thyroid. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for phosphatase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the phosphatase nucleic acid expression in the cells and tissues that  
30 express the protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the phosphatase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in phosphatase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in phosphatase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the phosphatase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the phosphatase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a phosphatase protein.

Individuals carrying mutations in the phosphatase gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention

encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a phosphatase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant phosphatase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*,



*Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the phosphatase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control phosphatase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of phosphatase protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into phosphatase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of phosphatase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired phosphatase nucleic acid expression. This

technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the phosphatase protein, such as substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in phosphatase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired phosphatase protein to treat the individual.

The invention also encompasses kits for detecting the presence of a phosphatase nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting phosphatase nucleic acid in a biological sample; means for determining the amount of phosphatase nucleic acid in the sample; and means for comparing the amount of phosphatase nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect phosphatase protein mRNA or DNA.

#### Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. *et al.* (1996; Proc. Natl. Acad. Sci.

93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique,  
5 single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or  
10 detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or  
15 detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization.  
20 In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-  
25 directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated  
30 herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and

machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the phosphatase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the phosphatase gene of the present invention. Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and

the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to*  
5 *Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

10 The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system  
15 utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of  
20 the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips  
25 of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which  
30 contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified phosphatase gene of the present invention can be routinely identified using the sequence

information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

#### Vectors/host cells

5       The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double  
10       stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

      A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid  
15       molecules when the host cell replicates.

      The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

      Expression vectors contain cis-acting regulatory regions that are operably linked in the  
20       vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting  
25       factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

      The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not  
30       limited to, the left promoter from bacteriophage  $\lambda$ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

5 In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in  
10 expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived  
15 from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids.  
20 Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by  
25 temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an  
30 expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells

include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein.

- 5 Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety.
- 10 Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterophosphatase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors
- 15 include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

- Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*
- 20 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

- The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include
- 25 pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

- The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in
- 30 cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian



expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral

vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as phosphatases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with phosphatases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

#### Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a phosphatase protein or peptide that can be further

purified to produce desired amounts of phosphatase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the phosphatase protein or phosphatase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native phosphatase protein is useful for assaying compounds that stimulate or inhibit phosphatase protein function.

Host cells are also useful for identifying phosphatase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant phosphatase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native phosphatase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a phosphatase protein and identifying and evaluating modulators of phosphatase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the phosphatase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the phosphatase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for

production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further  
5 be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a  
10 system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al. PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al. Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase  
15 and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al. Nature* 385:810-813 (1997) and PCT  
20 International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G<sub>0</sub> phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then  
25 transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect substrate binding,  
30 kinase protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* phosphatase protein function, including substrate interaction, the effect of specific mutant phosphatase proteins on phosphatase protein function and substrate interaction, and the effect of

chimeric phosphatase proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more phosphatase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

### Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
  - (a) an amino acid sequence shown in SEQ ID NO:2;
  - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
  - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
  - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
  - (a) an amino acid sequence shown in SEQ ID NO:2;
  - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
  - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
  - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.



16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.

17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human phosphatase protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human phosphatase peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human phosphatase peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

1/32

```

1  ATGGAGGACG TGAAGCTGGA GTTCCCTTCC CTTCCACAGT GCAAGGAAGA
51  CGCCGAGGAG TGGACCTACC CTATGAGACG AGAGATGCAG GAAATTTTAC
101 CTGGATTGTT CTTAGGCCCA TATTCATCTG CTATGAAAAG CAAGCTACCT
151 GTACTACAGA AACATGGAAT AACCCATATA ATATGCATAC GACAAAATAT
201 TGAAGCAAAAC TTTATTAAAC CAAACTTTCA GCAGTTATTT AGATATTTAG
251 TCCTGGATAT TGCAGATAAT CCAGTTGAAA ATATAATACG TTTTTCCTT
301 ATGACTAAGG AATTATTGTA TGGGAGCTTA CAAATGGGAG GAAAAGTTCT
351 TGTGCATGGA AATGCAGGGA TCTCCAGAAG TGCAGCCTTT GTTATTGCAT
401 ACATTATGGA AACATTTGGA ATGAAGTACA GAGATGCTTT TGCTTATGTT
451 CAAGAAAGAA GATTTGTAT TAATCCTAAT GCTGGATTG TCCATCAACT
501 TCAGGAATAT GAAGCCATCT ACCTAGCAAA ATTAACAATA CAGATGATGT
551 CACCACTCCA GATAGAAAGG TCATTATCTG TTCATTCTGG TACCACAGGC
601 AGTTTGAAGA GAACACATGA AGAAGAGGAT GATTTTGGA CCATGCAAGT
651 GCGGACTGCA CAGAATGGCT GA

```

**FEATURES:**

Start codon: 1

Stop codon: 670

**cDNA Sequence:**

```

1  AACACCACGC GTCCGGCAGC GGCATGGCGG CCGGGTGTA GACGCCCAGC
51  CCTCCTCTTC CCTGTCTTCG CCGCCGCCGC TGCTGGAGTC ACTGGGACCC
101 TGTAAGTCTGC GTGTGTTAGT TGTAATCCCG CCGCCCTCCT GTCAGCCCTC
151 CGCTCCGCCG GCCCTCCTTC CTTCCGCCGC CGCAGCCAGC CCGAGGGTCG
201 GCCGGCTGTG TAACACTCTC CCACCCACCC CACCAGCCCG CGGGCCAGCA
251 CCATGGAGGA CGTGAAGCTG GAGTTCCTT CCCTTCCACA GTGCAAGGAA
301 GACGCCGAGG AGTGGACCTA CCCTATGAGA CGAGAGATGC AGGAAATTTT
351 ACCTGGATTG TTCTTAGGCC CATATTCATC TGCTATGAAA AGCAAGCTAC
401 CTGTACTACA GAAACATGGA ATAACCCATA TAATATGCAT ACGACAAAAT
451 ATTGAAGCAA ACTTTATTAA ACCAACTTT CAGCAGTTAT TTAGATATTT
501 AGTCCTGGAT ATTGCAGATA ATCCAGTTGA AAATATAATA CGTTTTTTCC
551 CTATGACTAA GGAATTTATG GATGGGAGCT TACAAATGGG AGGAAAAGTT
601 CTTGTGCATG GAAATGCAGG GATCTCCAGA AGTGCAGCCT TTGTTATTGC
651 ATACATTATG GAAACATTG GAATGAAGTA CAGAGATGCT TTTGCTTATG
701 TTCAAGAAAG AAGATTTTGT ATTAATCCTA ATGCTGGATT TGTCCATCAA
751 CTTCAGGAAT ATGAAGCCAT CTACCTAGCA AAATTAACAA TACAGATGAT
801 GTCACCACTC CAGATAGAAA GGTCAATTATC TGTTCAATCT GGTACCACAG
851 GCAGTTTGAA GAGAACACAT GAAGAAGAGG ATGATTTTGG AACCATGCAA
901 GTGGCGACTG CACAGAATGG CTGACTTGAA GAGCAACATC ATAGAGTGTG
951 AATTTCATAT TGGGAAGGAG AAAATACAAG AGAAAATTAT AATGTAAAAT
1001 GGTAAAAACA TAAGTAGTTT TTTTTCATAT TACATGTTGC TTCCAGACAT
1051 ACTTCTCTGC AACTTGTTGA GCAACATTTT AAGATGTTGG ACTTCTGCAA
1101 TAGATGACAC TGATGGTTTT ACTCCTTTT TTTAAAAACA CATGCGCGCG
1151 CACACACACA TGCTTTACAA GTTTTATTAT AAACCAAGAA TTTTGGACTT
1201 GCAAAAAAAA AAAAAAAA

```

**FEATURES:**

Start codon: 253

Stop codon: 922

**FIGURE 1**

2/32

**Homologous proteins:****Top 10 BLAST Hits**

gi 2137698 pir  I49365 protein tyrosine phosphatase - mouse >gi...	462	e-129
gi 2137697 pir  I49364 protein tyrosine phosphatase - mouse >gi...	356	1e-97
gi 1842088 (U87169) tyrosine phosphatase-like protein homolog h...	141	5e-33
gi 4758206 ref NP_004409.1   dual specificity phosphatase 2 >gi...	94	9e-19
gi 4758212 ref NP_004411.1   dual specificity phosphatase 8 >gi...	93	2e-18
gi 6679156 ref NP_032774.1   neuronal tyrosine/threonine phosph...	93	2e-18
gi 4758204 ref NP_004408.1   dual specificity phosphatase 1 >gi...	92	5e-18
gi 1050849 emb CAA58710  (X83742) MAP kinase phosphatase [Xenop...	91	8e-18
gi 4150963 emb CAA77232  (Y18620) DsPTP1 protein [Arabidopsis t...	90	1e-17
gi 6714641 dbj BAA89534.1  (AB036834) MAP kinase phosphatase [D...	90	1e-17

**EST**

gi 2059098 gb AA404320.1 AA404320 zw36g07.s1 Soares_total_fetus...	761	0.0
gi 2810244 gb AA761314.1 AA761314 nz21c05.s1 NCI_CGAP_GCB1 Homo...	630	e-178
gi 1472397 gb AA011350.1 AA011350 zi01b04.s1 Soares_fetal_liver...	607	e-171
gi 1230791 gb N73506.1 N73506 za49c05.s1 Soares_fetal_liver_spl...	597	e-168
gi 4389706 gb AI497724.1 AI497724 ti50c07.x1 NCI_CGAP_Lym12 Hom...	379	e-103

**EXPRESSION INFORMATION FOR MODULATORY USE:**

gi 2059098 gb AA404320.1	Human total fetus
gi 2810244 gb AA761314.1	Human Germinal B cell
gi 1472397 gb AA011350.1	Human fetal liver
gi 1230791 gb N73506.1	Human fetal liver spleen
gi 4389706 gb AI497724.1	Human Lymph node

**PCR-BASED TISSUE SCREENING PANEL:**

Human fetal brain, human Brain, human heart, human liver, human lung, human placenta, human thyroid.

FIGURE 1.

3/32

```

1  MEDVKLEFPS LPQCKEDAEW WTYPMRREMQ EILPGLFLGP YSSAMKSKLP
51 VLQKHGITHI ICIRQNIEN FIKPNFQQLF RYLVLDIADN PVENIIREFP
101 MTKEFIDGSL QMGKVLVHG NAGISRSAF VIAYIMETFG MKYRDAFAYV
151 QERRFCINPN AGFVHQLQEQ EAIYLAKLTI QMSPLQIER SLSVHSGTTG
201 SLKRTHEED DFGTMQVATA QNG

```

**FEATURES:****Functional domains and key regions:**

-----

[1] PDOC00005 PS00005 PKC\_PHOSPHO\_SITE  
Protein kinase C phosphorylation site  
201-203 SLK

-----

[2] PDOC00006 PS00006 CK2\_PHOSPHO\_SITE  
Casein kinase II phosphorylation site  
205-208 THEE

-----

[3] PDOC00007 PS00007 TYR\_PHOSPHO\_SITE  
Tyrosine kinase phosphorylation site  
Number of matches: 2 1 15-23 KEDAEWTY 2 142-149 KYRDAFAY

-----

[4] PDOC00008 PS00008 MYRISTYL  
N-myristoylation site  
Number of matches: 2 1 123-128 GISRSA 2 197-202 GTTGSL

-----

**Membrane spanning structure and domains:**

Helix	Begin	End	Score	Certainty
1	123	143	0.626	Putative

4/32

**BLAST Alignment to Top Hit:**

```
>gi|2137698|pir||I49365 protein tyrosine phosphatase - mouse
>gi|1063626|gb|AAA87037.1| (U34973) protein tyrosine
phosphatase-like [Mus musculus]
Length = 223
```

Score = 444 bits (1131), Expect = e-124  
Identities = 214/223 (95%), Positives = 221/223 (98%)

```
Query: 1 MEDVKLEFPSLPQCKEDAEWTYPMRREMQEILPGLFLGPYSSAMKSKLPVLQKHGITHI 60
MEDVKLEFPS+PQCK+DAEWTYPMRREMQE+LPGLFLGPYSSAMKSKLP+LQKHGITHI
Sbjct: 1 MEDVKLEFPSVPQCKDDAEWTYPMRREMQEVLPGLFLGPYSSAMKSKLPILQKHGITHI 60

Query: 61 ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQMGKVLVHG 120
ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQ GGVVLVHG
Sbjct: 61 ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQMGKVLVHG 120

Query: 121 NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQEYEAIIYLAKLTI 180
NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQEYEAIIYLAKLTI
Sbjct: 121 NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQEYEAIIYLAKLTI 180

Query: 181 QMMSPLQIERSLSVHSGTTGSLKRTHEEEDDFGTMQVATAQNG 223
QMMSPLQIERSL+VHSGTTGS+KRTHEE+DDFG MQVATAQNG
Sbjct: 181 QMMSPLQIERSLAVHSGTTGSVKRTHEEEDDFGNMQVATAQNG 223
```

**Hammer search results (Pfam):**

Scores for sequence family classification (score includes all domains):

Model	Description	Score	E-value	N
PF00782	Dual specificity phosphatase, catalytic doma	221.5	1.2e-62	1

5/32

```

1  TTGAAATCCA AAAATATCTG AAGCTACATT TGGACCCCTG TAAATAATGT
51  AATGTATAAG GATTTTTCCA AAATAAGTCT TAATTTCACT TTTCATATAT
101 CAACAAAAAG GTACTATTAG GAGTACATAG TTGCCACACT TGAGACATAT
151 TCCAAATGCA TACACCTAAC GGTACTACTA TTACAGAACA GCACATTCTA
201 ATCCACATAT ACACGAGTTT TAATTAATTT TAGCACTATG TCTATAATCA
251 GAATGAATAC CTGGAATACA TGTTCCTAGC AGGAATATTT GTTAGCAGCT
301 TTAAGGTACT TGAATCACC ATAATCATT CTATTTTAAA TTTAAATTTT
351 ACTACTGGGG TAAATCCAT GAGGGAAGGT TGTGGCTATG AATTTTTTATT
401 TATTCTTTTT CTTTGTGGT AAATATGGAG AACTTACCAA ATCTCTTATA
451 TAGCCTGGCT GTAGATGGCA ATGCGAGGAA AGAAAAAGGA AGCAGAAAGA
501 AAAAAAAGG CAATCAGAAA AAATGGCAAC GAAGCAAAGA AAAAGTTGCG
551 GTCACCTGCA AACCAAAATT CCAGCCAAAA GTCATGCAAA AAACACTTTT
601 AGGTAGAAAC CAAGCAAAGT AAATGCAAGA ATGAAAAATG AAAATGAGGA
651 AGCAGCAATT ACTTTCATT TAGAACACTG AGAACACTC CACATTATTT
701 TAGAATGTTA AATGTTGCTA AAGAACCCTA GGGTAGAAT TTGTAGGGAG
751 AAGATAAAAA GAGCAATAT TCTTTTCCCC CTACATCGTG TACCCAGTTA
801 CATCGTGAC CCAGTTCTCA CCGGTTAAGG TAAAGCCAAT TATTTTAGTA
851 GCAAAAATAA AGTATCCAAA AGCCTTTAAA GTCTCTCAG ATTTAGTCAG
901 ATAATATGAT CCATGCACTG CTTTCAGAA ATAAGAATTT GAAGGCATAA
951 AATAAGTGCA GTGCCATCT GTTCTTTTT TTACACAAGA AAAGCAAACC
1001 CCTCAGTTAC CATGTGTTTT TTGCATCCTT TTTCTGGAA GGGAAAAACA
1051 AGAGATGCCG TATACTACAT GAGGAATTTT GGCTTTATGG CATTAGTCAT
1101 TTCCATTTAG ATTAACATAA ATCAACATAT AGAATAATTC TTCAAAATTT
1151 AAAAAATCCAG TTTGAGAGTC ATATTTATTT AAAAATACCC ACAGCATGTT
1201 TAGTTAATAT ATATATAATT GAAGGGAATT AAAGTAGGTT AAATACAACA
1251 GGTTATTTTG ATAGACCCAA AAGAAACTA CGAGTCTATG CCCAGGTAGG
1301 GAAGAAATGTC CTTGTGGCCT GCACATCTTC CTACAGCCTC CAGAACGCAA
1351 CTGGATACAG CTTAATAAAT ACTGAGCACT ATGTCCAGTG TGACTAGTGT
1401 GGTATCTGAC ACACAGTAGC AACTAAACTT CTGAATGTCA CTACTACTA
1451 GGCACCAGGG CAATAACATC ATGGTCGCTA TTCTCTGGAA ACAATTTTTT
1501 TTTCTGACAC GGAGTTTAC TCTTGTGCC CAGGCTGGAG TGCAATGGCG
1551 CCATCTTGGC TCACTGCAAC CTCCACCTCC CAGGTACAGG TGATTCTCCT
1601 GCCTCAGCCT CCCAAGTAGC TGGCATTATA GGCCTGCACC ACCATGCCTG
1651 GCTAATTTTT GTAGTTTTAG TAGAGATGGG GTTTCACCAT GTTGGCCAGG
1701 CTGGTCTCGA ACTCCTGACC TCAGGTGTTT CACTCACCTC GGCTCCCTA
1751 AGTGTCTGGA TTACAGGTGT GAGCCACCGC ACCTAGCCCA ACACAACTAT
1801 TCAATAGAAA TTTCTCTCTC GGTGAGCAT GGTGGCTCAC GCCTGTAATC
1851 CCAGCACTCT GGGAGGCTGA GGTGGGTGGA TCATCTGAGG TCAGGAGTTC
1901 AAGACCAGCC TGCCAATACA GTGAAACCCC ATCTCTCTA AAAGTACAAA
1951 AATTAGCCAG GTGTGGTGGT GGCCTCTGTA GTCCAGCTA CTCAGGAGGC
2001 TGAGACAGGA GAATCTCTT TACCCGGGAG GCAGAGGTTG CAATGAGCCA
2051 AGATCATGCC ATTGCACTCC AGCCTGGGCA ACAGACTCTG TCTCAAAAAA
2101 AAAGAAATTT CTCTCTTAAG TTAGTGGTAC TATAAGTAAT TTAATTTGGA
2151 CTTTCAGATC TTCAATTTCT CTAGTCTCTA CTTTCTCTCC TTGAATCAGT
2201 CTTGAGAGCA GAACATACTG TTCTTTAAAA GCTGCCGTGG CAAAATGCCA
2251 ACAGATAAAA ATTGTATATA CTTTTCTCT TGGTATGTTG TCAATCCAT
2301 CCCCCATTTT AGAATTATTT TGTGTTGTAT TTTCAAATGC AAACAGTAT
2351 AGATCTTTTG AGTTGTGTTT TTGTTTATA TGTTCAATTTG ACTTAACTGA
2401 TTTTTTTGTG GTATAATTTT TCATTGAGGT ATAATTACAT TAAAAAATG
2451 TAGATCTTTA AGTGTACATT TCAAATATGT TTGGACAAGT TATATATCTG
2501 TGTAACCATC ACCCCAATCA AGTGTGTTG TTATTTAAAA AACATTATTT
2551 GAAATTTTTT AGATTTAAGA GATCTTAAAT CTACCTGGAG CAAAACCTCT
2601 TAATATAAAT GGTTTTACCT AGCATGGAAG TCTAGGTCTA TTAAGAATTA
2651 TGATGTGTAC ACCTAATAA GGTGATATTT GACTTAGAGT ATTTGAAAGT
2701 ACATFAAAAA TCTTGACTAA CTTTTAAGA AAGATTTAAC TTCTTTTCTA
2751 GGTGATAGAA TTACCTCTTA CAAACCCAGA GTTATTTTCT CGTGTAGGAA
2801 TAATACCTCC AAAAGGCTGT TTGTTATATG GACCACCAGG TTGGTATGTA
2851 ATTATTTCTA CTCCACCAAT AAGATAAATG AATTAAGGAA TTAATAAAAA
2901 AAAGACAATT TTTTATTTT TATTTTTTTG AGACACGGTC TCACCTCTGT
2951 GCCCAGGCTG TAGTGCAGTG GCACAATCTG GGCTAACTGC AACCTCTGCC
3001 TTCCGGGCTC AAGTGATTCT CCCACCTCAG TCTCCACAGT AGCTGGGACT
3051 GCAGGCGTGC ATCACCATGT CTGGTTAATT TTTGTATGTT TTGTAGAGAA
3101 GCAATTTTGC CATGTTGCTC AGGCTATCTC AAACCTCTG ACTCAAGCGA
3151 TCTGCCACAC TTAGCCTCCC AAAATGTTGG GATTACAAGC ATAAACCAC

```

FIGURE 3

6/32

```

3201 GCGCCTGGCC ATAAGGTGGA AATTTGATGT GGGCAGTTCC AACTTCTCCT
3251 CTCTTCAGAG TGAGAATGAG ATAGGATATT TATGTCTACT GTTCTTTGAG
3301 GCATGCTTAG TGCATTTGTG CTCACAGTA CATTATCTT AACAGGCCAT
3351 GTGATTCTAG TGCAACAGTC CTCAAATTGT GGTTCACAGA CCCAGAGGTG
3401 CTTTCATGGA CTCTGTAAGG TCAAACTAC TTTATAATAC TGAAATGTTA
3451 AGCCAGGCCG AGTGGCTCAC ACCTGTAATC CCAGCACTTC GGGAGGCCGA
3501 GGCAGGCAGA TCACCAGAGG TCAGGAGTTT GAGAGCAGCC TGGCCAACCA
3551 ACATGATGAA ACCCTGTCTC TACTAAAAAT ACAAATGA GCCAGGCGTG
3601 GTGGCGTGCA CCTGTAATCC CAGCTACTCG GGAAGCTGAG GCAGGAGAAT
3651 TGCTTGAACC TGGGAGGCAG AGGTTGCAGT GAGCCGAGAT TGCCCCACTG
3701 CACTCCAGCC TGGCTGACAG AGTGAGACTC CTTCTCAAAA AAAAAAAAAA
3751 AAAAAAAAAA ATTTTTTATA TAAAGCAAA GTACCTATAG CATACTGCTT
3801 GACATATGTA GCCCCACAAT GACACAAAAC AAAAACTAA AATGTTGTTT
3851 GGCTCTCCA CTGTGTTGAC ATTTGTGCTG ATGGTGCAAG AGCACCATGG
3901 GTAAATTTAA ATTACTTGCA CTGTAGTGTG AATCAGCATT AGTGGCATGA
3951 AACGGTGCCT GTTAGTAGCC ATTGCGTTCT TGACTGCCAC ATACTTGCGAG
4001 TGTAAAAAAA AAAAAAGTC AGTTTCACTA TAAAGTCCTT GGTGAAACAG
4051 TAAAAATTAT TAATTTTGT AAATCTTCAT CTTTGGGTAA TATTTTGTGT
4101 TCTTCATGAT AAAAGGGAAA ATAAATATAA AGTACTGCTG CATATTGAAT
4151 AAGATAGTTG TCTTAGGAA AAGCACTGT GCAGTTATT AAGTTGCCAG
4201 CTGAATTCAT TGCTTTTTAT GGAATACTAT TTTTGCTTGA ATGGACCATT
4251 TACAGATATG CTGTGATTAT CAGACTGGTT ATTGGTTATT AGTTATTGAT
4301 TACTCAAGAC TGTTTTTTGG TTATTTGGCG CACATTTTTT CCAAAGCGAA
4351 CAAATTAAGC CTGTCATGTT AAACAACGA CACCATCTAT TGCCATTGAT
4401 AAAATATGAA ATGTCAAGTG AAAATTAGAA TTTTATAGAA CATATATCTG
4451 GCACTATGTG GTTGAAGCTT TTTCTTTTTT TCTTTCTTTT TCTTTTTTTT
4501 TTTTTTGATA AGGTGTTACT CTGTTACCCA GGCTGGAGTG CAGTGGCGTG
4551 ATCATCCTGG CTCGCTGCAA CTCTGCCTC TTGGGCTCAG GTGATTCTTC
4601 CACCTCAGCC TCCTGAGTAG CTGGTACTAC AGGTGTGTG CACCATGCCA
4651 GGCTAATTTT TGTGTTTTTA GTAGAGGCAG GGTTTTGCCA TGTGCCCAG
4701 GCTGGTCTTG AATTCCTGGG CTCAGCAAC CCGCCACCT CAGCCTCCCA
4751 AAGTGCTGGG ATTACAGGCA TGAGCCCAA TGTCCAGCCA CGGCAGCTTT
4801 CTAATATATT AATACTTAAA GACTTTTCTG ATGAGATAAG TGGTGAGAAT
4851 AACAAAAAAT TTTTATAATG TGTGGTGAA AATGTCAACA TTTGGAAGAT
4901 TTGCATAACT CAACCAAGTA TTTCCAAATA ATCAATGCTT GATATTAAAA
4951 TATTCATAAG TAAAGATCC AGTCAGTGCA CAGGATAGAC CAATGTATT
5001 TAATGTAACA GAAGTTTCTG TCATAGTCCA TGTGTAAAGT AGATAGCTAT
5051 TATAAAAAAG ACAAAAGTGT TTGCAAGATG TAGAGAAAAG AGAAAGAACC
5101 CTTGTACACT ACTGGTGGGA ATGTAATTA GCACAGCCAT TTTGAAAAC
5151 ATGGAGGTTT CTCAAAAAC TAAAAATAGA ATTACCATAT GATTACAGCA
5201 TCCCACTTCT GGGTTTATAT CTAAGGAAT TGAAATCAGT GTGTCAGAGA
5251 TAGCTGCAT CCCATGATTA TTTACAATA GCCAAGATAT AGAAACAGCC
5301 TAAAAATTGC CCATCAATGG ATGAATGGAT AAAGAAAATG TGGTAGCCGG
5351 GTGCAGTGGC TCATACCTGT AGTGCCAACA CTTTGGGAGG CCGAGGCGGG
5401 CGGATCACCT GAGGTCGGGA GTTCGAGACC AGCCTGACCA ACATGGAGAA
5451 ACCCGTCTC TGCTGAAAAT ACAAATTAG CTGGGTGTAG TAGTTCATGC
5501 CTGTAATCCC AGCTACTCGG GAGGCAGAGG CAGGAGAATC ACTTGAACCT
5551 GGGAGGCAGA GGTTCAGTG AGCTGAGATC ATGCCATTGC ACTCCAGCCT
5601 GGGCAACAAG AGTGAAACT CATCTCAAAA AAAAAAGAAA AAGAAATGTG
5651 GTAAATACAC ACATTGGAAT ACTATTGAGC CTAAAAAAG GAACTCTGT
5701 CATTTGTGAC AATATGGATG AATCTAGAGG ATGTTTACT AAGTGAAATA
5751 AGCCAGACAC AGAAAGACAG TTACCACATA ATCTCATTTT CATGTGGAAT
5801 CTTAAAAAAT TGAATCTGTA GAAACCAAGA GTAGAATGGT GGTACCAGA
5851 AGTTGTGGTG GTGTATGGG ATAGGGGAGA TGTGGTCAA AGGATATAAA
5901 GTTCACTTAG ACAGGAGGAA TAAGTTCTAG GTGACATATT GCATAGCATG
5951 GTGACTATAA TTAATAATGT ATTAGCTATT TCAAAATTGC TAAAAGTAGA
6001 TTTTAAATGT TCTAACCACA AAGTAATGCT AAGCATGTGA GGCATGGAT
6051 ATGTTGATTT GCCTGATTTA ATCATCTTTC AATATATACA TGTATCATAA
6101 TTTAACCAT AAATATACAA TTTATTTGTC AATTTAAAAT AGATTTTAAA
6151 AATTATAACA TTTTGATTAA AATTTAATG TTGACAGCAG AAGTACTTTG
6201 GAATTTTTTT TTTTTTTTT TTTTGTGAGA CAGAGTCTTG CTCTGTCACC
6251 CAGGCTGGAG TGCAGTGGCG AGATTATAAG CTCACTGCAA CCCCACCTC
6301 CCGGATTCAA GCGATTCTCC TGCTCAGCC TCCCAGTAG GTGGGACTAC
6351 AGGCATGTGC CACCACGCTC AGCTAATTTT TTGTATTTT AGTAGAGACG
6401 GGGTTTCACT GTGTTTCGAT CTCCTGACCC TGTGATCTGC CCGCCTCAGC

```

FIGURE 3

7/32

```

6451 CTCCCAAAGT GCTGGGATTA CAGGTGTGAG CCACCACACC TGGCCAAGTA
6501 CTTTGGGAATT TTAAATGAAA ATTCTATTTA GGATTTAGCT TTCATTTTGG
6551 AAAATTTACT TGCCAAACGA TTATATTCTT AAAAGGATTT TAAAAATTTG
6601 TTTACATAG GCCGGGTGCG GTGGGTTCTG CCTGTAATCC CAGCACTTTG
6651 GGAGGCTGAA GTGGCAGGAT CACCTGAGCC CAAGAGTTCA AGACCAGCAT
6701 GCGCCAACAC AGAGAGACCC CGTCTCTGAA AAACAAACAG ACAAAACAAA
6751 AACTTAGCTG TGCGTGATGG CACATGCCTG TCATCCCAGC TACTTGGGAG
6801 GCTGAGGTGG GAAAATCGCT TAGGTCTGGG AGGTCAAGGT TGCAGTGAGC
6851 TGTGATCTCG CCACACTCCC AGCCTAGGTG ACAGAGTGAT TGCCTGTCTC
6901 AAAACAAATT TTTTCTACC TTACCATCTA ATTAAGACTT CTTTGTCTAT
6951 TCTTAGGTAC GGGAAAAACA CTCTGGCAC GAGCCGTTGC TAGCCAGCTG
7001 GACTGCAATT TCTTAAAGGT AAAGGAAGA TTATTTTGTA CTTATTGAAA
7051 TTTAATTTTA CTTGAATTAT CTTATATTTA CCTTACTGTT TTTCCTTTAA
7101 TCAGGTTGTA TCTAGTTCTA TTGTAGACAA GTACATTGGT GAAAGTGCTC
7151 GTTTGATCAG AGAAATGTTT AATTATGCTA GAGATCATCA ACCATGCATC
7201 ATTTTTATGG ATGAAATAGA TGCTATTGGT AAGAATAACA CCCTTGTTGA
7251 AAGTTTTAGG ACTTTTTTTT AAATGTAAAA GAACCTTTT CCCTCTCTTA
7301 ATCTGTAATT GTGACTTGTA TGAAGTAGAT ACCACAATGA ATCAGATGTT
7351 AGTTTAAACA ATTTTAATAA ATAACCTTTC ATGGCCGGGT GTGGTGGCTC
7401 ATGCCGTGTA TCCCAGCACT TTGAGAGGCC AAGGTGGGCA GATCACCAGG
7451 TCAGGAGATC GAGACCATCT GGCCAACATG GTGAAACCCT GTCTCTACTA
7501 AAAATACAAA AATTAGCTGG ATGTGGTGGC ACATGCCTGT AATCCCAGCT
7551 ACTGAGGAGG CTGAGGCACG AGAATCGCTT GAACCCAGGA GACGTAGGTT
7601 GCAGTGAGCC GAGATCACAC CACTGCATCT CAGCCTGGCG ACAGAGCGAG
7651 ACTCCGTCTC AATAAATAAC CTTTCACTTT AACAAAATGA GAAATGTTAC
7701 ACCAAATCA AGTCTAACTT TGTACGATA ATTCTTGCTC TTTAATTTTC
7751 ATCTTAATGT TTTAAGCCAC AGACTGTTAT GTTCTGTTTT CTTAAATGAT
7801 GGTGTAGAG GAAAAGAGTA ATGCATATAA ATTTCCAAAT CTACTATCTT
7851 AGGTGGTCTG CGGTTTTCTG AGGGTACTTC AGCTGACAGA GAGATTCAGA
7901 GAACGTTAAT GGAGGTAATA TTTGGTAAAG GGGGTTTATA AAGAAACCAA
7951 TGTTTATTAA ATGAAGAAGT GAACATTGCA TATTTGATAG TCAAAATATA
8001 TAGAACATTT TAAATGAAAT ATGAAATTG AAAATATTGT CAGGAACAAA
8051 CATGTTTCTC TATCACAAC TCTAAGCAA ATGACTACTG GAAATAAAGG
8101 CTATCTGCCA AATTCCATTT GGTATACACC TGTACTATTC TGTGTTTTTT
8151 TGAGTAGATC AGTCATTCAT ATATTTAAAT TCTTATGAAT GTGATCTTGC
8201 GGTAGTTTAA TGAAGACATT TTTGTAAATG GTCATATTAA GACTGTTGGC
8251 AATAAATGAG CTATAATTAT GTATGAAGCT GCTCTAAAAA TTATTTTTTT
8301 CTCTCACTTT ATTGCTGAGA CTGAGGCAAC TAAATAGTT TTGATAATTG
8351 AAGAGGATAG ATGACAGAAT GAAAGAATGC ACATAAAGCC TTCTCCAGT
8401 TTTACCTTTC CCCACTCAA ATTCTGTGAA AGTGATATCA AGAGTCCAAA
8451 TACATTTTCC ACTTCAAATA GAACTAGGT AGCATGGGTA ATGCAGTGTC
8501 AAATTCCTTC TCCTTAGAAG TATTTGAAA ATCTTTTTTC ATAAATTATA
8551 CAGATCCGCT CAGAAGATAA CATAGCATTT GGAAATTATA AAATCTCTTA
8601 GAAACCTTAA ATTGAGATAT TTTTAAATA CACAAATACT CATTTTATT
8651 CAAGTAACTA ATATATCATC AACTAACACA TTGTCAGGAC TAGCTATATT
8701 TTTAGAGAGG TTTGTTAAAT GCAGTAAAGG TTTTTCATTT ATTCAAGAAA
8751 ACTTTAGAAA TTGAGGACAA TATTTTTTAT GTCTTTTAGT ATTTCTGTGT
8801 ACAGTAGAAT TATTTGAAA AATAGGCCAG GCATGGTGGC TTCTGCCTGT
8851 AATCCAGCA CTTTGGGAGG CCCAGCTGGG CAGATCATGA GGTCTGAGCA
8901 TTGAGACCAG CCTGACCAAC GTAGCGAAAC ACCATCTCTA GTAAAGATAC
8951 AAAAATTAGC TGGGCGTGGT GCGGTGTGCC TGTAATCCCA GTTACTCAGG
9001 AGGCTGAGGC AGGAGAATTG CTTGAACCCA GGAGGTGAGG TTGCAGTGGG
9051 CTGAGATCGC CCCATTGCAC TCCAGCCTGG GTGACAGAGC GAGAGTCTGT
9101 CTCCAAAAAA AAAAAAAA AAAAGCAGTC CCAGCTACTC AGGAGGTTGA
9151 GGTGGGAGGA CTGGTCGAGC CCAGGAGGTG AAGGTTGCAG TGAGCGATGA
9201 TCAGGCCACA GTACTCCAGC CTGGGTGACA GAGTGAAACT CTGTCTCAAA
9251 AAAAAAAGA CTATCAAATA TGCAATGTTT ATTATCAGTT TATTATCAAA
9301 TTTGTAGAAA AATCTTTGTA TCCATTTATC CTAATATAAA TGTATGTCT
9351 GACATATCAT AAGCACTTTA TATATTGGAT TTTATTATTA GCTTTTCCTT
9401 TAAAAAATAA TTGATGAAAT TTTGGACATT GGAAATTAGA TCCACATAGT
9451 TTAATTTTCT AATTCTTGAC ATGATGGAAG CCTTCAGATT TATTAAAACT
9501 ACCTGGTAGC TATAGAAAGA TACATAGCTA TTAAGAGGTA CATAATCTAG
9551 CTTAGAACTT TGAGGCTAGA AAGTATATCC CTTTATATAA GAGAGAGAAA
9601 AAGAATTCTA TCAAATGACC ATTCTGAAGA TAGAACATAT CTATCTGTAG
9651 ACAATACATT TCATGGCATT AGACATATAA AAGGTGTGTG CTATTTTTTT

```

FIGURE 3



8/32

```

9701 TAATGGTTAG AATTTTGTGA AAATCTGATT CTTAATATTC TTAGTTACTG
9751 AATCAAATGG ATGGATTTGA TACTCTGCAT AGAGTTAAAA TGATCATGGC
9801 TACAAACAGA CCAGATACAC TGGATCCTGC TTGCTGCGT CCAGGAAGAT
9851 TAGATAGAAA AATACGTGAG TTAAGATTCT TTACCTACTG TCCATTTCCC
9901 TTTGTGCCCA TTTCTTTTTC CATACTTCAC TTCACCTTCC ACTGTATTTT
9951 AAAAAAGATA AAACCTGGACT ATAAAAATAT TTTTATTTT CAGATATTGA
10001 TTTGCCAAAT GAACAAGCAA GATTAGACAT ACTGAAATC CATGCAGGTC
10051 CCATTACAAA GCATGGTGAA ATAGGTAAGG AAGTCATCTA TTTTATATGT
10101 ATTTACATTT GGTAAATGAA GAAAAATACT TTTAGAAAT ACTGATAGTT
10151 TCCTAATCT GGTTTTAAAT TCAGCAAATG TGGTGGTTT AAATTCAGCA
10201 AATAGTTATT GAGCATCTAC TATAAGCTAG GAACCATGT AAGTGTTTTG
10251 TAAGGGCTGA CAATATAGCA AGGAACAAAA CAGACAAAT TCTGCCATTA
10301 GAGAACTTAT ATTCTTGTTA GAAAAAACA GATAAAGTTA GTAAAAACAA
10351 GTATAATAGA TGATGATAAG TGCTATGGAG AAAAATAAAG CAAGAAAGTG
10401 GGGGGCGGGC ATGGTGGCTC ACTCCTGTAA TCCTAATGGT TTTGGAGGCC
10451 GAGGCAGAAG GACCGCTTGA GGCCAGGAGT TTGAGGTTGC AGGGAGCTAT
10501 GATCATGTGA CTGCACTCCA GTTGGCAAG ACGCTGTTT AGGGGAAAAA
10551 AAAAGAAAAG GGGGATAGGA AATTAGGGAA GTGCCAGGAC CAGGCATGAG
10601 GATATGTTTT TAAATGACAG GGAGGATTAG CACAGGGAAG GCCTTACCAA
10651 GAAGGTAATT TATTTTTTAG AGACAGGGTC TCACCTTGC CCAGGCTGGA
10701 GTGCAATGGT GTGATCCCAG CTCACTGCAA CTTCTGCCTC CCAAGTTCAA
10751 ATGATCCTCA CACCTCAGCC TCCTGATTAG CTGGGACTAC AGGCACACAC
10801 CACCAACCCT GGCTTGTITT TTTGTAGGGA TGGGGTTTCA CCATGTTGCC
10851 CAGGCTGATC TTGAACCTACT GGGCTCAAGC AATCTGCCCA CCTCGGCCAC
10901 CCAAGTTCT GGGATAACAG GCGTGTGCCA CTGCACCCGG CCTGGTTGTT
10951 TGTTTGTTTT TTTTAAAT TGATTCTGT TAAATGCTGA CAATAGGTCA
11001 GATAAAGAGT TCTCAGAGTA GACCTTTGGA TTTAACTATA TGGAGGTCAT
11051 TGGTAATCTT GTCAAAAGTA GCTTCTTGGG AGTGGTGGAG GTGAAAGCCT
11101 ATTTCAGATG GGTTCAGAG AGATTGGGAG GAGAGGCATT GAGTTTAGAC
11151 ATTTCTTTTA AGAGTTCTAC AGAGGGGGCA GAAGAAGTAG AAGGGGAATG
11201 CCGATGAGGA GTTGGCAGAG TTTTCTATAA GATGGAAGAG TTTATGACCC
11251 CCCTGCCCTT TTTTTTTTTT TTTAATAAT GCTACTGGGA ATGACCTAGG
11301 AGAAAGAGAA ATTGGCAATG TTCTTTCCTT GAAGAGGGAT TGGCCCTATA
11351 TATATGTGTA CTTTATGAG ACTGGAGGAA AGGCAGAGTA CATAGATGCT
11401 TATGATGACA GGTCTTAGA TAGTGCAAGG ACTTGTGGAA GTGTTTTTTT
11451 CTGAATGCTT CTGTTTTCTC AGTGAAGTAG AATGCACGTT CAGAATGAAG
11501 ATAGGGAAGT GTTCTTAGAG ATTTGAGGAC AAAGGAGAAG GTATAAAGTC
11551 ATTATCTATG GAAGTGAGGG ATTGGACTAG GGTGCAGGCC AGTAAACAT
11601 GGCTTGTGAA CCAAATCTG CCTGCCCTGT GTTTTGGAA ACACACAAG
11651 TTTTGTGTA ACCCAAGCAT GCTCATTTAT CTGTTGTCTA TGGCTGCTTT
11701 CCTACTGGAA TAGCTGAGTT GAATAGTTAC AACAGAAACC ATATGGCTTG
11751 CAAAGCATACT AGTATTTACT CTCTGGCCCT TTACATAAAA AGTTTGCTGA
11801 CCTCCAGACT AGGGAATCT AGTATAATT CCAGGCAGCC TTAATAACTC
11851 TTTAGAAGTT AATGGTCCAG AATAATGACA AATAGCTGAT TGTGAATTT
11901 CACTATCTTC ATTGCCCTG TTAGAGAGTT TTGAGCTGGA AAGACCGAAC
11951 TGAACAAAGG ATGTCAATGT ATAGGTTTCT TCCACAAATA CTGAGCTCTT
12001 GCTAGATGCC AGATACTGTG CTAGCCTTGG GAATCTTGC TCTCAGGAAG
12051 CTTACAATGA ACTTAAACCT GATTAAAGAC AATTCATGAA TATATGTGTG
12101 ATTTCAAATA GAGAACGACA TGCCCTATAT TGCCTGACCA AACGGTGCAT
12151 CATCAAAGTT ATTCAACTG TAGTAGCCTG TGCTGTCTTA CTCTCTTCC
12201 TATTCTGTAT CAGATCCATT GTTGCTACCC CAATCCTATA GCTCTTTGAT
12251 TCATGTCTGT TATGTGGGTG GATGGAGAAC TCACCTTATT ACTGCTACCA
12301 TAGATCTGAT ACTTCACCAC TTGAATCTTG CACAGAAACC AGAGAAGCTA
12351 GCTAATGCAT GCTGTAGCAT TTAATAATTC CATGTGATAC AATTATGTAT
12401 GATTACATTT CAGTTTGTCT ATACTTTATA TTTGGCTTGT ATGATTAAAG
12451 TAAACAAAGT AAATCCATT GTTATAATTG GTTTTGAAGT TATAGGTTT
12501 ATTCAAATCC AAGATTTGAT TACAGTTTTG ATAAGAGTCA CAGCTTAACA
12551 GGTATCTGGA GTTCACATGT GCATAGCTAT TTCCTGTAT AAAAATAGAT
12601 TAAGATATTT TGAGATTTTG GTGATATTC CTGTTTTTAA AGTTTCAGGG
12651 GTGTGTCTAA TTCTTCTTGG TGCTGGTTTA TTTAACAGAA GTCTTAGTTT
12701 TTGGATATTA ATATTGTGGA AAGTTAACAG AGCTGATGTC TAGCTGATCA
12751 AACTCAAAGT AAGCTCTTCA GTTTAAATTT TCGATGTGGG CATAAATCAA
12801 GTAAAGGTCT AATTTTTAAA ACTAATTTCC AGTATTTTTT CTAACAGAT
12851 TATGAAGCAA TTGTGAAGCT TTCGGATGGC TTTAATGGAG CAGATCTGAG
12901 AAATGTTTTG ACTGAAGCAG GTAAGGGTTT AAAGTACAGT TTTACTATTG

```

FIGURE 3

9/32

```

12951 ATTTTGATTT TTAAATTTG CTGAACTGT TTTGAGTTTA TCTGAAAGCG
13001 GAGCATAGAC TTTGCAAGGA TTTGGGTTCA TGCTGTTCTT TTAGGAATCG
13051 ATTCACAGAA ATAGGAGAAG CAGGGCAAGT GAGATGGAAA GAGGGAAAGC
13101 TAATATGAGG GTGCACCATT GAGGTAGGTG CTGTAGGAAA GGGAGGTTAG
13151 ATCTCAGAGA AGCATACAGA ATGCCTTCCA GGATCACCCA GCTGAAAGTT
13201 GGGAGACTAG AACATTGATT TACCAGTACT CATCCCCCAT TGGATGAGAT
13251 TTGTCTTGG TAGTGTGAC TCCTTTGCAC TTCTACCTGC CTTAGGGCAG
13301 AATGTGGAAG GAGAGGCATG TAATAGAACA CTGGCCCCCT AAAGTAAGTC
13351 TGAGGTGCTA CAGAATTGCC TACCACACCT GTGGCTGGAA TTAGAATGGG
13401 CCAGCACCAG AGGTATCTGC TGCAAAATGA ATTGTGTATG TTGTCTAATA
13451 CTAGTCTGTG AGCAGTGTGT TGAAAGATTG ATTTATGAAT TATGTGATCA
13501 TGCCATTTGT GTAAATGTA GTATTTAAAT ATAATTCTCT GTGGATTGTG
13551 TGATACTATT TTTTTCACCT CTACATGGTA TGTAATAAAT GTGTGATGCT
13601 ATTTTATTTT CCAGTACCAA GTAGCTTTAA TACCTTACCT AGAATCATTT
13651 AGTTTTTGTG TTCCATACAG AATCTTTAAA TAGAAAAAAT AAACCTCTAC
13701 AGTATAGTTA CTGACTTTAT AGGTTATAGA TTTTCTTAAG TATAGAATA
13751 TGTGATTTCC TCTTGCTTTT CATATCATGT TTAGCCTTAG TAAATTCAAC
13801 ACAGTGTTTA AAGTGGCTGC TCAGGGAGGG CTTCTCAGTA CAGGTATCTT
13851 CATGGGTATT GGGTATGCTG TGAGTCAGTA TCTGCATCAG ATATGCAGGT
13901 CAGATACTTC TGTTCACGTC TAGAAATGCT GTCAATGCAA ATTAGGGTAA
13951 ATCATGCTCA CAGAGCGTTA TCAATAAACT AAACATTTTA GAGGTAACT
14001 GTCATATAGC TTGAACAAGT TAGAGTAATT TATGACATTC TCTTCCAAA
14051 ATGTAACCA GACCAATTA TTATCAGAAG ATTGCTTTGG TTAGATTGTA
14101 ATCCAAATGC AAGCTGTGCA GTGAACCTAA AGGCTGTTGC TATCAAAATA
14151 TACGCTTTTT TTCCTTACAT ATTCTTACAA ATTTACCTTT AGTTATTGCA
14201 AATGAGCTAT AACTTCTGTG TGGATTAAAA TTGTAGTTCT TTTTAACTA
14251 GGTGGGACAT TCACATCTGG AAACATACTG AAATTTTTAT CTTCTTTTTA
14301 GACTTGAAGG CTTTTTGTG AACATTTTTC GTAAGTAAA ATACACTTGA
14351 TTCAACTACA GTTGCCCTTC CTGTTACGGT CCTGACATTA TCTCTTTTGG
14401 ATTATAATAC ATCTCTATTT TATTTTTTCT TTTGAGACGG AGTCTCACTC
14451 TGGCCCAAGC TGGAGTGCAG TGGCATGATC ACTGCTCCCT GTAGCCCAAG
14501 CCTGATCAT TCTCCTTTAT CTCCCAGTAG CTGGGACTAT AGGCGTGCGC
14551 CACCACACCC AGCTAATTTT TGTATTTTTT GTAGAGACGG GTTTCACCAT
14601 GTTGTCAGG CTGGTCTCAA ATTCCTGGGC CCGAGTAATC CACCCACCTG
14651 GGCTTCCCAA AATGCTGGGA TTACAGGCAC AAGCTACCAG GCCTGGCCAG
14701 GCATCTCTTG TGCAGATTTA CTTATTCAC TAAAGTATTT GGAATATAGC
14751 CATGTGTGCA AGGTTTACAA AAATAACTTA CCTAGTTTCA CTGTAGCTTT
14801 CTAAACAAGT TTTGAAACTT TGTATTTTTT TAAAAATCAG TCATTTCCAT
14851 TCACCCGGTT TCTAGGACAA CATAGATTGT TTCCTTATGT AGAAATCTAG
14901 AAAGGAAGTA ATCCTTGAAA TCTTCTATAT TAACCCCTC ATTTTATGTA
14951 AGTGAAAATT CAATACAGGC AGATCCTCAG TGGAAATTTT AGAATTCATT
15001 TAATTAGTAG ATAGCAATAA ACTTACCTGC TTTAGTTTAT CATGAGTTAG
15051 GATTATCTCA AAATCTGGGA CCCATATCCA TAACACAAC TATGTTTAAA
15101 AAATGTCATA CAAGGAAACT TTTACCCCTT TGTCAAATAC TGTGTGAGAA
15151 GGTACTTGTC AAAAAGTTGA AGGAAAAAAT TGAGTTGTGA TACTCAAATA
15201 TGAATCAAAT AAAAATACCA ATTTGTACAT AAATAGGTA AATTTTAAAC
15251 CATGAATAAT GACTCCGAGT TTTGCTAAAA CCCGCTGTTG GCTTTCTATA
15301 TGATTCCCTA TTCTCAACGT TTTTGATTAT TAACAAAGAA TGGCTATCAA
15351 ACTTACTCAA GATTTTTTTT CCCCATAAA TGTGTGCCTT CCAGCAAAAT
15401 GCTTCTGTGC AAGTTAAGTT ACGCTTAAAA TGTGTATGTG TTGGTAGTTT
15451 TGATTGCTTC GGTTTTTTAT GCTTGTTTTT ATTAAGAGCT ACAATCAGAT
15501 ACAGGGACCA TTTAAGCCTG ATTTTATTTT ATTTTATTTT TTTGAGACAG
15551 AGCCTCACTC TGTCAACCAG ACTGGAGTGC AGTGGTGCAG TCTTGGCTCA
15601 CTGCAACCTC TGCCCTCCGG GTTCAAGCGA TTCTCCTGCC TCAGCCTCCC
15651 AAGTAGCTGG GGTACAGAT GCCCACTACT ACGCCAGCT AATTTTTGTG
15701 TTTTATAGTAG AAACGGGGTT TTACCATGTT GGCTAGGCTG GTCTCGAACT
15751 CCCGACCCCA GGTAAATCCG CCACCTTGGC CTCCCAAAGT GTTGGGATTA
15801 CAGGTGTGAG CCACCGTGCC CAGCCTTGAA CCGGATGTTA AATATTCATA
15851 TAATGGTCAT ACCTGTTTTT GTTTTAGAAC ATAATCACAA CACCGCTATG
15901 GATTTTTTTT TTTTTTTTTT TTTTGAGATG GGGTCTCGCT CTGTTGCCAG
15951 GCTGGAGTGC AGTGCCACTA TCTCAGCTCA CTGCAACCTC CGCCTCCTGG
16001 GTTCAAGCCA TTCTCCTGCC TTAGCCTCCC GAGTAGCTGG GACTACAGGC
16051 GCGCCGCCAC ATGCCAGCT AATTTTTTTT TTTTTTTGTA TTTTATAGTAG
16101 AGATGGGGTT TCACCGTGTG GGCCAGGATG GTCTTAATCT CTTGACATTG
16151 CAATCTGCCC ATCTTGGCCT CCTAAAGTGT TGGGATTACA GGCGTGAGCC

```

FIGURE 3

10/32

```

16201 ACCGCACCCG GCCTGTGGAT TTTAATTGAA AAAAGATAGT GGTTTTTCAGC
16251 AAATTACAAC TACTGGCTCA GAAGTAATAA ATCTAAGCTT CACATTTTATT
16301 CCATAGAATT ATATTGTTTT TCTTATAATG AACATATAAT TCATATGTGA
16351 TATATAGCAG TCATGTTGTT TTATTCTCTA CAGGTATGTT CGCAATTCGT
16401 GCTGATCATG ATTTTGTAGT ACAGGAAGAC TTCATGAAAG CAGTCAGAAA
16451 AGTGGCTGAT TCTAAGAAGC TGGAGTCTAA ATTGGACTAC AAACCTGTGT
16501 AATTTACTGT AAGATTTTTG ATGGCTGCAT GACAGATGTT GGCTTATTGT
16551 AAAAATAAAG TTAAAGAAAA TAATGTATGT ATTGGCAATG ATGTCATTAA
16601 AAGTATATGA ATAAAAATAT GAGTAACATC ATAAAAATTA GTAATTCAAC
16651 TTTTAAGATA CAGAAGAAAT TTGTATGTTT GTTAAAGTTG CATTATTTCG
16701 AGCAAGTTAC AAAGGGAAAG TGTGAAGCT TTTTCATATT GCTGCGTGAG
16751 CATTTTGTAA AATATTGAAA GTGGTTGAG ATAGTGGTAT AAGAAAGCAT
16801 TTCTTATGAC TTATTTTGTA TCATTTGTTT TCCTCATCTA AAAAGTTGAA
16851 TAAATCTGT TTGATTCAGT TCTCCTACAT ATATATTCTT GTCTTTTCG
16901 AGTATATTTA CTGTGGTCCT TTAGGTTCTT TAGCAAGTAA ACTATTTGAT
16951 AACCCAGATG GATTGTGGAT TTTTGAATAT TATTTTAAAA TAGTACACAT
17001 ACTTAATGTT CATAAGATCA TCTTCTTAAA TAAAACATGG ATGTGTGGGT
17051 ATGTCGTGAC TCCTCCTTTC AGAAAGTGTT TACATATTCT TCATCTACTG
17101 TGATTAAGCT CATGTGTTGG TAATTGAAAA TATACATGCA CATCCATAAC
17151 TTTTAAAGA GTATGATTCA ACGTAATATT TGCTAATATG TGACTGGGTT
17201 TTCTTGGTTT ATGTAAGACG ATAGGTCCCT GTTGAGGATG TGAAGGTCTG
17251 GACCTCTTTC CAGGAAAAAT TCTAACATAC AATTTTGCGT ATACTATAAT
17301 TTCAGGAAT TTATGTGTTT CCAAGCTCAT CCAAGGATTC TTTAGGTATG
17351 TATGGATACC TGGCTAAGAG TGTATGATG AGGGGATGTA GGAGTGTCTG
17401 AAATGTTCAA AACATGATTT CTGTTACCTA TACATGATT TATATCATC
17451 TGGCAATAAA AGCTATAACA AAGTACACAA AGGAATCATC ATTGGGCATC
17501 AATAATTATT AAAGATGCTG GTGAAAGAA AAGACAACCT CAGTTTCATA
17551 AACACTAAAG AACCAAAAT ACATGACCTA GCTAATTATA CAATAATTCT
17601 TCAATATAAA AACTTCCTAG CAGGATATTA TGTGCCTTTT TATAATTTTT
17651 AGAAAGATGA ACAGTTAAAA TAGAAAATGG AGTGGTCAAG TTAGCCATCT
17701 CATACTCAAA ATTATTGTAC AGTTCATTT CTATGTGTTG GCAGTGCATT
17751 TTATGTGACA AAAAGTAGAA TGTAGGGGGA GGTTTAAGTC AAATATCTAT
17801 GTGATCTTTT CACTTATAAT TTGCATTAG TTAAGGAGTG ACTACTCTGC
17851 CTTTACCTT TGTGCTGGCG GTGGTTTTTT AAAGAATCAA TTTGGTGTAC
17901 AAATCCTTTC TTTCTTTTTT TATTTTGTAT TTTTTTTGAG ATGGAGTTTC
17951 GCTCTTGTG CCCAGGCTAT AGTGCCATTG CACTATCTCA GCTCATTGCA
18001 ACCTCCGCC CTCCGATTTA AGCGGTCTC CTGCCCTCAGC CTTCTAAGTA
18051 GCTGCGATTA CTGGCATGCG CCACCACACC CAGCTAATTT TTGTATTTT
18101 AGTAGAGACG GGGTTTTTCC ATGTTGGTCA GGCTGGTCTC AAACCTCCGA
18151 CCTCAGGTGA TCCACACGCC TCAGCCGCC AAAGTGCTGG GATTACAGGC
18201 GTGAGCCTCC GCGCCCGGCC CAAATCTTTT CACCATGGGT TTACAGGCAT
18251 AACGCCACCA CCCCAGGGA ATTTTAAAA TGTTTTTTAG AGAGGGGGGT
18301 CTTACTATTT TGCTCAGGCT GGCAACTCC TTTTAAAGA TATTGAAAGC
18351 CATCTGGTTT ATTATTTTAA TTTCAAAATA TAATAATGGA AGAAATTTTA
18401 CAGTATTATA TACAATTTAC TGAGTCAGCT ATCAGTTCCT TTTTCTGATT
18451 TTTTCTAGT TGCCATTCTT GATATTTTCT AGGTAATCTA AACTGAGTTG
18501 TATTTTCAAG TACTCTTCAA ATACTTTAAA AAATTTTAAA TTGAGCCGTT
18551 TAATCTTTG CTTAAAGGTG ATGGGTATTT TATTTTCTGT ATGGCACCAC
18601 GTGATTTTAA ATTGAACCTC TCATTTATTA GTCATTTGGT TATAAATCTA
18651 GCATAGATTG CGCAGAAATT TGAGAGGGA GAAACTATAG CTTTCTTTC
18701 GGATGCCACT GGTGGGTAGC CTGTTTGGC TGTGTTTCT TATGTTAAAG
18751 AAGGGCTCTA CGTCCTGTCT GGAAAGGGCG GAGCTGGCTC GGACCGCCCC
18801 ACTGCCTTTC CCAGGACCTT CACTCGTCT GTCCACCAGC AGCCCCGCTT
18851 CCTCCAGGCC GGTGAGCTG TGGCCTAGCA GCATCCGAGG CTCCGCCCCC
18901 CCCACCCCC AGCGTCTGCG CTCTAGCGAA GGGGCGGAGC AGGGCGGTGG
18951 CGCGCTGACA CCTGGCGGCG GCGGAGGGCG GGCAGAAGGC GAGCGTGGGC
19001 TGGGATTGGC TGAGGCGACG CGGGTGGAGG GGGCGGGAAG GAGGCGGGGA
19051 GACGGGTTGT CGGGCTGGTT CCTGTGCTGG ATCCTGGGCG GCCTGAGGGG
19101 TACGAGAGCT CTGGGGGAGG GAGACGGCAG CGGCATGGCG GCCGGGTGTA
19151 AGACGCCCCA CCCTCCTCTT CCCTGTCTTC GCCGCCGCG CTGCTGGAGT
19201 CACTGGGACC CTCTAGTCTG CGTGTGTTAG TTGTAATCCC GCCGCCCTCC
19251 TGTAGCCCT CCGCTCCGCC GGCCCTCCTT CCTTCCGCG CGCAGCCAG
19301 CCCGAGGGT GCGCGGCTGT GTAACACTCT CCCACCCAC CCACAGCCCC
19351 GCGGGCCAGC ACCATGGAGG ACGTGAAGCT GGAGTTCCCT TCCCTTCCAC
19401 AGTCAAGGA AGACGCCGAG GTGAGTCGCT CCCGTGGCTG CCACGCACAG

```

FIGURE 3

11/32

```

19451 GCCTCTCCCT GTGGCTCCGG CCGAGGGGCG ACCCCAGTCC CCAACCGTCT
19501 TAGCCGCCAC CTGTACGGGC GCCCTGCCTC CTAAGGGCGT CCCGGGACCT
19551 CTGAAGCCGA GCGGTCGGCT CCAATCCCCA CTGAGTTGCT CGTCTCTCTC
19601 AGACCCCGCG GAGGGGCAGC GTCTGGTGT CTTACATTG AGAAGAGGAA
19651 AAGCAATCCC TTAGTCCCTA GGCTTGGCAT CCAGGACTGA CCTGGAGTAA
19701 GGTTCCTCTT TTATTGTCAA AGTAACAAGA GAGCGAAGTT GGTTTAGTCT
19751 CCTTTTGAGG AATATCTGTG GTGTAAACGA TTCACTGTG GGACACATGG
19801 CCCCACATGT GAAATAGACT CGGCGCCTGA AGTTTGAAG CGCGCCTTCG
19851 AAAAGTTTCC CAAAGTTTTT TGTGTGTTT TGGACAAAGC TATGACCCGC
19901 ACAACAAAGT GTCTCAAAGC TAGCTCATCT TAATCTGAGA ACTCTTAATC
19951 AGAAATCTTG ACCTTTGGAG GAAAATTAAT ATTGAAAGTA AAATACTATA
20001 TACCTTTTCT CCTGGTTTCT AATTTGTGGC TATTTTACT CCACCTTAGA
20051 TCCCTGCCTG CTGTTTCTAC TCGGATTTT TTTCACTGT TGCTAGTTTA
20101 ACATTTTACG GCATTGCAGA CTAATAAAT AGAATTTTCT GGAGGCTAAA
20151 TTAACAAGAC GAAGATACTC AGCTATACTT TAGTAGGATT AAGAAAGAAA
20201 ATCTAACATC GCTAGTTAAA AATACCTTTA AAGTAGTTGG GAAAAATAAA
20251 GCCCTATTTT TAGGAGACCA TTCAATTTAT TCCGAATATT TATTCTATTG
20301 AATATCTTCA TTGGAGGTTT ACTTTTTTTT TTTTTTTTTT TTTGAGACGG
20351 AGTCTTGCTC TGTGCGCAGG CTGGAGTGCA ATGTGGCGCG ATCTCGGCTC
20401 ACTGCAACCT CCGCCTTCCG GGTCAAGCG ATTCTCTGCG CTCAGCCTCC
20451 TGAGTAGCTG GAACTACAGG CGCGCACCAC CACGCCAGC TAATTTTGT
20501 GTTTTLAGGG GAGACGGGTT TCACCATTTT GGCCAGGGTG GTCTCGATCT
20551 CCTGACCTTG TGATCCGCCG GACTCGGCCT CCCAAAGTGC TGAATTTGCA
20601 GGTATGAGCC ACCGCGCCCG GCCTAGGTTT ACATTTTGT TTTGAGGGCT
20651 CTCTTGTTGG ATTGATGCTT GACAATTACA TTTGTTTTAA GAGTAGAGAC
20701 TTTGTTTGTG ACTATCACTG TTGCAAAATG TAGTGCACTG GTGTGATCTC
20751 GGTTCCTGCT AGTCTCGAAC TCCCATGCTC AAGCCATCCT TTCACCTCAG
20801 CCTCTGGAGT AGCTGGGACC ATGCCGGGCT AATTTTCTT TTTTTTTTTT
20851 TTGTAGCGAT GGGTTTTTTC TCCAGGCTGG TCTCGAACTC TTGGCCTCAA
20901 GATCCTCCCG CCTGTCTCTC CGAAAGTGT GGGATTACAG GTGTGAGCCA
20951 CTGCACCTGG CCCAAGAATA TACTCATGGT TTTTTTGT TTTTTTTTTT
21001 TTTGACACAG AGTTTCACTC TTGTTGCCCC AGGCTGGAGT GCAGTGGCGC
21051 TGTCTCAGCC CACCGCAGCC TCTGCCTCGG GTCCCGGTTT AAACAGTTCT
21101 CCTGCCTAAG CCTCTGAGT AGCTGGGGAT TACAGGCGCG CACCGCCAGG
21151 CCCAGCTTTT TTTTTTTTTT TTTTTTGAGA CAGAGTCTCA CTCTGTCGCC
21201 CAGGCTGGAA TGATCTTGCA GTGGTGCGAT CTGGGCTCAC TGCAAGCTCT
21251 GCCTCCCGTG TTTCAGCCAT TCTCCCGCCT CAGCCTCCCG AGTAGCTGGG
21301 ACTGCAGGCA CCCGCTACCA CACCGGGCTA ATTTTTTTGT ATTTTATAGTA
21351 GAGACGGGGT TTCACCATAT TGGCCAGGAT GGTCTCAAAC TCCTGACCTT
21401 GTGATCCGCC TGGCTTGGCC TCCCAAAGTG CAGGGATTAC AGGCGTGAGC
21451 TACCGCGCCC GGCCAATATA CTCTTAGAAA ACAGGAGGTC ATATTTAGGC
21501 TAGTTATAAA AATGAATTTA TACTTAACAT ACAATAATGT GAATGAAGAG
21551 FATGCTTTTA TTTATTTATT TATTTTTTTG AGACGGAGTT TCACTCTTGT
21601 TGCCCAGGCT GGAATGCAGT GCGCGCATCT CCGCTCACTG CAACCTCCGC
21651 CTCCACGCTT CAAAAGATTC TCCTGCCTCA GCCGCTGAG TAGCTGGGAT
21701 TACAGGCGCC CGCCACCACT CCGTCTAAT TTTTGTACTT TTAGTAGAGA
21751 CGGGGTTTCA CCATGTTGGC CCTGCTGGTC TGGAACGCCA GACCTCAAGT
21801 GATCCGCTCG CCTCGGCTC CCAAAGTGCT GGGATTACAG GCTTGAGCCA
21851 CCGCGAAGGA GTATGCTTTC ATATCCTCAA AATGATTGAG TAATTTGAGC
21901 ACTTAACTGC AAGCAACCTT ACAAATAATG TAGAGGAGTC CCACATTCCA
21951 GGTGAAGAAA TTGTACCTTA CTGAAAATAA GTGATGTGCC AAATTAACAA
22001 CACAGTAGCA CAAGACACAG AAGGACCTCG GCCTCCTAAT TCATTGTTCT
22051 TTTTAATACA CTTCAATTCT TCCCTGCCCT AATCTTAAAA ATTCTAGTTT
22101 AAAATTTTCC CGGACTTTGC ATTTAATCTG TTAGTGTTGA TATCATTTAG
22151 TATGCTTTAT TCCTGCAAAA CTGATAAATT CTTGCTGGGA ATATATACCT
22201 GTCTTTTCTG TGTGGGACTT GAAAACACAC TCTTTTTTTT ATGCTACCAG
22251 ATGTGTGGGG GTTTTTCAT ACCAAGCAGT TTTCCAGCAG GCATGAACCTG
22301 AATGTCCCAT AATTCAATTC TGACACATAT GTACCTGAAG TTAGTCAGAT
22351 CCCACAGGTT AATGGGCTCA GTCCCGCAAG GCTGCCCCCA ACCTCAGATG
22401 GTAATCACAA GTAGTAGGTT GTCACCTATA CACTCCTGAC TGACTGTAAA
22451 TCAGGGTTCC CGTTACTCCC TCCTTGGTTC AGTTAACTTG CTAGAGTGAC
22501 TTACAGGACT CAGGGAAGTA CATTTACGGG TTTATTATAA AGGATACTAC
22551 AAAAGATCAG TGAACAGCCA GTAGGAAGAG ATGAATAGG CAGGATATGG
22601 GGAAGGGGCG ACACCACCAT CCCAGTGTCA CCAGTAGAGT CATGATTGCA
22651 AGCTGTCCAG GTTCTTGCGG TTTTGAACAA AGAATTGGAC AAAACTCCAA

```

FIGURE 3.

12/32

```

22701 GCAAAGAAAG AATGAAGCAA CAAAAGAACA AAAGCAGGGA TTTATTGAAA
22751 ACAAAGTAC ACTCCACAGT GTGGGAGCTG CCCTAGCAGC ACTCCCCCCC
22801 GACCCCCGCT GCTTTACCGA ATCTTCTTGG GTCCAAATAC CCCCTAGAAG
22851 TTTCCCATG GCCATTCCAT GCTCACCTCA TGTAATGAA GAGGTGGCTT
22901 GCAATTGGTC TGATTGGTTG CCAGACCCAC CCCACATCA GTCCGCTTGG
22951 TTGTGGACAG CGACCATTCA GTGGCTAGAG TGAAGTTACA AAGTTGCAAA
23001 CGAAGATTCC ACCCGCAGTC AGTCTGATTT GTTGAGGACA GCCAATTTC
23051 CGTCTACTGT GCAGAAAAGG TAGGTGGTTT GCAACGGGAG TAGCCTCTGG
23101 TCCTTTTGT ACTTAGGCGT GGAAAGTTAG GGTTTTCCCT TCAAGTTAGT
23151 TCTGGGAAGT CCGGGTGAAA CAGCCTTAGA TTCCCTGCCT CCAGACCTTA
23201 TCTACCTGCC TCACTAGCAC CTCAGTGTT TTCATCCAGA AGCTCAACAA
23251 ATCTTATTCA ACGGTTTTTA TAGAACTTCA TCTCCATCCC CTCCCATAGA
23301 GGTGTGTGTG TGTGTGAGGC TGAGAGTTCA ACCCTCTTGT CACATGGTCT
23351 TTCTGGTGAC TGGCCCCACC CTAATCACT TCATTAGCAT AATCAGGTTT
23401 GATCAAAAA AGTGGCTCAT AAATAACCAA AGACACTCCT ATTAGAAAA
23451 TCCAAGAGTT TTAGGAGGAC TGTGACAGGA ACTGGAGAGA AAGACCATGT
23501 ATTTCATATT ATATCACAGG GACAGAGGTA ATGGTTAAAG CTAGTGGATA
23551 ATGATGCAAG TATTGTCTGC TGAAAGCCAA TTCGTTCCGT ATTTCTTAAT
23601 ATTGCATGTT TGGTATCTTT TGGTTGCAAG CAACAAAAAC GAATTTAAGA
23651 AAAAGAAGAA GTAATTAAAT CCGGCCGGGC GCGGTGGCTC ACGCCTGTAA
23701 TCCCAGCACT GTGGGAGGCC GAGGCGGACG GATCACGAGG TCAGGAGATC
23751 AAGACCATCC TGGCTAACAC GGTAAACCC CGTCTCTACT TAAAAAATAA
23801 TTAGCTAGGT ATGGTGGCGG GCGCCTGTAG TCCCAGCTAC TTGGGAGGCT
23851 GAGGCAGGAG AATGGCATGA ACCCGGGAGG CGGAGCTTGC AGTGAGCCGA
23901 GATCTAGCCA CTGCACTCCA GCCTGGGAGA CAGAGCGAGA CTCCATCTCA
23951 AAAAAAATAA AAGTAATTAA ATCCAGAAGG GTAGTGGTGC AGCTAGTTTC
24001 AAGATTTGA CCAAAACCAG GTATTATAAA GCATCAGAAC TGCCCTTTGTC
24051 TCTCATGAGT TCTTATCTCT ACTTTCTCTC AGAGTCTCTG CTTTCTCTCT
24101 GCGTCTCTCA AGATGTGAAG CTTGGCCATC TGGGGTCAAC CCTTTATGAG
24151 CTTGGTTATT GAGGAATAAA ACTGAACACT TCCAGCTTCT GTGTTTGAAA
24201 TCTAGAGGAA TTGCCCAATT TAATTATGTT TCCACACTT TGGATCAGTC
24251 ACTGTAGCCA GGAAGGGGCA GATACAATGA GGGGCCCAT CTAGGTCATA
24301 TCCCTAATTC CTTGGCTAGA GGAGTGAAGT TTATTGTTGG TAGCCCTCCC
24351 ACCAAAACCA TAGGAACATT TCCACAGGTA GAGGGTACTT TCTGGGCTGA
24401 TAAACTATA CATAGGGGCC ACATAAATAA ACTATTAAAT AGGAGCATAT
24451 AGTTATTCAT AATAAACTGA CTAATAAGCA CTGTTAATTT TCTAATCTCC
24501 ATGAGATGTA TGTAAAGTGT CAAATGGTCT TAAGTAGTTA GAGTGATCAG
24551 CCAGCATTGT TTCTTTGACA CAGGGAGCAC TACCTGGAAA TCCAAATTAC
24601 AGACCAAAAT TAATAAAAC GGAATTCAAG CAGAGAGTTC AGGGAATGCT
24651 TTTAATGTTA ATGTGATCAA GCTATGATAG GTTGATGATT CTGTCACTTC
24701 TACAAGAATA TTACTTTCAC GTTCTTGAA ATATTGGTAT TCTTTGTATA
24751 GGACAGTGCT AACAAAAATT TAGATCAGTC AGTTTGTGAA AAGATTGTTA
24801 CTTTTTTTGT TTAACACTTT TTCATGAATT TCCATTGTTT TGAAGATGAA
24851 ATTTAAACCC TTGACATTAT TTCCAGGGTC CTGTATGGTC TGACATCTGC
24901 ATACCTCTCT AACCTCATT TGAGCTACTC TTCTTGCTCC TTTCTCTGTA
24951 AGCCCTAGCC ATATTTATCT TCTCTCAGT CCTGGAATGC TTAATTTCC
25001 ACCCCCCGCC TTCAGAGCCT TTATGTTTGC TATTTTCCCC TGCCCTGGCT
25051 GCCAGCACCT TCCTTACCCT CACCTAATTA ACTGCTTACC CTGGGGTAG
25101 ATCCCACTTT AGGCAACATT TCTTCAGAGA AGCTTTTCCT GTTGGCCAGT
25151 TTCTCTAACT CCTTTCCTCA TCCTCTAGAC TGGTTCAATT CCCAGCTAC
25201 TATGGCACTT GGTACTTTAA TACTTACCTT TGTAACATTT AACAAATTTT
25251 GGTCATTGTC TATTTTCCAT TTAGACTGAA CCTTTCATAA GAGAGCTTAG
25301 ATATTAGGAA GAAGGAGTAG CTGATAGTAC CAATTTTTTA GCAAAATGGT
25351 TGTAGCTGGG GCTATTGGTT TTATAATTTA AAAGTTAATG TTTTATCTTC
25401 TCTTCTGACA GAAAGTGAAA TATTTATTTT CATTGCAGTT TAGCAACTTT
25451 CCATGTTTCC CTTTCCATTT TTCTTGTAAG TCCCGTAGTA CAGGATCAAA
25501 GATAGGAATT ATTTAACATA CATGGCTGAG GATTCCTTTT CTAGCTCCTT
25551 TATTTAGAAT GGTGCTTTTT AACCTTACT CTAGAGTAAG GAATTTTTTA
25601 AAAAFACTGA TGCCTGGACC CTACCAGCAC CTATTGTAGT TTAATTTATC
25651 TGAATGAAGC TAGATGATTC TAATGTTTCA TCAGGTTTAA AAATGCTGG
25701 TTTAGAAAAT ATCTTGAGTA CTCTTCTGCC CCTCCAGTCC CTGCCCACCT
25751 TCTCTTTTTT TTTGAGTGAA ACATTTTCTT TTCTCCTTTG ATTTAAGCAA
25801 AGCTCAAGCT TGGTGTGGGA ATGAAAGGAA AAGGACTTTG GAGGGATTTA
25851 CCTATTTTTT CTAGGAGAGA AAGTGCAATA CTAACTTTTT TGTTTTGTGG
25901 AATGTCCAG TGCAAGTCTA GTATTCTGAT GTTTTTTTTC TTCCCCAAC

```

FIGURE 3

13/32

```

25951 TGTGTGCCCC CACCTCCAGC CTATGTACAA TTTGTGTTTT ATTTTAGTAT
26001 TGTGTATATA GGATTCAGCA CTATCCTCAA ATGTATGAAC ATATCCCCTG
26051 TGGATAAGGG GGGACTACTG TATTTGTAAA AGTTCATATT TCATATTTCA
26101 ATGCATATAA GAATTATTTT ATCTAATGGT TACAGTCTAT ATCCTTCATT
26151 GATGTGTTTA TTTGAGGGTC TTTGAACATT TTTGTAACCT TTCTCTATCC
26201 AAATGCAGTT TTATAGATCA TTTTATGGA AAGGAAGGAG ATAATTCGGA
26251 AGGATGTTTT AACATGTGGT ACTTCTACC TCATGTTGAT CGAAAGATT
26301 TCACTTGTGA ATTAATTTGT CTCAGAATCA TGGTGTTCa CAATAGAGGG
26351 TTATTTTGGT TTATCTGGCT TGCCTTGGTT TGGTTAATGT GGTGAACTG
26401 CTTGGCTACT CATAAAGTTT GGGAAATTGA TTTCTACTAA TTAATTACAA
26451 TAGTAACTTA AAATAGATCA TTGCTGGTGA TATGGAGATG CCTCCATTAA
26501 TACCACGGTT TCTAAATGA TAGATTTTcAG GAGTAGTGTG AGCAGGCTGA
26551 GATTAAGAAT TAAGTGTGAT AGTGGCAAGA CTGGGTATT AGACGTGTGT
26601 TCAGACGGAT GTGTGGTAGA AGAAGACTAT GAGCATTcAG ACTTAAATC
26651 TTGGTTAGTA AGATCCATAG ACAGGCAGGG TTTTTTGTG TGTGTTGTTG
26701 TTTTAAcAGG TTGGAGTGCA GTGGCAGGAT CTCAACTCAC TGCAAGCTCC
26751 GCCTCCCGGG TTCACGCCAT TCTCTGCCT CAGCCTCCCC AGTAGCTGGG
26801 ACTACAGCGC CCCGCCACCA TGCCCGGCTA ATTTTTTGTA TTTTGGTAG
26851 AGACGGGGTG TCAACCATGT TAGCCAGGAT GGTCTCGATC TCCTGACCCCT
26901 GTGATCCACC CTCTTGGCC TCCCAAAGTG CTGGGATTAC AGGCGTGAGC
26951 CACTGTGCCC GGGCAACAGG CAGGTTTAAg GTTTGTCTG TAGGTGGTAA
27001 TCTGGGTTAG GGCAGCAAAG AAGGTGGATT CTGAGATCAG CATCTGATGA
27051 TAACACCAGG AATAGTTCCA AATGAACTTT TCTGTGAGAG AAAGCTTTCT
27101 AAGTTTCAAA GGATCCATAC CTATTGCAGT AATTACTAAT GTTCTCTGAA
27151 GAAGGCTTCT TATCTGTCCT GTGACTAGGA ATAATTTTTC ATTCCCTCCT
27201 ACTATACAAC TTGCTTTTCC CTCTTATAAT ATCTTCCATA TATATATATA
27251 TCTCAAGAGA GTCTTTCATG TTGTATTACA TATAACCTTA TGGAAAGCTC
27301 AAAAGTTCTT TGAAGCCTCT TGTTTTGCTA AAAGGTCAG GTAAATTTTG
27351 CATTCTATCC CATATGTGCC TGTTTGTTT AATATAAAAA TTGTTTAAAT
27401 TAGTAACCAG TGAAAATACT GTTCTCCCT AAAGAATTTT TTTGATAAAA
27451 TTGATACTTC AGTGGCTTTG AGTGTCTTTT GGCATATTGC CAAATGAAGG
27501 TGTTGAGGAA ATGCCACTCC AAAATATGAC ACCTTGATAT ATTGATTACT
27551 TTAAGTTGGA AACACTTGCA AAGTAGCAAA TGCAAGAAA CACTTCTCT
27601 GAACTCTGT TACCTACCTA AGGACAGATC CTCCAAAAGA AGCTCAATTT
27651 GCTCCTAGGG AGTTTGATCA ACCAGGGAAG ATTGTCTCT ATCACTGGAG
27701 AGGAGAGTAA AAGTCAGCAC CACACCCAGA CAAACTGACA CAAAGTATCA
27751 TCTATTATTA TTCTAAGGGC CCATTTATCT TTCTCCAGAA TTGTTCTTCT
27801 AAATTGCCTG TATACCTCTA CCCCATGCT ATATAAAGG TATATAAACT
27851 CCTAAATATC ACTTTTTTTT TTTTGTATA CACGTTCTT TCCTGTGATA
27901 CCCCATGCA CATAATGAAT CTGTATACCT TTTCTCCGT TAGTTTATT
27951 CTAGACTGG TTTGAAATAT CACGGATTTT GTTTGTTTT GTATACACT
28001 TTTTAAAAAT ATCACTTTTT TTTTTTGGT ATACACTTTT CTTTCTGTG
28051 ATACTCCCAT ACACATAATA AATTTGTATA CATTTCTCC ATTTAGTTTA
28101 TTTCATAGAC TGTATCGAA TCCTGATGGT AGAGGGAAAG TCTTCTTGC
28151 CTTACACAAG TATTTCCAG AATATATTTA CACCATCTCT TGATATGTGT
28201 TGCCCTGTTT TTTTTCTTT AATTACACAA AATTTAGTGA TTTCACTTTA
28251 GATAAATTCA AAAGTACGCA TTTCTTTAAT TGATTTTCTT CTTTATCACA
28301 GCTCTGACAA GTTGCTTCAG GAAGATAAGG CTGGCTGTTA GACTACTTGA
28351 GAATCTTTTA AAAAGAAAAA AGTCAATAAC ATTTAGTGCA GTAGATCTCT
28401 GAAATGCATC TATTTGTGc TTATTCTGTG TCAGGCACTG TGCTTATCAT
28451 TAGGGGTACC ATGACTAAAA AGAGTATTG GCCTAAAGTC TTTAAAAACT
28501 GTTTCTTTTT TCCTTCTTT CTTTTTTTTT TTTTTTTTTT TTTCGTTGAG
28551 ATAGGCTCTG TCTCTGTTG CcAGGCTGGA GTGCAATGGC ACCATGATGA
28601 CTCACTGCAG CCTCGACCTC CCAAGCCGGA GTGATCTTCC TGCCTCAGCC
28651 TCCCAAGTAG CTAGGACCTC AGTCATGCAC CACCACCGCA CCTGGCTAAT
28701 TTTTTAATTT TTGTAGAGAT GAGGTCTCCC TATATTGCCC AGGCTGGTCT
28751 TGAACTCGGG CTCAGCTAT CCTCTGCCC CAGCCTTCCA AAGGCTGGG
28801 ATTGCAGGTG TGAGCTACCA TACCTGGCTA AAAAActCAT ATATAAAAAG
28851 ATTACCATAA CACATTGGTA AGTTAAAGAA TCTAGGCTGG GCGCGGTGGC
28901 TCATGCCTGT AATCCCAGCA CTTGAGAGG CCGAGGCAGG TGGATCATGA
28951 GGTcAGGAGT TCAAGACCAA CCTGGCCAAg ATGGTGAAAC CCCATCTCTA
29001 CTA AAAAATAC AAAAATTAGC CAGGTTTGGT GGTGGGCGCT TGTAATCCCA
29051 CTACTCAGG AGGCTGAGGC AGATAATTGC TTGAACCTGG GAAGCGGAGG
29101 TTGcAGTGAG CTGAGATCGT GCCACTGCAT TGCACTCCAG CCTAGGCGAC
29151 AGAGCGAGAC TCCGTCTCAA AAAGAAAAA AAAGTATCTA GTAAACAATT

```

FIGURE 3

14/32

```

29201 ACATTTCCCT CATTGCTGGC TTAGAAATTA CATGCTTTAT TTCTATTCTG
29251 TTAATATCCA TAAATTAGTC ATTATTTTAT GCAGCCAATA TTTGTTTAAT
29301 TGTAACGTGA TGTTGCCGT AAAGTTCATT CTTACATTGA AAGACTGTAT
29351 AGTATATTGA TTCAGAGAAT GAACTCTGGG TTCAGACTAT CTGGATCCAA
29401 AATCAAGTTA CTTAGGTTCT CTATGACTAA AATAGACAGT GATAGTATCC
29451 CTCTTCAAAA GAACATTTTA ACTTTTTTTC TTAAAGATA TTTTCCGAG
29501 CATATATTCT TAATTAACAG TTGTTTTGT CCTGCCACTA TGAATGAATT
29551 ATTTGTGTCC TCTGGCTTCT GTTCATGCAA TTGAGAAGTC AGTGTCCATC
29601 TGATTGTCCT TCCTTTGTGT GTAATCTGTC TTTTGTCTAG TTGATCTTTT
29651 TTAATAAAGG TAAAATTTAT ATAGTGAAT GTACAAATAG TAAGTGTGCA
29701 GTTCATTGAG TTTTGATGAA CATACACTAA TCCACCCCAT CAAGATACAA
29751 GAACATTCTA TTAGCATAGA AGGTTACATC TATTTCCAGG CATTTCTCTC
29801 CCCATTCCAC AATAGGAAC CAGATTTCTA TCAACATAGA TTAGTTTTCC
29851 TTGCTCTTGA ACTTGATACA AATGGAATCA TGCAAATGGA CTCTTTTGTG
29901 TGTGGCTTTC TTCACTGAGC ATAATGTCAA TGAAATTCAT CCATGTTGTT
29951 GTGTTTATGA GTACTTCGTA GACTTTTATC CCTGAGTACT ACTATTCCCT
30001 TGTATGAAGA GACCATAGAC ATTTGAGTTC TTTGAGACTA CAATAAATAA
30051 AGCTGCTATA AATATTCATG TATAAGTCTT TGTGTGGATA TATGTTTTTA
30101 TATATATATA TATATTTTTT TTTTTTTGG TAAAGCCTAG GAGTGGAAATG
30151 GCTAGATATT ATAATAGGGT AGGTGTATGT TTACCATTTC ATTTTACATT
30201 CCCACCAGCA ATGTGTGAGA GTCCAGTTG CTCACATCA TCACCAGCAT
30251 TTGGTGTGT CAATTTTTTT AACTTTAACC ATTCTAATGG TAGGTAATGA
30301 TATCTTTTGA TTTTACTTTT GAGTTTCGTG TGTGTGTGTA TGAGAGATGG
30351 AGTCTCACTC TGTCACCAG GCTGGAGTGC AGTGGTGCAA TCTCGGCTCA
30401 CTGCAGCTTC CACCTCCCAG ATTCAAGCAA CTCTCCTGCC TCAGCCTCCC
30451 GGGTAGCTGG GACTACAGGC GTGCCACCTC CATGCCTGGC TAATTTTTAT
30501 ATTTTTAGTA GAGACAGGGT TTCACCATGT TGCCCAAGCT GGTAAACTTC
30551 TGAGCTCAAG TGATCCGCCT ACCTCAGTCT CCCAAAGTAC TTGGTAATTT
30601 ACAGGTGTAA GCCACCGCAC CTGGCCTATT CACTGATTTT TAATTTCAAT
30651 TATACTTCTT ATTTCTACAT ATTCTGTGTT TTTAAAAATC AATTTCTTAG
30701 TCTGGTCATA TTTTGATACT CTAATTTCTT TAAATTTTTT ATATTTTTCG
30751 TTATTGCTTA TAATATCTGC AGTTTTGTAA GTGTAACCA GTTGTCTCTG
30801 CTTCTGTGG TGGCTCATTT CCTGTTTTTA AATTAGTTTT TGATTGTGAG
30851 CTTGTTGGGA CTTTATCTGT GTGAATTATT TCTGATCTAG GTTTAAGGTG
30901 TGTTTTTCTA GAGAATATGC ATTTGCTTCT TCCAGGAATC CAGGGATGCA
30951 ATCTACCCAG GACCACTTAC ATTAAATCT CACTGGCCT CACAAAAGTA
31001 ACTGAATTCT AACCCCAAAC TTGAGTGGAT GCCAGATTGT GGTAGGAAG
31051 ACCCACTCC ACCACTACCA ATACCTACCC AGAGCCAAAG CTAGGAAGGA
31101 CAAGAGTACT CACTTCTGTG GGATGAGTTG AGTTTTTGT TTTCTTTCTT
31151 TCCCTAGTTT ATCTTTCAC TGGATGTTG CCTTTGGGAG TTCTAGCTTT
31201 TTGGTCTTGA TCTGAGTTCG ACTTTGAGCA GATCATAGAC TTTGCTTAT
31251 GTTTACAAGT ACGTTTCCAC TTAAATAAG GCCGTAGTGA AGATGTAGAA
31301 CAACTAGAAG TCCCATACAT TGCTGGTGGG AGTGTACAGT GGTTTTACAA
31351 AACTTTTGGC AGTATCTAGT AAAGCCAAAC ATAGGCCTAC CCTGTGTCAA
31401 AAGACAAAT TACAACAAAT TTAGCTTAAA AATCTAACTC ACTTTTATTA
31451 GTGGTTCATG AATCAGGCAG TGTGTCATCA AAAGATTTAG AAAAGGCATT
31501 TCAGTGTGCT GAGCAGAGGA AGTTGAATTT ATAGGCAAAA TCTAGCTAAA
31551 TAAAGCAGAA ATGAAACAAA AAGTGGATTG GTCATTTCAA AGTTAGTTTC
31601 TTTATAGTAT TAAAACACAG GGGACTTCCT TATGCTGGCT CAGGATAACT
31651 GGCCTCCTTC TGATTGATTG CTATGAATCT TTTGATTTTT TTTTTTTTTT
31701 TGAGATGGAG TTTCACTGAT GTGCCTAGG CCTGGAGTGC AATGCCACGA
31751 TCTCATCTCA CTGCAACCTC CGCTTCCAGG CATCAAGGGA TCCTCCTGCC
31801 TCACCCCTCC ACGCAGCTGG GATTACAGGC TCCCTCCACC ATGCCTGGCT
31851 AGTTTTTGTG TCTTAAATCT AGAAGGACCC CCACCCTGCA GCCCAGGCGA
31901 CAGACTGATA CCCACCTAA AGAGATCCAC CCGCCTCATC CTCCCAATTT
31951 GCCAGGGGGC AGACTGCATT CCACCGTCC CTGATTTGGG TGCTTAAAC
32001 TCAGAAATTT CTGGGGATT TTGGTCTCCG ACGTTATCGG GGAAAACGTG
32051 TTTTAACTT TATTTTGAA ACAATTTTAG GATCTTTGAA AAGTTGCAAA
32101 AATCCTCCAT GGAATTCAT TTACCCCTTC CCCAGTTTT TTCTTAGNNN
32151 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNGG
32201 TCCCGCCCCA TGCTGGCTA ATTTTGTAT TTTTAGTAGA GATGGAGTTT
32251 CACCATGTTG GCCAGGCTGG TCTCAAATTC CTAACCTCAG GTGATCCACC
32301 CGCCTCAGCC TCCCAAAGTG CTGGGATTAC AGGTGTGAGC CACCGCGCCC
32351 GGCTTTTGA TTTTTTTAAA CTGTCATTAC TCGGGGTTTA TAGTCTACTA
32401 CTATATTGCT GAGAACAGTT TTCAAGATTA AAAATAAAAA TGTTTTCTGT

```

FIGURE 3



15/32

```

32451 TTCTCTTAGT TAAAAAAAAA AACCTGTCTC TCATTGTAGG ATTATTATTC
32501 TCTCTTTTCA TTATAGATGT ATACTATTTC TACCTTCTGT GTTAAAAATA
32551 CTTTTCTGGG CCGGGGGCAG TAGCTCACTC CCGAAATCCC AGCACTTTGG
32601 GAGGCCGAGG CGGGCAGATC ACGAGGTCAG GAGATCAAGA CCATCTTGGC
32651 TAACACGGTG AAACCCCGTC TCTACTAAAA GCACACAAAA AAATTATGGC
32701 GTGGTGGTGG GTGCCTGTAG TCCCAGCTAC TCGGGAGGCT GAGGCAGGAG
32751 AATGGTGTGA ACCCGGGAGA CGGAGCTTGC ATTGAGCCGA GATCGCGCCA
32801 CTGCACTCCA ACCTGGATGA CAGTGTAAAG CTCGGTCTCA AAAATAAAAA
32851 AAATAAAAAA AATACTTTTC TGACTTAGAG AATCTGGGTG AAGGGTAAAT
32901 GGAATTCCTT GTACTATTTT TGCAACTTTT CTATAATCCT AAAATTGTTT
32951 CAAAAATAAA GGTAAAAAAA ATATTTTCCA GACTACTTCA GAAACCTAAT
33001 TACTAATAAT AATTCTGAGT TTTAAGCAAC CAACTTAGAA ACTTTTGGAA
33051 TGCAGTCAAC CCACTGACAA ATGAGGACTA TCTGTACTAT AGTATTTTTT
33101 TAGACGGGGT CTCAGTCTGT CACCCTAGCT GGAGTGGTGG GGTGATCTCA
33151 GCTCATTGCA ACCTCTGCCT CCAGGCTCA AGCATCTTC CCACCTCAGC
33201 CTCCTGTGTA GATGGGATTA CAGGCAGGCT CCACCATGCC CAACGAATT
33251 TTTTGATTTT TTAGTAGAGA AGGGGTTTCA CCCTGTTTCC CAGGCTGGTC
33301 TCAAACTCCT GAGCTCAAGC AATCTGCCTG CCTCGGCATC CCAAAGTGCT
33351 GGGATTACAG ACATGAGCCA CAGAGCCTGG CCTTTTAGTC TATTTTCGATT
33401 CTTCAATTCA ATTCACTATA CTTTTTTTCT AAGTTTAAAT ATATTTTTTA
33451 TCTTTTACCA TTGACATTTT GTGTGTGTTT ACAGCTTCTT TATATTGGTC
33501 TGCATTCCAA AGACAAAATG AAGTCTCTTA TGTTTTGTGA TATGTGTTAA
33551 AATAATTGAA CTAGACAAGA ATGTTAGGCC CAAGTGAGAT GAAGGAAAGG
33601 CTCTTTGATA AGCATTGGC ATTTTAGATC AGAGATGGCA AGTACGTATG
33651 ACATAGCATT CTTCTTTTAT ACATTTTCTA TATTATTTGT TGATCAGACA
33701 CTCTTCTTCC TGTCTTGGAC CACACAGTGT TTTAGGTATC TGCTGTCAGT
33751 TGATCAGAGT TGGCATGAGA AACAAAAAAA ATCTATTGGC ATCTCTGACT
33801 TAGAAGATCA GTTTTGGGAG AATCTTCTGG AATATCTATT CTATTCTTAA
33851 GTTAAATGAG TAATTTTATC CATTTTATGA AGTAACATAA CAATTCTGGA
33901 AGCCTAGTTA TTTAAAGAAT GCTTTAAGCT TTGTTTCTTG TCACTTCAAT
33951 TTTTCAGATG TTGTGAAACC AAGTCTGCTA TTTTAAATAA ATGTTCTTAA
34001 AGTATAATGT AACTTTAAAA AATCTACATA CTTGTGTGTC ACATCTTTAG
34051 CCTTTAATTG GGTGACTTTT TAAATGTTAT CTACTTTTAT TCTTATGTTT
34101 TCCTTCCCAG GAGTGGACCT ACCCTATGAG ACGAGAGATG CAGGTATGGC
34151 AACCTTTTCT TTGTTCAAAC CAACCCATGT TATTATCATA ATAAGAACCT
34201 TAGTTTATAG GATTTGAGAC CTGCTGATTT CATGATCTGT AGGTTTATCA
34251 TTATGTATTT TAAATAATTA TTTTAAATAT TTAAGGTTAA TCTTGGATCT
34301 TAAAACGATG GGAAATTAGA AAGAGGAACG TAGTAATAGG TGTATGTGCT
34351 TAATGAGTCA CTTTCTCTTG GTTTTTTTTT TGTTTTTTTT TTTTGAAC
34401 AGAGTTTCGC TCTTGTGGCC CAGGCTAGAG TGCAATGGCA CGATCTCGGC
34451 TCACCCGAAC GTCCACCTCC CGGGTTCAAG TGATCTCCT GCCTCAGCCT
34501 CCCGAGTAGC TGGGATTACA GGCATGCGCC ACCACACCCA GCTAATTTTG
34551 TATTTTTAGT AGAGACAGGG TTTCTCCTTG TTCAGGCTGG TCTCACACTC
34601 CTGACCTCAG GTGATCCAGT GACCTCAGGT GATCCACCCA CCTTGGCCTC
34651 CCAAAGTGCT GGGATTACAG GCATGAGCCA CCGTGCCTGG CCAATGAGTC
34701 ACTTTTCTTT TCCTCACGTG AAAAATTGGA TACTTTCTTT GTATTCCTTT
34751 TGAAAGCAGT TTGCTTCTC TGTTGTCTA GATAAGTTAG GGAGAGTTGT
34801 CTGTACAACA AATAAGCATT GTTCATTTTG TGTCCGATTT TTAATCAACT
34851 TCCACAATTA AGTCTTCTAG AAGATCAAA TGAATACTTT CAGTTTGGAA
34901 TGAATTAAAC GATAGCTAAC CCTCATAGCA GTTCATTTTC TTTTGCATTT
34951 CATACCATTT ACCGTCAAGT CTGTTTGCCC CAGGATTAAG CAGTATCTTG
35001 TTCCTGGGAA TCCCATGACT TCTAAAAATC TGTTACTTTT CTCTCTTAAT
35051 GAAAGTTTAC TTTGAAAAAA TAGGTGAGTA CCTATGAGGC ATTTTACTTG
35101 GTGTTAGGAG GAATGCAAAG ATGACTAAAT GTAATTTCTG CCCACAAAAG
35151 CCTGGTGGAA GAAATCAGTT TTATATACAA ATAATTATGA CTTATAGAAC
35201 TGAATATAAA AGTTACTGTT AGTATCTAGG GTATGATATA TCCAGACTGA
35251 AAGCTTTCTG TATTGAATTT ACATAAAATA AATTTGAATT CAACATCTGG
35301 AAGGTACATA CTTGTTGAAA TTTTGTCAAC TGGCAAATAT TTGAATTTGG
35351 AATTTTATG TTACAGTAAT AATTGCTTC TATTAACAT AGATAATAGT
35401 TTTAGGTCAG GCACAGGAGT TCATGCTGT AATTCCAGCC GTTTGGGAGG
35451 CTGAGGCAGA AGGATCACTA GAGCCCAGGA GTTCCTTATC AGCCTGGGCA
35501 ACATAGTGAG ACTTCGTCTC TATTTTTTAA AGAAAAAAA AAAGATTAAA
35551 AAAATAGATA ATAGTTCCAA TCTTGTTGTA TCTTGTGCTG CTTTGTGATT
35601 GGCCAAATAA GGTGTGCTT ATTTATATAG CCTTATAGAT TTAAATTGCT
35651 GATGGTAAAT ACCTCAAATT TTTTTTTTTT TAGGAAATTT TACCTGGATT

```

FIGURE 3



16/32

```

35701 GTTCTTAGGC CCATATTCAT CTGCTATGAA AAGCAAGGTA TGAAC TTTGT
35751 TAGATTCATC AAGAGAGACT TTTATTAACC AACTTTTCTT GGGTAAGTTT
35801 TTTAGTAATA AAGAGTTTTA TTTTAGGGAG CATCCACAAA TACTGTCTGT
35851 TAACAGTAAT TGTCACCTCTG GAGTACCTTC CTCTTTCCCT ATTTTACTAG
35901 ACCAGTAGTT CTCAAGTGTT TCACCACAAA TCAGAGTTTT TGTTTTTTCC
35951 TCATGAAATT TGTA TGTTTG AAAGATTAC CAAATAACTG ACCTTTAATA
36001 ACTTATTAC TCTCTAAAC ACTAGACATC TGTAAATTGCT AATCATAGCT
36051 TCAGAACAAAT ATGAGATGTA GTTAAAGCCC AAAATAAGGA ATTTCAATGT
36101 TTAGTTAAAC CTTCCCTATC AAGGGTAAGA CTGTGTGTGT TAATTGAAAG
36151 TCATTCACCT TAGTTCTGTT TTGCCAGCCA GACTTTAGAG AGCTAGTTGG
36201 TATCCCCGCT CTGAAATTG AAAC TTTTG AGCACCAGTA TGCTACTCGA
36251 AGGAAATCCT CACTGGAGTA TTTCCGATT CGGATTTTG GATTAGGGAT
36301 GCTCAATTAT AAGTATAATG CAAATAGGCA AAACAAACAA ATCCAAACTC
36351 TGAATATTT CTGGTCCCTG GCATTTTAAA TAAGGGATAT TCAATCCGTA
36401 TAGATATTCT ACATAGTCAA ACTTTAATGG ACTTACTCAG TTGCAGTTAA
36451 AATAGGTAGA TCTCATTTTA ATAAATATAG CAATGTTCTT GCCACTTCTA
36501 AAAGATTCAA TGCTACTAAT TCTCTTTGAG TTACAACGTG GAACATATCA
36551 CAGATGTCTT TCCCAATAC TTTGCCTATT CAGAAGTCAG TATACTTAAA
36601 TTGTGTTTGA TATATCCATA ATTTAATTG ATGTTCTTAG GAATTTAACC
36651 GGTTTTAAA GGTCAATTGAT TTTGAACTG GAAGATTTT TTGACAGTTG
36701 AGACATGGCT AAGAGTAAAC CTGGTCATCT TGATGATTTT TGCTTAGTTG
36751 GAAAGATAGG GAGTTAGTAA AAATAAGTAC TAGGGAAAGG ATAGGGCAGG
36801 TAACTATAGA CATAGCCGTA ATTTATTTTG TAAAAGACAG ATGTAAACAA
36851 GGTTATTGTC CATATAATTT GCTATTCACC AAGTACTAGT CTTCCAGATG
36901 GTTTTAGATA ATTTACATTT TTGAAATTCC CACTGTACTT TATAAATATA
36951 CATACAGTAT TTATCACATT AAATTAAGT ATTTGTTTAA AGGTCTATCT
37001 CCTCAATGGG AGGCTGAGGC AGGCGGATTA CATGAGGCCA GGAGTTCGAG
37051 ACCAGCTGG CCAACATGGC AAAACCCCGT CTCTACTAAA AATACAAAAA
37101 TTAGCTGTTT ATGGTGGTAC ACACCTGTAA TCCAGCTAC TCACGAGGCT
37151 GAGGCGCGAG AATTGCTTGA ATCTGGGAGG TAGAAGTTGC AGTGAGCCAA
37201 CATGGCACCA CTGTACTCCA GCCTGGTTGA CAGAGTGAGA CTTTGTCTCA
37251 AAATGAAACA AAAACACGCA CAAAAAAGG TCTAGTTCTT CAAACTTCT
37301 TTTCTTGAAA TGTCAACATG GTCTTATTAG ACAGGAAAAG CCTCTGTGGC
37351 AGTTTATTTC CCACCCTAGG TAACCATAAT ATAGCCATA TTTCTTTTCA
37401 TACCATTATC TAAAAACAAC AACAAAAAT AATAATGGAG ATAAACCTAA
37451 ATGGATAAAC TCCTTTTAA ACACCTCATT ACTGTTATTA TTTTGTGGGA
37501 GAGGAGTGGG GTCTTGCTCT GTTACCCAGG CTGGAGTACA GTGGCGCGCT
37551 CTCATAGCTC ACTGTAACCT CAAACTCCTG GGCTCAAGCT GTCTTCCAC
37601 CTTAGTCTCC CAAGTAGCCA GGA CTACGGG CACACACCAC CATGCCTGGC
37651 TTAATCTCA AAGTTTTTGT AGAGATGGAG TCTGGCTATG CTGGCCACAT
37701 TTA CTTAAGT ATATCTTTTT ATTAATTC AATACAGTTT AAATAAAGG
37751 GACAAATTTA GGGCCTTTGT AATTAGTAAA CGGTTTGT TTGTAAAGTT
37801 TTTCTACTGT TTTTAAATGT GAGGTAAGGT CATAATTGCT TTCATATTAG
37851 GTTGGTGCAA AAGTAATTGC AGATCTGCCT CTGAAAAGTA CAAATCTAT
37901 TCGCTGTTAC GTTAGGGCTC TATTTTGATA GTTATTTTT ATTTAGTAGT
37951 AGTCTATTGG GCCTTCAAAA CTTGTTTAAG CATATTTATA CATAATTATG
38001 TGCATCGTCT TGTGCTTTCT CACATTCATA AAGTAGATAG GAAACTCCA
38051 TAGGCATCAA GTGTAAACGA AGGACTTAAT GTTGAATTTG TTGTGGAAT
38101 TGGCACAAAT CTCAATATAG AACATTGGTT AATTATTAAT CTTACCAAAT
38151 GCTTATCTCA CTTCCCTAA CTCAGTTAT ACTCAAGAAA TACAAAGATA
38201 ATTGAATTCT AATCTATGCT GACATAAAAC TTGCTGCAGA AATTAACT
38251 TAAACTTGC AAATTATATT GTCTTAGCCC AGGCTGCTCA AACAAATAC
38301 CATAGACAGG GTGGCTTAAA CAACAGACGA TTATTTGAGT TCTGGAGGCT
38351 GGCAAGTCCA CAGTCATGGT CCGGCTCTGG TGAGGACCTT CTGCTGGCT
38401 GCGAGATCCC TCCCTTCTTG CTGTATCCTC ACACGGCCAA GAGAACGAGT
38451 TCTTGCCTCT TCTTACAAGG GTACAATCCT GTCATGGAGG TTTCTACCT
38501 CATGACCTCA ATCTAAACT GATTATCTC CAGAGACTCC ACCATCACAT
38551 CTTGGGGGTA AGGATTCAA CATAAGAATT TGAGGTGATG CAAACATTTA
38601 GTTCATAACA CATATAAATT ATTTTTTTT ACTTTGCTCA TGAATTATTA
38651 GTGCTACTGT TTTGTACTAT TTAAATGCA GAAATGGGA ATTAATATA
38701 TAGGATTTAA AACAATGTGT CAAGAAATTC AAGGTTATCT GATTCTCATG
38751 CCATCGTGAC TTGTTAGTTC ATTTATTGAA CAGGTAATTA TTGAACAACT
38801 TAACTAGTTA TACATACTTG ATACTTAAGT GAATTGTATT ATACATTTTA
38851 CACATACTAT GTATCAGTGA ACATAAAAA ATCTTTTCTG TCATGGAAC
38901 TAATGCTCTA GGTAATAAAA TAACATCTAT AAAC TCACTT AAAC TATCA

```

FIGURE 3.

17/32

```

38951 CTAGCAAATG AAAACTTATT ATCTGGTAAT TTCTAGAATT GTCATGTTAA
39001 ATTGCTTTAA GTATGGAGCC AAAAGCACTA CAGGTTGAGT ATCCCTAATC
39051 TGAAAAATCT GAAATGCTCC AAAGTGAAAC TTTTGTAGTG TCAGCATGAC
39101 AGCACAAAGTG AATTCCACAC CTGACCCCAT GTAATGGGTC ACTGTCAAAA
39151 TTTTGTTCAT TGCACCAAAT GACTGTATGA AATTACGTTT AGAGTATATA
39201 TGGTGTGTGT GAAACATAAA TGAATTTTGT GTTTAACTT GGATACCATC
39251 CCCAAGACAT CTGAGTATGT ATATGCAAAT ATTTCAAAT CTGAAATCTG
39301 AAACACTTCT GGTCTACCT TGGGACCAGC ATTTTAGATA AGGGATACTC
39351 AACCTGTATT GAATATAATA AGATGTCATT GAAGTTGCCA TTTTAACTT
39401 CAGGAAAATT TTTAAATGGT AAAAGGTAA TTAGATTCTG TGAAGTATGT
39451 AAATTAATTC TGACTCTTAA AGTATACTGG GAGAGGCAAG GAGTTGTCTA
39501 GAGATTGGG TTCCAGTACT GCTGTTAACT AGGTCGGTGA TGTTCAAGTA
39551 TTTGGTAATG TAACTGTTTT ATGTCCTAGT GGTTCCTCTT AAACAATAAA
39601 GATTGCAGTC AATATATATT AACTACCATT TATTAAACAC TTGCTGTGTG
39651 TCCAGGTGC TATGCCAAAC ATCTTACATA AAGGTTCCAT CAAGCTCTAA
39701 AATTGTAGGT ATGAAATATC CCTGTTAACC TTTTGAGGAC ATTAATGTAT
39751 TAATCTTGAA TCATTGAAAT ATCTTGCTGC CCACTTCAGG TATATTATAA
39801 AATTAGCTTT AATTCCCTGG ACTTAAGCAG AGATGTGGGT TCTGTGTATT
39851 TTCAAACATC TGTGTTATAT AGTAAGATGA TGTTGATAT TTTAAATAT
39901 TTATCTTCCC TGTCCTCCCC CTGCTTTTTT TTTTATACAG CTACCTGTAC
39951 TACAGAAACA TGGAAATAACC CATATAATAT GCATACGACA AAATATTGAA
40001 GCAAACCTTA TTAAACCAA CTTTCAGCAG TTATTAGGT AAGAATTATT
40051 GCTATGATTT GTAAACACT TAATGAAGTT TCATTTGAGG TTTTGTACCA
40101 TCAGTTGTTT CTGTACATAT CTAGTTTGTA AAAATGGGTC ATATAGTACA
40151 TAGTTTTTTA AAATAAATTT TACTTAAAT ACTTAAATAA ATTATGCCCA
40201 TAATGCAGAA TTCTAAAGGT TCAAAAGAGT GTATATTGTC AAGAAGTTTC
40251 TGGGAAAGTA AAAATAAAAA AGAATTTAAA AATAATGTAT ACTGAAAAAT
40301 AGGTTTGTGT GTACATTATT TTATCTTTG AGGGATAAAG GAATTGAGTA
40351 TCTAGGGGAT AGGTTTAGGG AAACAGCATC TACTGTTACC TCTTTATTGG
40401 GTAGTTTTTG AGTGTAGGT TAAATTTATG AGCATAGTCT TATAGATAAA
40451 TTTTTTTTTT CATTTGGCTT CTTTTTACT TTATATTTTT TGGAGATTGG
40501 TTTATATCGG TATGTATATC AACTGCTTA TTCTTTTTAA GTTGCAATTGT
40551 AATCCATTGT ATGGCTATAC TAAAATTAT TCAATTAGTC TGTAGATAT
40601 TTAGATTGTT TCTGGCCTTG TACTAATATG TATAGCATAT AGTGAATATC
40651 ATTGTACATA TTACTCAATT TATATGTGAG CATATTGATA GGGCTTATTT
40701 GCAGAAATGC TGGATATAAG AGTATGAACA TTTTAAATTT TGATAGATGT
40751 TGCAGATTGT TTTCCAGTGC GTTGATCAG TGTACATTCC CATTATCAAG
40801 TATGTGAGAG TGACTCTTCC CTTAGTATCT CTCCAAGACG GAATTGTGAA
40851 ACATTTTTTA TTTCTCAAAG TCTAATGGAG TAAAATGGT ATCTCATTTG
40901 ATGTTCTTAT TTATCTTGTA AGTTCAGTTG AGCATGTAAT GGTTTTTAAT
40951 GTTCTTTTAT TTAACCTCAT TTTTAAATA GAGTATATTA CGCATGGTAC
41001 AAAAGTGAAA GGATATGTAA ACATATATAA TGAAAGTAAC TCTACTTTTT
41051 CTCTTAACCC AAGCCACCTT GTCCTATCC TGGGAGGCAG CTTCTTCCTT
41101 CAATATCTAT GTAAAAGTAT ATATGTTAAA AATATTTTAG GCCAGCACGG
41151 TGGCTCAGCG CTGTAATCCC AGCATTTTGG GAGGCCGAGG TGGGCAGATC
41201 ACCTGAGGTC AGGAGTTCTG GACCAGCCTG GCCAACATGG CAAAACCCCA
41251 TCTCTACTAA AACAAAAATT ACCTGAGCGT GGTGGCACAT GCCTGTAATC
41301 CCAGCAGCTC AGGAGACTGA GGCAGGAGAA TTGCTTGAAC CCAGAAGGCA
41351 GAGGTTACAG TGAGCCGAGA TCACACCACT GCACTCCAGC CTGGGCAACA
41401 GAGCAAGACA CCGTCTCAA AACAAAACAA AACAAAACAA AAAAAAACA
41451 GTGCTGTGGC TTACACCTAT AATCCCAGTA CTTTGGGAGG CTGAGGAGGG
41501 TGGATCACGA GGTGAGATT GAGACTGTCC TGGCCAACAC AGTGAGACCC
41551 CGTCTCTACT AAAAATACAA AAATTATCTG GCGTGGTGG CACATGCCTG
41601 TAGTCCCAGC TACTCAGGAG GCTGAGGAG GAGAATCACT TGAACCTGGG
41651 AGGCAGAGGT TTCAGTGAGC CAAGATTGCC CCACTGCACT CCAGCCTGGC
41701 GACAGAGCAA GACTCTGTCT CAAAAATAAA AAAAAAATT TAATGCTCTG
41751 CTTTATTTTT ACAATGAAC CAATCTATAA ATATCTGTAA ATACAAGATA
41801 CATACTCTAA AATACATTGT GTGAACATAT AATAGAATAC TAGTAAACCA
41851 TGAAAAAGAA TGAATATAT GTATGTGTTT GGATTGGGA TGATCTCCAA
41901 GATAATGCAT TACATGAATA AAGCAGGGTG TGGAACAATG TATATATTTG
41951 CAATGTGTTG AGTAAATATA TATATACTAC ATTCATATA TTTATTCTTA
42001 ATATATGCAT AGAAAATTC TGGACCAAGA GGCTAGAAAC TTCATAGTGA
42051 TTGCTTCTAA GAAGGAAAT TCAGGGCCTG TGATGGTAGA GGGACGTATT
42101 TTTCTTTCGT TTTTAATTTT GTTTTTTTTT GTTGTGTTG TTTTTTTTTT
42151 TTTTGTGAGA TGGAGTCTCA CTCTGTCACC CAGGCTGGAG TGCAGTGGTG

```

FIGURE 3

18/32

```

42201 TGATCTTGGC TCACTGCAAC CTCTGCCTCC TGGGTTCAAG CGATTCTCCT
42251 GCCTCAGCCT CCTGAGTAGC TGGGATTACA GGCATGTGCC ACCACACCCA
42301 GCTAATTTTT TTTTTTTTTT TTTTTTTGGA CAGAGTTTCG CTCTGTTGCC
42351 CAGGCTGGAG TGCAGTGGCA TGATCTCGGC TCACTGCATC CTCCGCCTCC
42401 CAGGTTTAAG CAATTCTCTG CGTCAGCCTT CTAAGTAGCT GAGATTACAG
42451 GTGCCCCACCA CCACTCCCAG ATAATTTTTT TTGTATTATT AGTAGAGACG
42501 GGGTTTCAGC ATCTTGGCCA GGCTGATCTT GAACTCCTGA CCTCTTGATC
42551 CACCTGCCTC AGCCTCCCAA AGCACTGGGA TTACAGGTGT GAGCCACCGC
42601 ACCTGGCCTA ATTTTGTAT TTTTAGTACA GACGGGGTTT CACCATGTTG
42651 GCCAGGCTGG TCTCGAACTC CTGACCTCGT GATCTGCCCC CCTCGGCCTC
42701 CCAAAGCACT GGGATTTACA GGCCTAAGCC ACTACGCTCA GCCGAGGGAC
42751 ATATTTTTCA TGGTACCCTT GATATCCATG GGGGATTGCC TCCAGGAACC
42801 CCCATGAATA ACAAATCCT CAGATGCCTA AGTCCCTTAT ATAAACTGGT
42851 GTAATATTG CATATAACCT GTGCACATTC TCTCATATAC ATTAATCAT
42901 CTCTAGATTA CTTCTAATAC TTAGTACAGT GTAAGTGCTG TGTGAATAGT
42951 ATTGGATTTT ATTTTATTA TTTTAGTGT TGATTTTAC CTTATTTTTT
43001 GTTAATGTTT TTTATTGTTG TCGGTTGAAT CCACAGGTAT GAAATCTTG
43051 GATATGGAGG GCTGACTCTT TACTTTTGTA GTGTTTTTTT TTTACACCAT
43101 ATTTAGTTTA TTAATACTAG TTATTAATAA GGAATATCCC AAAACACTGA
43151 TTTTTTTTTT TTTTTTTTTT TTTTTTTGAG ACAGAGTCTC GCTCTGTCAT
43201 CCAGGCTAGA ATGCAGGGCT CACTGCAACC TCTGCCTCCC AAGTTCAGGC
43251 AATTCTTCTG CCTCAGCCTC CTGAGTAGCA GAGATTACAG GCATGTGCCA
43301 CCACGCCTGG CTAATTTTTG TATTTTGTAGT AGAGACGGGG TTTCAACATG
43351 TTGGTCAGGC TGGTCTCAA CTCCTGACCT CGTGATCCGC CTGCTTGGC
43401 CTCCACAGT GCTGGGATTA CAGGCGTGAG CCACTGCGCC CGGCCTGAAT
43451 TTTTATATAT TATGAAAGAA ATACTTTTTT TTTTTCAAA GATAGGATCT
43501 TTCTCTGCTG CCCAGCCTGG ATTGCAATGG CATGATTTCT GTTCATTGTA
43551 GCCTTGACCT CCCAGGCTCA AGCAATCTTC CTGCCTCAGC CTCCAAGTA
43601 GCTGGGACTA CAGGTGCACC ACCGGATCGG GCTAATTTTT TTTTTTTTTT
43651 TCTAGAGATG GGGTTTGTCT GTGTTGCCCA GGCTGTTCTT GAACTCCTGA
43701 GCTTAAGCGA TCTACCCACC TCAGCCTCCC AAAGTGCTGG GGTACAGGC
43751 ATGAGCCACC ACACCTGGCC ATGAAACACT TATCTTTAT AAGTACTTCG
43801 GAAGGTATAG AATGACACCA AGAAAAATAT TTAAATCATC TACAGTTCCA
43851 CAATTCAGAG AAAACACTTT TGTTAACATT TGGAAATATT CCTTTTAAAT
43901 CGTTCTCTGT TGTGTATGTG TATTTACGTA TATATGCATA GAATTATTAA
43951 AGAAAATGAG AATGTTGTAT TTTAAATAT CAACTATAT AAGGTGAAAC
44001 TAATCTTAAG AAAAAACAAA AAAGCCAAAA AATCATACTA TTCATTCTA
44051 ATGTGTACAG ACTTTTGTG TTAATTTATA ATGTTGTTG TGCAGGTTCT
44101 TTATCCTAAT GGAAGAACCA TTTCTCCTTA AACTTTTACA ATACTAGCTT
44151 CTTAGAGATT GATAGTTCTA CTAGCAGTGC TTGACACTGA AAATGTTATG
44201 CGTTAAATA TTAATTTCA TTCTGAGTTA ACATTTTCC CCGTAAGCAT
44251 TATTTATGT AACTGGAATA CCCAGTCACT TCAGGATACA GTCATTGTCG
44301 AAATCCTTGT AGGTTAAATA TTGGATTTTC CTCAGATCCT GAGGTTCAGC
44351 TTCGTGTTT TTTTGTGTT GTTTTTTGT TTTTTTTTTT TTGTTTTTGA
44401 AACAGAGTCT TGCTGTTCA CCCAGGCTGG AGTGCAGTGG CACAATTTG
44451 GCCCCTGCA ACCTCTGCCT CCCGGGTTTA AGTGATTCTC CTGCCTCAGC
44501 CTCTGAGTA GCTGGGATTA CAGGTGTGCA CCACCATGCC TGGCTAATTT
44551 TTATATTTTT AGTAGAGATG GGGTTTCACC ATGTTGGCCA GGATGGTCTT
44601 GAACTCCTGA CCTCAGGCAA TCCACCTGCC TCGGCTTCCC CAAGTGCTGG
44651 GATTACAAGC ATGAGCCACC ATGCTCAGCC TCAGCTTCTC TGTATTAAAG
44701 TCCTGAATTC TTTGAAGTTG TTACCACCTA AATGATCATT GAAAAACTGT
44751 ATTTTTTAGT GCAAAATGT TCTTAAACT AATTTAATAA CTTAGCTAAT
44801 TGCCTATAGT TGTGTTAATA AACAGTGGTC TTAGAAACGC TTAGAAATGG
44851 AAGTTTTTTA CAAAAATAAG CTAACATATT TAAATGCCT TTTAAGTATT
44901 TTGTAAGTG TAAATTCAG TACAGGTGCT CTCTCAGCTA GTTTTTTTTT
44951 TTTTTTTTTT TTCCCTTTA CTAAGATGA GTTCAAACAG TGAATGTTG
45001 ACTCCTGGTT CCATAGACCA TACCTCCGT TTTTATTGT TCGTCTCTT
45051 AGACTTTGGA CTCTCTGA AATGTCTCT GTAGGTTTAT GAGCAGGAGT
45101 CACAGGACCA CTTAGAGAAC AATCTTCTGG TCTTAGAGAA ATTGGTAGAA
45151 ATAAAAGAA AACATAACGA TTACAGGTAC TTTTGTCTTT ATTTCTAGGT
45201 CCACTCTAAT CTAGAGGAAT GTATCTTCTT GCTTGTGATT TTTCTATTTT
45251 AACCAGATGG TTCATTATAT GCAATAAAAA TATGATTTA TTTTGAGAT
45301 AAGAATCTTG CTCTGTTACC CAGGCTGGAG TGCAGTGGCC CAATCACAGC
45351 TTAATATATC CTTGACTTCC AGGCTCACAC AGTTCTACCT CAGCCCCCTT
45401 AGTAGCTGGG ACTATAAGTG CACACCACGA CACCCAGCTA ATTTTTTAAT

```

FIGURE 3

19/32

```

45451 ATTCTGTAGA GATGGAGTCT CCTCTGTGG CTCAGGCTGG TCTCGAATCC
45501 CTGGGCTCAA GTGATCCTCC CACCTTGGCC TCCCAAAAGA GTTCTTTTTT
45551 GCTGGGATTA TAGGCATGAG CCCATTGTGC CCAGCCTGAT GGATTTTTTA
45601 AATACTTAAA TATCAGAGAT GTTAACATGG TGTTTCAGGT TTTAATGCCT
45651 TCAAGCAATG TAAAATCTAC CACACAGTTC TTGGGAATAT GATACTTTGA
45701 AAGTTGTTTT GCATTCTTGC CATGGTTAAC AAGAAATAAT GAGTTATTTT
45751 TTTAAAGTAC CTTAAGTGT TTAAGTAAAG TGTGCTTATC ACAAAATACT
45801 CTATTTTCAG ATATTTAGTC CTGGATATTG CAGATAATCC AGTTGAAAAT
45851 ATAATACGTT TTTTCCCTAT GGTAGGTACC AGTATTTTTT AAATATCATT
45901 TAAAATTTAT TTATGATTG ACTTCTTAGT TGTGCTTTTT TTTTTTTTTT
45951 TTTTTTTTTT TTTGAGACAA GAGTTTTACT CTTGTTGCCC AGGCTGGAGT
46001 GCAATGGCGC AATCTTGGCT CACCACAACC TCTGCTTCCC GGGTTCAGT
46051 GATTTTTCTG CCTCAGCCTC CCAAGTGGCT GGGATTACAG GCATGAGCCG
46101 CCATGCCCAG CTAATTTTGT ATTTTLAGTA GAGACGGGGT TTCTCCATGT
46151 TGATCAGGCT GGTCTCAAAT TCTCGACCTC AGGTGATCTG CCTGCCTCAG
46201 CCTCCCAAAG TGCTGGCATT ACAGGCGTGA GCCACCGTGC CCAGCCCTT
46251 TAATTGTGCT TGTAAAGCTT GCTACTTTTA CTTTGCTATG ACTGAAAATT
46301 ATGTGATTGT GTTTTTAAAA GAATTATTTG TAGAAAATT TTTATGATCT
46351 CCAGAAATTT GAGGAATCAT ATTGTGAATG TATTGGACTT AAATTAATTT
46401 TTGGCTTCTT TAATTTTTTT GGACTTGTA TAGTCTATT TATAGCATT
46451 TGGAATTTGG TGAATCAAAA TAATTTTTAT ACATATAAAT TAGGAAATTG
46501 TTTTCAATAG GTTTCATTTT GTTTCATTAT ATGCATTTAT TTTATGCTTA
46551 CATTAATCCA CATGCTTTTT GCCTCCAGAC TAAGGAATTT ATTGATGGGA
46601 GCTTACAAAT GGGAGGTAAA TAACATTTCC TTTCTTAACT TAATGTTTAT
46651 ATTTTGATTA TTTGTTAATT TTTTAGTTGG TATTTGTCTT AAATGCAGGA
46701 TATGGAAGTT ACAATTATAT GTAGTAGCTT ACTCCCAAAT TTGTATTTTC
46751 CCAATTACTT GTTTCATTTG GATAGGCTTT CTGGAGTATC CCTGTAGACT
46801 GTTTTCAAAT TCTCTGTGAG CTTTCAGTTT CTTTAATAAG AGTCTGCTAT
46851 ATTCTCTACA CAGTTGATAA TAACAAATTG TAAAGATTG AGATATCCA
46901 AGTGATTATA GTATATAAGG AGTTACTTTA CTGTGGTTTC AATGTAGTTC
46951 AGCTACTGAC TCAGGTGTTT TTCTATTAGA ATAATGAATT CATGTTTTTC
47001 AGGAAAAGTT CTGTGTCATG GAAATGCAGG GATCTCCAGA AGGTATGAAG
47051 TTAGAAATTA TCTTCTTTC TATAACATTT AATTAATGGG CTGTATTTTC
47101 TGGTTGTTTT TAAAATTATT TTCCCTCTT CAGTGCAGCC TTTGTTATTG
47151 CATACATTAT GGAAACATTT GGAATGAAGT ACAGGTAAGA AAATACCCTA
47201 AAACCTAGCC ACAGTTTAAA TTCTCATTAA AATGAACTT AATGGGAATA
47251 GTTTGGAAGT TTGAAGTTCT TATTTCCCTG ATTATTTTTC ATGTAGTCAT
47301 GTTTGATTAG GCAGGCCCTT ATTCCATGAT TAGTCTTAAC CTAATTTATC
47351 TACTTGATA GATATGCATA GGCTAATATG GAAATCCTAT GGAAACTAC
47401 TTACCTACCA CAAGGGAATT GGTGGGTATG AGTATAAAAA CTCGTGACCA
47451 CAAATGTTAG TGCTTGCCTT ATTTAAAGGG CTAATTTATC ATGTTCTCCT
47501 TTAACAATAG TTGGATGAAA AATTACCTAG GAATTTGTTG CAGCATCTAT
47551 TTACAATCA GAGTAGTCTT TCTTATCAA AATCATCTTT TCCAAGCATT
47601 CTGTATAGAT TTTTTAAAAG ATAGGGGGTG GTAATGAGCT TCTTGCCCCC
47651 AAGACAAAGC AAAAGCCTGG GCCAGTGAC AGTATTTCTT TTCTCAGCTT
47701 TTCTTGTCT ACAAATTAGA AATCTTATAG TAATCATTGA CACATCTTTC
47751 TATTTCAGTC CCCTTTTATA TCTAAATTAG AATGGATAAC TTTGCTTAAA
47801 AATATCTATT CTAAAGGAA TATTATTTGA ATACAAATAT TTATTATTTT
47851 ATTTTGTAGA CGGCTCTTG CTCTATTGGC AGGCTGGAGT GCAGTGGTGC
47901 GATCTCAGCT CACTGCAACC CCCGCTCCC AGATTCAGC AATTCTCCTG
47951 CCTCAGCCTC CCTAGTAGCT GAGACTACAG GTGCACACCA CCACGCTGG
48001 CTAATTTTTG TATTTTATT AGAGATGGGG TTTCACCATG TTGGCCAGGA
48051 TGGTCTCGAT TTCTTGACCT TGTGATCCAC CTGCCTCGGC CTCCCAAGGT
48101 GCTGGTATTA CAGGGGTGAG CCACTGCACC CAGCCAGAAT ACAAATATT
48151 AATTGAAAAA AGATTAAACA TGTATTGATG GACTTTATGT TTTATATATT
48201 GTTTTATTA TTTGAAATTT TGTGAGACCA TTAATGTTGG AAATAACTTG
48251 TATTTATTGG GTCTCTGCTA TGAGCTCAGT ACTATTATAG GCACTTTAAG
48301 CCTCATAACA AAGTAAATA AACCTCTTA ACCAGTGATA GTATTTTGAG
48351 CTGAACTTG TACTATATGC ACAAATGCT TACATTTTAT ATATTTATTT
48401 TAGAGACAGG GTCTTCCTTT GTTCTCAGG CTGGAGTGA GTGGCACAAT
48451 CATAGCTCAC TGTAGTCTCA GACTTGAGGA CTCAAGTAAT CCTCCACCT
48501 CAGCCTCTCA AGAAGCTGGG ACTATACCAC ATCACTGTGC CTGGCTAATT
48551 TTTAAGTTTT TTGTAGAGAT GGGGTCTTAC TACATTGCC AGGCTGGTCT
48601 CAAAGTCTCG GCTTCAAGCA GTCCCTCTGT GTTGGCCTCT CAAAGGATTG
48651 GGGTTACAGG CAAGAGCCAC TGCACCTGGC CACTTTACAC TTACCTCCTA

```

FIGURE 3

20/32

```

48701 TTCATAGTAG TTCCCCAAGG TAGGTGTTAT TAGACTCTTC ATTTTACCAA
48751 TGGACAAAAT AGAGCTTAGA GAAGTTGAGC AAGCTGCCGT AAGCATATAG
48801 CTGGTGAGAA AAGGAATTGT GATATTTAAT CTCATCATGC TTTTCCATT
48851 ACAACTCATT ACCCTCTCT ATTGCTAAGT TGTATGATTA TGATTAATTC
48901 ATTAAATAAT GCTATCACAT TAACACTCTT TTTCTGTTTT CAGAGATGCT
48951 TTTGCTTATG TTCAAGAAAG AAGATTTTGT ATTAATCCTA ATGCTGGATT
49001 TGTCCATCAA CTTCAGGTAA CTTTCTTCC TCTTTAAGGC AATCAGAAGT
49051 AAGATATAAA ATCTTTTATA CATGTAATTT AGGTGTACAA TTTACTTTGT
49101 GAATACTTAA AATTGCCATA ATCTGACTAC TTTGATGCTT TATTCAAGTT
49151 TATATCTCTA TTTAGAAGTA TTTTCTTGGC TGGGTGTGGT GGCTTATACC
49201 TATAATCACA GCACTTTGGG AGAACAAGGC ATTTGGATTG CTTGAGGCCA
49251 GAAGTATGAG ATCAGCCTGA GCAACAAGT GAGACCCAAT CTCTAAAAAA
49301 TAAAAAATTA AAAAAAATT AGCCAGTCAT GGTGGTGCAT GGCTGTGGTC
49351 CCAGCTACTC AGGAGGCTGA GATGGGAGGA TTGCTTGAGC CCAGGAGTTT
49401 GAGGCTACAG TGAACAGTGT GTCTTGCAC FCCAGCCTGG CCCACAGAGT
49451 GAGACCCCAT CCCTAAAAAA TTAaaaaaac TTTTCTTCT TAAAGGCTGG
49501 CATTACCAAG AAAAAAGGGT TAAAGACACA TTATCAAATC TAAAGTAAAA
49551 TAATTGCTGT TAGAAATGTC TGATTTTTTT TTGTTGTTCA TTTTGATCAC
49601 ACAGAGCATA AGACAGTTTT GATTCTAAGT ATACTAACTA TAACAGCTTT
49651 TTCTATTCTA TGTTTATCTT TTCCATGTTG TTTCATATTT TGTGATGCC
49701 TGGCAGATGC ACTGACAAAG ATGATAAGTC TATGAATTAA CCTAATTAGA
49751 CCACGTTGCT CAGTTTATTC CAAGAGGCAA AATCATAGGC TGCAGAATGT
49801 GCTCTGGCTA ATTACATCCA ATTATGTAGG AATAAAGCTC ATGTTTCAAC
49851 ATCAAGAATA TTTATTACAA AATATATTGT TATAGTTACC AAGGTTTAAA
49901 TTTTATTTTA ATATTTAATT TACTTTTAAT TTTTACTACA TTCAAAAGAG
49951 AAACAGTGTC ATCTGTGTTC AGCCTGTTC TGTAAAATGT TTGTCTTCTA
50001 ACTTTGTAAG TTTCTTTGCC TTTTACCATG TTGTAGAAAA CATTTGTTTTT
50051 TTTCATTTTT TTTAAACTAT TTTTAAAGCT TTTCTTTTTT TTGTGGATAC
50101 ATAGTAGGTT AGGTATTTTG ATACAGGCAT GCAATGTGTA ATAATCACAT
50151 CATGAAAAAA TAGAGTATCC ATCCCATCAA TCATTTATCC TTTGTGXXXX
50201 XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXCCTCCCA AGTAGCTGGG
50251 ATTACAGGCA CGTGCCACCA CGCCCAGGTA ATTTTGTAT TTTAATAGA
50301 GATGGGATGG CCGGTGTGG TGCTCACGC CTGTAATCCC AACACTTGG
50351 GAGGCTGAGG TGGGTGGATC ACCTGAGATC AGGAGTTTGA GACCAGCCTG
50401 GCCAACATCG TGAACCCCTG TCTCTACTAA AATTACAAAA ATTAGCCAGG
50451 CGTGGTGGCA GGTGCCTGTA ATCCCAGCTA ACNNNNNNNN NNNNNNNNN
50501 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNTGCTGGAA AGGGATCACC
50551 TGAGTATCAG GAGTTTGAGA CCAGCCTGGC CAACATCGTG AAACCCCTGC
50601 TCTACTAAAA TTACAAAAAT TAGCCAGGCG TGGTGGCAGG TGCTGTAAAT
50651 CCCAGCTACT TGGGAGGCTG AGGCAGGAGA ATTGCTTGAA CTGGGAGGC
50701 GGAGGTTGCA GTGAGCCGAG ATGGCATCAT TGCCTCCAG CCTGCGGAAC
50751 AAGAGCAAGA CTTGCTCACA AAAGAAAAAA AAAAATAGAG ATAGGGTTT
50801 GCCATGTTGC CCAGGATGGT CTTGAATCC TGACCTCAGG TGATCCACCC
50851 ACCTTGGCCT CTCAAAGTGC TGGAAATACA GGCGTGAGCC ACCACTCCTG
50901 GCCCCAAAAT GTTTTATCAG ATTTTGTGTA TCATTTGTTG GTGTTCTCT
50951 CACCGGTTTG TAAGAGCTCT TTTTATATTA TGGAAATCTA TTTATAGCCT
51001 ACCGATTTGA AATATCATTT TTATTTTATA CCATTTCTG ATATGTCCTT
51051 TAGAAGTTTG AAGTTTCTT TTTTAAAGGTG CTTATGGAAT GGCTAGTTCT
51101 AGTTTTTGAA CCGTTAATAT GGTGACTTGA GTTACTGGAT CACATTAGAT
51151 TGGATTTCCCT AATATTGAAT CATCCTTTTG GTCCAGCAAT GGATCCCACT
51201 TGGTATGAT AGACTGTTCT GTTAATGTAT TGCTGGATTG TATTTGCTAA
51251 TCTTTTGTG CAGGATTTTG GAATCAGTTA AATAGTAAAT TGGTTTGTCT
51301 TTCTTTTTTT TTTCTGTACT ATCCTTTTCT GGTTTTACTA TCTCTGTCAC
51351 AGTGTCTCA TTTTGTAGTG GAAGCTTCC ATTTCTCTTT GTGCCATGGA
51401 TCAATTTAAA TTAGATTGGA GTTACTTGTC TCTTAATGCA TTAGTATATG
51451 GCACCTGTGA AATATCTGAC CATAATGTTT TATCTAATTC AGTTATTCAT
51501 TATTTCAATC ATTCATATAT TTTGACAATA GACCAGTTCT CAGACAACAT
51551 TCTTCATTTG GTGTATCGGT TTGATTTTTT CTTTCTTTC TTTCTTCTT
51601 TTTTTTTTTT TTTTTTTTTT TTTTTTTTGA GGCAGAGTCT TCTGCTCTGT
51651 TGCCAGGCT GGAATGCAGT GGTGCAATCT CAACCTACTG CAACCTCTGC
51701 CACCTGGGTT CAAGTGATTC TGCTGCCTCA GCCTCCAAAA TAGCTGGGAT
51751 TTACAGGTGC CTGCCACCAC AACTGGCTAA TTTTGTATTT TCAGTAGAGA
51801 CGAGGTTTCA CCACATTGGC CAGGCTGGTC TCAAACCTCT AACCTCTGGT
51851 GATCCGCCCG CCTCGGCCCC CAGAGTGCTG GGGTTACAGA TGTAGCCAC
51901 TGCTCCTGGC CTGGTTTGAT TTTCTGATAC CCCTCAGGTC ACTTTGGATG

```

FIGURE 3

21/32

```

51951 TATTTATGAT CTTCTGTGTA ATCATTGATT TCATAAGAGT TCTACATAGA
52001 ATTAAGGAAA ATAATATCTT GTACTTTAAT ATCTTTTGGT TCTATTATTT
52051 TTTTCTTCA TCTGGTTAGT CCATGTTGTT TTTCTGTATT CTAATTCTCG
52101 CTTCTTGGT ACTTTGCTTT AGTGTGTTT GCTGCTGCTG TTGTGAATTT
52151 CCTGAGTTGA AACTTGGTT TCTTTTATT CTTTCAAAAA TTCAAGGCTA
52201 TTAATTATCC TCTTGCATT GTGTTAGTCG CATGCTGCAG ATTCTCATCT
52251 GCATTATTTT TATGTTATAG CTTGATATTC TGTGATTCA GTTTTGGTTT
52301 CATTTTTTAT CTAATATGTG TTGAGATTTT TTTTATTGTA TAGGTGACTG
52351 GGTTTTAAAT TTTTATTTT TGTTCATATT TAGTTTTATT ACATTGTAAT
52401 CACAGAAATG TTTGTAGTAC TTGTATTTT TGATGTTTC TTTGTGGTTT
52451 AATATGTAGT TGTTTTCATG AATTTTATGG GCATTTGAAA AGAAGATGCA
52501 TTTGTTTTTC AGGGGATAAA GTTAAATGTA TTTGTCCACT TGATCTGTCT
52551 TGGGCTGAAA TCAGTGAATT GAAATCTTTT ACTATATTGT GTTTATTTTTT
52601 TCTTTATTTT CCCTTTTTTG GTTCTGCAAG TTTTTTTCTG TACTTAACTA
52651 TTTGGTACAT AAAAATTCAG GTTAGGTTTT TATTTTAGTT GTACCTGTT
52701 TAAATTTTCA GGTTTTTTGT TGTGTTGTT GAGACAGAT CTTGCTCTGT
52751 GGCCAGGCT GGAGTGCAGT GGTGCGATCT CGGCTCACTG CAACCTCTGC
52801 CTCTGGGTT CAAGTGATT CCGCTCCCA GCTCCCAAG TAGCTGGGAT
52851 TACAGGCATG CATCACCAG CCCGGCTAAT TTTTGTATT TTAGTAGAGA
52901 CGGGTTTTCA CCATGTTGGC CAGGCTGGT TCGAACTCT GACCTCATGA
52951 TCCTCCCACT CGGCCTCCC AAAGTGCTGG GATTACAGGT GTGAGCCACT
53001 GTGCTGGAC AAATTTGCGT TATTTTACCT TGCAGTTAAT CTCGTTAAT
53051 ATTGTGAAT CTAATCTTTC TGTTCGCTG CTACCTTTTG AGTTTTCCCA
53101 TTTCTTTTCC TTCAAGCTTT CTAAATCACT TGATTTTGA TGCTTTTCTT
53151 CAGTGTAGT TAGGATTGAG TTTTGCTATT AGATTTGGTA TCATTGTTT
53201 CTAATAGGTG AATTTAACCC ACTTTCATTT ACTGAAATG ACAGATACAA
53251 TCTTATCTAT TATTATTCCA TATTATGCTT TCTGTTTTAA ATGAATCCTT
53301 TTTTAACTT TCTGCTATAG TTTAAAATTT TTTGGTGTGT TTATGTTTGT
53351 TACATAAATT TTAAGGTTTT ATTTATTTAC TTTTCTTTT TTTTTTTTT
53401 TTTTGTAGT TAGAGTCTCA CACTCTTGCC CAGGCTGGAG TACAGTGGT
53451 TGATCTCGGC TCACTGCAAC CTTTGCCTCC TGGGTTCAAG CGATTACAC
53501 ACCTCAGCCT CCCGAGTAGC TGGGATTACA GACATATGTC ACCACATCCA
53551 GCTAAATTTT GTATTTTGG TAGAGACGG GTTTGGCAT GTTGGCCAGG
53601 ATGGTCTCGA ATTCCTGAGA TCATGTGATC CACCCGCTC AGCATCCCGA
53651 AGTGCTGGGA TTACGGCGT GAGCCACGGC GCCCAGCCCC TTAATCCTAC
53701 ATTTAAATAG GGATTAGCC CAATCCTATT ACCTGTTTCC AGGGGTCTTT
53751 ATTAACCTT TGGACTTTAT TAAGAATAGT TTCATGGAAT CTATATTCCC
53801 AGGGAAACT ATCCCTTGC ATATTGGAAT AATATTTTTC TTTTGCCTT
53851 TATATTGAA TGACAGTGGC TAGATATAAA ATAGGTATTT AATACTTTTT
53901 CCTTAGTGAT TTTGTACACA GACCTGATAT TAAATATTTT TTGTTTGT
53951 TTTATTTTTT GGAGATGGAG TCTCACTCTG TCGCCAGGC TGGAAATGAGT
54001 GCAGTGTGAT AATCTAGGCT CACTGCAATC TCCACCTCCC GAGTTCAAGT
54051 GATTCTCCGC TTCAGCCTCC TGATTAGCTG GGATTACAGG CACATGCCAC
54101 CACACCCAGC TAATTTTATA TTTTGAAG AGATGGAATT TCACCATGTT
54151 AGCTAGGCTG GTCTCAAACT TCCGACCTCA GGTGATCTGC CCTCCTCGGC
54201 TCCCAAAGT GTTGGGATTA CAGGTGTGAG CCACCGTGCC TGGCCTAAAT
54251 ATTGTTTTAG AGAAGTTTGA AGGCAGACCA ATTTTAAGAT TCCCCCTTA
54301 GGTGAATTGA TTTGTATCAG GAGAAGGTTG TCTAGATCAG CAGTCTCCAA
54351 CCTTTTTTAC ACCAAGGACC AGTTTCATGA AAGACAATTT TTCCACGGAT
54401 GGGGTGGCGG GGGAGATGGT TTCAGGACAA AACTGTTCTA TATCAGATCA
54451 TCAGGCATTA GTTAAGGAGT GTGCAACCTA GATCCCTCGC ATACCATAGG
54501 GAGGGATAGG TTTACCATAG GGTTCGCTC CCTGTGAGAC TCTAATGCTG
54551 CTGTTGATCT GAGAGGAGGT GGTGCTCAGA TGGTAATGCT CCCTGGAGTG
54601 CCACTCACCT CCTGCTGTGT GGCCTGGTTC CTGACAGGCG ATGGACCGAT
54651 TCTGGGCTCT GCAGTCCAGG GGTGGGGACC CTCATCTAGA TGACCATAAG
54701 ATGCTTTATC AAGGTGTATC CTGGTTTTTT ATGTTTTTGT TTTTGTAGGG
54751 GGTCTCGCAC TGTCAACCCAG GCTACAGTGC AGTGGCGCGA TCATGGTTCA
54801 CTGTAGCCTT GACCTCCTGG GCTCAAGTGA TCTTCCACC CTAGCTTCTT
54851 AAGTAGCTGG GACCATGGGT GCACACTATC ACACCTGCT AAGTTTTTGT
54901 TTTGTTGTTG TTTGAGACAA AGTCTCACTC TGTGCCCCAA GTTAGAGTGC
54951 AATGGGGCAA TCTTGGCTCA CTGCAACCTC TGCCTCCTGG GTTAAAGCGA
55001 TTCTTCTGCC TCAGTCTCCC AAGTTGCCAG GATTACAGGC ATGTGCCACC
55051 AAACCTCAGT AATTTTGTGA TTTTGTGAG AGAGACAGGG TTTCAACATG
55101 TAAGCCAGGC TGGTCTGGAA CTGCTGACCT CAGGTGATCT GCCTGCCTCG
55151 GCCTCCAAA GTGCTGGGAT TACGACGTGA GACCACACAC CTGGCTTAGT

```

FIGURE 3

22/32

```

55201 TTTTAAAT ATTTTGGTA GAGATGGGGT TTTGCCATAT TTTCCAGGTT
55251 GGTCTCAAAC TCCTGGGCTC AAGCGATCCT CCCACCTTGG CCTCACAAGG
55301 TGCTGGGATT ACAGGCATGA GCCACTATAT CCGGCCAAGA TGTATCTTGT
55351 TGATTGCTCT ACATCAGTTT TTTTCTGAGT CACAGTGTGC CCTTACCACT
55401 TGCAAATTC AAGCCTTCCCT GATTTCAGGA AAGTTGTCTT CTATTGTGTA
55451 TTTACCCTTT TGGTTGTTCT GTTTCTTTT CTTTTTAGTA TACCCCTTAC
55501 CCCGGTATAG TTTATGTTCC CTTTTTCTT TGTATTTCG TATTTTCTCT
55551 GTAATTATTT GCAGCTTTGT TCTTTTTTT TTTTCCACTT GATTTTTCTC
55601 ACGTTTGTTC TCCATGTCCC ATGCTGCATT GTTTCATTAA ATATTTATTT
55651 GGCATTGTTT TAGTTAGGCA CTGACAGTAA AGCAGAGAAC AAAACAGACA
55701 ATAATCCTTG ACCTCACGAA ACTTATTTAG TGGGAGAATC AGACAACAAA
55751 CAAAATGTAG TAGGCCAGAA GTAATGAATC CAAGAAAAAT AAGGCCATGT
55801 AAGGAAGGTG GGACGAGAAT TGTATTTTGA GAAGGGTGGT CAGAAATGGG
55851 CTTACTGAAA AGTGATATTT GAGCAAAGAC CTAAGAGAT GCACGTATTT
55901 GGGGAAAAGC ATTTGAGGTA GAGGAATAAG TGTAAGTGGT TTGAGGTGGG
55951 AGCATAGTTC TTAGAAGGAT ACTCATTTC TATAGGGCC AGTCCTCTCA
56001 TGACCTCATC CCAACTTAAT CACCTGCCAA AGTCCCCACA TTAAGTGTTC
56051 GGACTTCAAC ATATGAATTA TGAGGGGAAT GCAAACATTC AATCCCATAA
56101 CTGCCATATT TTCTTTGATT AATTTGTTCA TAGTTTTCAT CTGCTTCATG
56151 GTATAAGTTT TATGGCATTT TCTTTATGAC ATTTGGTTAT ACTCTTGCTT
56201 TTCTGTTTTT GTTTTGTTC GTTTTGTTC TTCTTGCAA ATCTTTGAGT
56251 AAGACCTAAC TGTTTCCTTC TTGATTATTG GTCATCTTTG AACTGGAGGT
56301 ATTCGTCTTA GATCAGCTAT TTACCCAAGA ATAAATTTGT GGGAAAGGGG
56351 CCAGAGGAGT GGTGGGGAA GGCTGACAGC TTGAATTTTC CCAGGTTTCT
56401 TTGGTGGCAT GAATCAGTGA GTAAGAAGCA GAGCTCCTTA TATCACAGGT
56451 TTATTTTGTT TAAATTGATA AACACTGATT CATATTAGAA TCACCTGGGG
56501 AATCCTTACC CATGCCAATG AAATCAAAAT CTGTGAGAGT GGGGCCTAGG
56551 TATATAGGTT TTAAGTGCC TCAGGTGATT CTCATGTATA TCCAGGCTAG
56601 AATTGCTGAT TTAGCCTTTA CTTTTAGCTA TCCAAGATCA ACTGATGCTT
56651 GGCTACATGC AACCAAATTT CACTTCCGCC TTACCATACT TAAACAGCCT
56701 GCTGCTTGCA AAAAATGGCA GGTGTAGGTG TTCACATTTT CCTTAATATG
56751 TCCCACCTTC TCCCATAGGC CACTCATATT TCCTGACTTT GTCATACCAT
56801 GCAAGGGCTT GTTGGTTTTA TTTAGGTCA CCTTTTTTAG CGAGCTATGA
56851 ACTGTACCTA CTCTGGCCCA CAGAGGAGTT ATCTGCTATG CCTAGCTTAG
56901 GATGTTCTTA TTTTTTTTGA AAATTTTATT GTGAAATTAT AATATAGAAA
56951 ATGCATAAAA TGTAATAAAA CATCCATGTA ACTATTGCCG AAGTATGGAA
57001 ACAGAATGTT TACCAGGACA CCAAAAGCCT TTTTCATGCC GCTTCTCAGG
57051 CACAAATCTG TTTCTCCCTC TGTAAGTAA CCACATCCT GACGTAGCTG
57101 GTAATCAATT CCTTTTCCCC TCATTCTTCT CATTTTCAGG GTAATGGATG
57151 TTTCTAGATT TCATCAAATG TTTTCTTGT TTTCAGAAAA GAGAGAAACA
57201 AAAATGCCCT TATCTTCTA TCTATAACTG GAAGCAGAGG ACTATTGAGA
57251 TTGCCAAATTT AAGTTTTTGG TGTTTTTTGG GGTTTTTTGA AACAGATGAA
57301 GTCAGAGATC ATTATAGCTA ATGCCATACT GACTGGCAGT TCAGCATGCA
57351 GTACCCTAGC ACAAACTATT AGCCGGGCTT GATTATAGT TATCAGTAGT
57401 TCTGAATTTA TGAGACAGGA ATTTTAAACT TCCATTTCTC TTCAAACAAT
57451 ATGGCACTAG ATTTTCAAT ACAGATGAAG AATACCAACA GTGTATACAT
57501 TAATCACTAT TTTGGGTATC CAAGAATGTA AATATATAAT TAAGTTAATT
57551 AACTTATTTT TTTTTTAGGA ATATGAAGCC ATCTACCTAG CAAAATTAAC
57601 AATACAGATG ATGTCACCAC TCCAGATAGA AAGGTCATTA TCTGTTTATT
57651 CTGGTACCAC AGGTAAGGAT TTTTTTCTT TTGGAGAAAT TTGGGAAGAA
57701 AGATAATGAA AGGTGGAGAA CTGCTACAA GTTACACTGA ACAATTTAAA
57751 TTGTTTAGAA AACTTGTTAA ACTATTGAGC TAATTCAGA AGGATTCAAT
57801 TTATAATGAA TAAATGTGTA CTATAATAAG CTTAAGTCTT TCAAGTAGTA
57851 GTACATCCGT GTTGTAAGA TTAATAAAT ACGAATCTGG AGAAGGGGCC
57901 CTAAACACGC TTAGGTGATC TTATTAAGA TAGAGGGCGG TTAATACAGC
57951 GTGTAGCATG GCTAATGTGA GCTTCTTCT CTTGCCATCA ATATTTCCAT
58001 CCTTTCCTCC CTCTGTTGCT ATTTCAGAAG TACCCTAAGC CCCTTATTTT
58051 CAAAGTTAAT CCAAGCATGC TCTTAAATC TTCCTTTCCC AAGACCTTGC
58101 TACTGTGTTT TATCACCTTT GTTCTCTCC CAACAAAGCA CACAAGGCAT
58151 TTTTACTTTA TTTCCAGTTT TTCCTACCCT GCAGTTCACT TCAATCTTTG
58201 AACCAACAGT TATATAAGGT AGTAAGAACA GCTTATATAC TTAGCACTGA
58251 CCTGGAAATTT GAGGACAGGT GATCTGATCC ACAAGTATAG AACTCTTTGC
58301 ACTCTACTGC ACTGCCATA GTAGTAATA TGACTGTATA TTCATCCCCA
58351 AGGCTCAACT TCCTAATTGT CATTGACTTT TTCATTTTCT TTGCCACATC
58401 TGTCTAATAA TTGCTCTCCA CATCCTATAG GGTCCGTTTT GTCAGTATTG

```

FIGURE 3



23/32

```

58451 TTAACATTCC TTCCTTTTTT TAATAGTGAC CTTAATCTAG TTCAGGTC CG
58501 GATTTGCCCTC CTTTCCAAAC TCTGTATT TGGTCTGTTC TGTACATTGT
58551 GGCCAGACTT ATTCCCATGA AAGATATTC TAATATTGAT ATTTTTCCTT
58601 TGCCAAAGCC TCCTTTGGCT TCATTCCTAC AAAAGTTTAT AGAATGCCAT
58651 ATGCCCTTCT GATTTTTTGG TTTCTTTCTC TCATTGTTCT TCTTTATGTC
58701 TGCATTTCAG AAAACAAC TGATGGTTT CCTGTGTGTG TCTTCTTTTC
58751 CCCACCTAAA ATGCATCACA TTTAGTCTCC CTATTCTTGG TTCATATGTC
58801 ATCTCCTCAG GAAGACATGA TGATTAATGC ACTCTTCCTC TAACCCCTAG
58851 TCATTGAGAG TTCCCATAGA AGCACAGCAC TTCATCTGAA ACTTAATCAC
58901 AGTATCTGGG TTTAGCCTGA GGGCTAGGAT ATTTTATCTC ATTCAATTGT
58951 ATTGATACTA TATTTTTATC TTTATGAATT TTATAGTGAA ACATTCTTCA
59001 ATTAGAATAT GCCCTCTGAA TTAACATTAT TATTACCATG ATATAACAGT
59051 CCTGTAGGGC ATAAGTTTAA GGTCA TGCCA TTGTTAGGCA AAAAACACAG
59101 CAGACCCTCT GCTGGTTTAA CTGTTCCCTA AAGTTTTCCT CCATTGAGAG
59151 TCTAATTTCT TGATTATAAC TTTTGGGGAT ACAGAGATAG CTTTGATTCT
59201 ATGTGGGAGA TTTCTGTACT AGCAGATGCT GGTATGAAGA ATAGATAAAA
59251 GAAATCTCTT TTATATGCTA CATGCCCTCC TTTCTCCCAA CCTAGACTTC
59301 GATAGCTTGA GTGGAAAAAT ATTTTCAGCT GCTCTTCATA ACAGCCTCTG
59351 TGAAAGCAAA AAGATTATCT AAAAAAATT ATACAAATAC AAGATTAATT
59401 TCCTAAATTT TATGCCCTAA GTCACATGTT TATGGTGCCT AAAAAACAAT
59451 TAACCTTGATA ACTAAACATT TATGTATTAT CTCTTGAAAA GGTCTATTTT
59501 CACACTATTT CAAAAATTAT TTATTTTATA TGCAATACCT AAGACATAAT
59551 ACTTGAGAAG GAAATATAT CTGTCTATGA AGATTAAAAA GTTATAATAT
59601 TTAGGTAATT TATCACAAG GAATTTACTA AATTTTGCTA TATCAGTTGT
59651 GGAATTTTCA TAGTGATATC ATGATCACTT AATAACAAAA TTTTACTTGC
59701 TGTAACCTTT TAACATGAAT TTATTTTAGT GCCCTTTTAA TCTTCATGCA
59751 ATAACTTTTA GGCAGTTTGA AGAGAACACA TGAAGAAGAG GATGATTTTG
59801 GAACCATGCA AGTGGCGACT GCACAGAATG GCTGACTTGA AGAGCAACAT
59851 CATAGAGTGT GAATTTCTAT TTGGGAAGGA GAAATACAA GAGAAAAATTA
59901 TAATGTAAAA TGGTAAAAAC ATAAGTAGTT TTTTTCCTCA TTACATGTTG
59951 CTTCCAGACA TACTTCTCTG CAACTTGTG AGCAACATTT TAAGATGTTG
60001 GACTTCTGCA ATAGATGACA CTGATGGTTT TACTCCTTTT TTTAAAAACA
60051 CATGCGCGCG CACACACACA TGCTTTACAA GTTTTATTAT AAACCAAGAA
60101 TTTTGGACTT GCAAAGAGGT ATTATTGCAA TAATGCACCT TTCATACTTG
60151 AAATTTATTT GTATGATATA AAGTTATTAC TTTAAACAAA ATGCAAGTAT
60201 GGGGGGATTG TTTATAAAGT TTGGGTAAAT TATAACAAAA TTTGCTAAGG
60251 TTTGCTAAAA ATTCAATTTT CTGTTCTATA TATTACATTT TTAACATAAT
60301 TTTACAGTTC AATTTTATGA TGGAGCCTCT TACAGAAACA TTAACAAAAT
60351 GCAGGAATCT GCCACATTTT TTTTCTAGTA TAACTTAATA GCTTAATTAC
60401 CATTTTATTT TTTTACTTTC TTCCATTATT AATCTTTAAA TCATGATCCT
60451 AATTAGCTGT CCTTACTTTA ACTTGATCTA ATTATTGCTT CCTTTCTTAT
60501 TACTTTCTTA ATTTTCTAT ATTTTAAAA CTACAGTTTC CATGATAAAA
60551 GGAAACGTTT TTGATTTATA GTACCAAGTG CTTAAACACA AGGATAGTGT
60601 TAGATTTTCG AGTGAATTTT CTTTTTGCAT TTTTGGCAG TAAAAGCCAA
60651 ACGTTGTATT TGTCTTTTTC AGAGTTGTCC AGCCCTTTT TCCTTTGTCC
60701 AAAATGATTC TAAATAGAAT CTAATAAACC AATGTAGCAT TATTTTTTTC
60751 TAAATGAAGC CCCAAAAAAG AAAAGTGCC TGCATCATT AAAAAAATA
60801 ATTAATCCTT CATGGCCTCT AAATTAGTAT GTAGAACACT GAAAAGTTCT
60851 TAACATTTTT GTGTAATTTT CTTTCTTTT AAACCATAAA TTAGTTTAAA
60901 CTGAAAGTAC GAGGCTGGAA GAAATATTAG TAAATTATTT GGAATATAGA
60951 ATGTTTACTC TTTCTTTTTA TGTGTCTTA ATGATTCTGT GAGATTGTTT
61001 CGGCTCAAAC AGAAGCTTTT CTTTGGGGAA GGTGATTTGT GGGAGACTCT
61051 AGTGTATTTT AAATTAGCAT TTTAATCCAT TCTTGACATT CAGTTAGTCC
61101 AGATCTGCCC CATAATTTGC TTTAGTAAAG TCATTTATG GATTTTTGGC
61151 TATGTTTTAG TTTGTGTGTA TAAAAGTTCT AAGAAAACAT TTTTGCTATT
61201 TTAAGTATGT AAGGGAAGAG AGGAGTGT TTAACTTTT ATAGTTGATG
61251 ACTTTAGGGG TAGCACAAAC AAACTCCTT TGTATCTAAC TTTTCTCAAT
61301 CCTCTCTTGA GGTGCTTTAC TAATGGGAAT GATTCTCTGA TGTCCCTTG
61351 GTACCCAAGA GGTACTATGC AAAGTAACCT ATTACACCAA GTTACTTGCT
61401 TTGCTTTTCT CTCTATGATG TGATAATACA GTAAAAGCTT TCTTACCCAG
61451 CATAGTGGGA GAGTGGAGAT TAATTAATAA TGTTAATTAA GAGTTAATTC
61501 CTATTGACCC AGGTGATATT TCTCTCTGA TTTCCCTCCC CTCCCTTCT
61551 CTTATCTTAC CACTGTGAAA ACAGCATATT GTTAATCTCG TTGTCGTTCA
61601 GTATTCTGCT TTGTGATTAG GTCTTTGAT GTACAGTGGT CTAGTGGAGT
61651 CAAGATTGCG ATTGGGTTTT CTAAAATTC AGTTGATAAA AGTTCCAGAT

```

FIGURE 3



24/32

```

61701 AACACAGCTT TCCTGTATAT AGATCACTAT TGGGCAGGTC AGCAAAGATC
61751 TCTTACAGTG TAATAATAAT CTATGATGCT TCATTTAGCA GAAACTCTGC
61801 TTAAAAGAAT CTCATAATA GTAAGTTTAG GTTTTAAAAA CTGTGTTTCAT
61851 AAATATACAT ATATCCTCTC TAGTAGTCTG GCCAAAAGAA CAGATTTTGT
61901 TATTGATAAT TTGTAGCTGG TAATTTTCCA CATTTTCTAT CCACTGTAAT
61951 TTTTATGTTG TCACTGAAGT GCCTGCCAG TACTGTATAT TACAGTCTCT
62001 CACAAACACT GGGAAAAGGG ACTGTCATCA TCTTGAGTAC TCTGTGTGTA
62051 TATATATATA TATAGATAGA TAGATTTTTT TTTTTTTTTT GAGACAGAGT
62101 CTCTAATGTC ACCCAGGCTG GAGTACAGTG GCACAATCTT GGCTCACTGC
62151 AACCTCCACC TCCTGGGTTC AAGTGATTTT CCTGCCTCAG CCTCCCAAGT
62201 AGCTGGGGTT AGAGGCACAT GCCACCATGC CTGGCTAATT TTTGTAGTTT
62251 TAGTAGAGAT GGGGTTTCAC CATGTTGGCC AGGCTGGTCT CAAACTCCTG
62301 ACCTCAAGTG ATCCACCCAC CTCGGCCTCC CAAAGTGCTG GGATTACAGG
62351 CGTGAGCCAC TGCGCCTGGC TGAGTACAAT ATTAATGTAG ACAACCATG
62401 AAGTTTATTA TTTTCATATA GAACATTACA GGTGTGTTT TTCTTGTCATG
62451 TCTGTCCACC TAATGTTTAA GTAGTCTGG TAGCTCTTCC TATTCTTTAT
62501 TCTATTTGAT TCCATTTCTG TGATTCCTTT ATTACCACTG ATGTTTTGTG
62551 ATAGTTAACT ATGATAAATT TAACTGATCA TGATTTATCT TCTAGAGTAT
62601 TTAAATAATG TATGAGTGAC CACCCAATTC CAACATTAAA AGTGTATATCT
62651 GGGCCCATAA TTTATAGTGA AATTGTATCA AAACATAGGG AAACGTGATT
62701 ACGTCCATT TTGAAATAT GAAACTTGAG TATTGAAAT ATTCAAACAT
62751 GGAATGGCAG TATTCTAATT TCAGTTAGTT GGTTCATGTT AATTTCTTAC
62801 CTGTTAGATG TTTAAACTGC AGTGACCTTT ACTTGATATCT ACTCTGTGGT
62851 GGAAATGTTA AACCATGATA GCTTTTGCTA CCAACTCAAC CACTTAACTT
62901 TTAGAGCAGT TTTGGGGAGA GTTTATGCTT CATCTGAGTT TAGAAGTAAT
62951 GTCAGAAAAT GTTAAGCATG TCTGTATTAA GAAAATATAA GGTTTCTAAT
63001 TGTCTTATTA ATATGGTAAT TCAAGTGAAT TAGAAATATT TAACTGCAAT
63051 CTTGAATTAT AAAGTTGAGA TATATATATA TATGTATCAA GATCTCAACT
63101 TGATGTAAAG TAAATGAGCA GTTACCTGGC GGATTTTTTT TTTTTTAAAT
63151 AACTGATTTA ATCCATAATC CCATAACAAA CATAGCTTCA CCTCAGTATT
63201 TTCTTCTTTT CTTTGTCAA CAGTGCTCCG ATAAGGGAAT GCTAGAAAAT
63251 AGATGAGAAG TACTGAAAGA CCTTTTTTTT TAATTGATTA GAAAAGTAAG
63301 TCTCTAGGTT CTTTGAATGC TGGAAATTTT TTTTTTTTTT TTGCTTTTCC
63351 ACTCTGTGGC AGCTAAAACA AAAATCACTC AAAATATTCA GGTTTACATG
63401 TTAGCTCTCT CTCATAGGGA GCTGCCATAC CTCACAGTTC AAAGTGTATT
63451 CTATAGATCA GTAACATTAT ACTGACATGT AATTGCAATT TACTATGCAG
63501 CAAAAATGAT TCAAGAAGAA AAATAACCTA CAGTGTCTGT ATACCTTTGT
63551 ATACACAATT GCTTAAGTTA CTCTGCTTTT AACATTTGTA CTGGATAAAA
63601 ATGCTTATGT CTGTATAGGA ATGTCACAGT GCAAGATGCT GCTAGCCCAG
63651 GCACAAAGTA TTAATAATAT TTTGTGAAGA TTGGTGGTTG TATTAAAACT
63701 GCTGTGCCAT TATACCTCCA AAATATTGAA AAGCTCATTC ATACTGCTGC
63751 TGTATACCTA AAACCTCTTT ACTTAGATTG TTATCTGCTG GGTAAGTA
63801 ACCCAAATTT ACTCTGAGTT AAGAAGAGTG GATGAACATT GAATGTTGAG
63851 AAGCACTTAA GAGTATACTC TAAAACACTG TGGTTACACA CACACACAAA
63901 ATTAGGTTCT GTAGTCCAGG CAAGCCTCAA ATTCCAGCTC AAGTTTATTT
63951 TTAAGGATTA GTTGAGCAAG TTTGGAGTTG GAAGTGAGAG AATCGTGT
64001 AAAGGAAAGG GTAGGTCATC CACAGAACAG CTTTCAGTCA TTACAAAAAA
64051 AAAATACTTC TTGCTTTTAT ATTACCATCT TCCCCATTA GGCCTACCTG
64101 CATACTGTGC TTCATCAAAT CTAAGATCAC CTCACAACTA TACCATTATT
64151 TTAGGCACCA CTAAAAGACA GTGTATTGCT AACAAAAC TAATAAACCA
64201 TTGATAATAT ATCCAGATTT CAGAGATGTT ACAGTGCATC TTAGTTGATG
64251 AAACAAAAT ATACAAAACA TGAGACACAG TAAAATGAT AAGTACCACC
64301 TCATTATACC TTTTCACAAG CAAATAGTGG CCAAAGATGT GAACGGCCAG
64351 ACACGGTAGC CGACATATGT AATCCAGAT ACTCTGGAGG CTGAGGCAGA
64401 GGATCACTTG AGCTCAGGAG TTTGAGACCG GCTTGGGCAA TATAGTAAGA
64451 CCCACAGAA AAATGTAAAG CCAGGTGTGA TGGCACACAC CTGTAGTTCC
64501 AGCTACTGGG GAGGCTGAGG CAGGAGGGAT GGCTTGAACC CAGGAAGTGG
64551 AGGATGCAGT GAGCTATGAT CACACCACTG GACTCCAGCC TGGGTGATGG
64601 AGTGGGACAG TGTCTCTTTA AAAATGTGG GCCAGGTGCA GTGGCTCGCA
64651 CCTGTCATCC AAGCACTTGG GGAGGCTGAG GTGGGAGGAT CACTTGAGCC
64701 TAGGAGTTAA GAGACCAGCC TGGGCAACAT AGACTCCACA CAAAAAATTT
64751 TTTTAATTAG CTGGGTGTGG TGGCATGCAC CTATAGTCCC AGCCACATGG
64801 GAGGCTGAGG TGAAGGATC ATTTGAGCCC AGGAGATTGA AGCGGCAGTG
64851 TGTGGTGATT GTGCCCTGTC GCTCTAGCCT GGGCAACAGC GAGACCTTGT
64901 CTCAACAACA ACAACAACAA AAGGCTATCT ATTTGTTGGTA CACTGCCTAT

```

FIGURE 3

25/32

```

64951 GGGGTAGTCC TGCTCCACAA GGAGCAGTTT TTAACAAAAA AAAGTTTAAG
65001 AAGTGTTTTA TGTAGCACTT TTTTCATATT TACATTTACT CACCATATGG
65051 CTTCAAAAAAT CATAAACATA CTCAACTAAA ATTACAGATC ACCATTGTCC
65101 TCAATGACAC AATTTTTGTA TGGGTACCT TACCTGTAAT TCTATTTTCT
65151 ATGGGAGGAT TTAAGAGATA TCTTAGGAAC ACTATTTAAA GGGATTTACT
65201 GAAGTGCCAA CCTGTGAAT GATTTTACCT CAAATGTTC AGTGGTAAGA
65251 AAGGTAATAA AGCATTTAGT TGTGCCTTTA AGTAGGCTAA TTTTTTTTGT
65301 TTTGTTTTGA GATGGAGTCT CTCTCTGTCG CCAGGCTGGA GTGCAGTGGT
65351 GTGATCTCAG CTCACTGCAA CCTTTGCCTC CCGGGTTCAA GCGATTCTCT
65401 CGCCTCAGCT TCCTGAGTAG CTGGGATTAC AGGCGCATGC CACCACGTCT
65451 GGCTAATTTT TCTTTTTTTT AGTAGAGACA GGGTTTCACC ATTTTGGTCA
65501 GGCTGGTCTC AAACCTCTGA CCTTGTGATC TGCCACCTC AGCCTCCCAA
65551 ATGTGCTGGGA TTACAGGCGT GAGCCACTGC ACCCGGCCTT ACCAGGCTAA
65601 TTTTAAAAA CATGCGTTTT TAATTACCAG GATTTACCTG ATAAAACTAC
65651 TCTTTGTCAA GGTGTAGGA CTTCTGAAAA GACAGAATA GCTTTGTTC
65701 GTTTCACGAA GGACAGATCA GTTCGTCTGT ATAGGCTATA AGCAGGTAAG
65751 TAGTGCATC TATTGGTGAA GGATTTCTGT TGTTTTGAA AGCCAATAT
65801 AGCTGGCTGC ATGGAGGGAA ATCCAAATC CAGATGACGT GGTGTGAGTC
65851 AATGGGATGA GAAACACTGG TATTTTCTTT ACAATTTCT TTTACAAAGA
65901 GCACATTAAA CTAAATTTT ATGAATTATG ACTTAATCTA ATAGTTCAAC
65951 AGCAGACTCA AGAAAAGCAC AGATGTGATT CTAACAGAAG ACTACTCATA
66001 TAAACAGGTT TAATGCAACA TGGAAATGCAA AAGATTAGAA CCATTAAAT
66051 ATTTAATCT TCAACTTAA AAAATTAAT AAAATCAAAA TAGGATAATG
66101 ACCAGAATAG TGCCATTATA ATCACAATCA AAAGCTTCCA TTAACATTTT
66151 ATGAATTTGG CAATCTAGTA CAATACATTA AGTATTGTGT TCACTCAAT
66201 TTTGTGATAC TCCATTTTGG AAAAACTTA GAGGCTTCAG ATACCCATGA
66251 AAAGAAAAA ATCAGGGTAG AAACACATAG GCTGAGGTTT GCTAATTCAC
66301 TGTTTACAGA GGACCTTAGA TGTCCCACTA TAATGTCTCT TAGGTATTTT
66351 TAACAAATGA ATAGTCATAA TTCACAGAAA AGACAAGTGG TACTTTTTAT
66401 CTACATAGAC TATACTATAT AAACCTTCAG TAAACATTT AAATTGTTTT
66451 ACTTTTAATC TTGTCAAGTA ATTTTCATTT CTTCTACTTC AAAAGGTTGA
66501 CCAGGTTGTT TGCTGTATT GGGATCAACG AATGTTGAC TATACTATGT
66551 TTAGTTATAA TAACTAATTT ATCCACCTG ACTTAATATG TGGGAACAA
66601 TACACCCCTA AGTGATTTGA GATGTTCTT TGAACAAAA ATATTTAAT
66651 TTAGCATGT GATAACAGC CTTATTCAAT GTACTCTTT TTTAAATGAG
66701 CAACACAGAT AGCAGACATA TAACTCCTTA TTACCCATAC TCTTGACTAC
66751 CAAGAAAGGA AGCCAAACTT TTAGAAAAAT ACAATGCAAG AAAAGATTCA
66801 AGTTAAAAAT ATATTCCTTT GGTTAAAAAT CATCCCTTT ATAATATTCA
66851 TTTGTAATCT AAATTCACAG CATGTCCAC CAGCCCAAAG TAATCTCTA
66901 AATGTCATTA TACTTGTAGT ATTACAATGT TTTTTCAGTC CAGTATTTAT
66951 GGAGGTCATC CGGCTGCAGC AACAAAATAT TTCAACTCTA GGAAGAGTGT
67001 AGCCTTGTAG CATTAGCCCC TTTGACAATT TTCTTACAAG ATTTTACTT
67051 TAGAAACCTC CGACACATGT AGTTTCTTC AGATACAGTA TATCCAACT
67101 TTTTATAGAA ACCAACATTT TGTGGTAGAC ATTCAAGGGT AATCTGTAA
67151 CAGTTCAGTT TCTTGCTTAG CAAAGTAAGG GTTGATAATA ACCTGAAATT
67201 TAAAAAGGGG GTAGGGTGAG GAGATAGCAT TTATTAATAA AAATTGATTC
67251 TAGTAACAAT ATGAATTAAT GTTATAAAC TTAAGTTTCC TTAGAAACAG
67301 GTTTAGATTA TGGCTTTTCC CACTGCATTC ATGTAAGTTG ATAAGCATTT
67351 AAATCACCAG AGCATTTTAA CTTAGAGTCA AATATACTTT TATCTAGTAA
67401 TCTCCAGCTC ACTAATAAAC AGGACAAATA CAAAACTCAC CCTAAGCCCT
67451 CTTTAAAAAT GAAATTTAAG GCTAGGTGCA GTGACTCATA CCTGTAATCC
67501 TAGCACTCTG GGAAGCCGAG GCAGGCGATC GCTAGAGCCC AGGGGTTTGA
67551 CACCAGCCTG GGAACACGG CAAAACCCCA TCTCTACAAA ATATAAAAAAT
67601 TAGTAGGGCA TGATGGCACA TGCCTAAAGT CGCAGCTACT CCAGAGGCTG
67651 AGGGGGGAAG ATCACCTGAG CCCAGAGAGG TCAAGGCTGC GGTGAGTAGT
67701 GATTGTGCCA CTGCACTCCA GCCTGGGCAA CAGAGTGAGT CTCTGCTTG
67751 AAAAGAAAA ACGAATTTTA AGATGCATGT TAACACTAAA AACTCAACCT
67801 TTAACAAAAA AAATGACCAA AATTATTTTG TAAAAATTCT TTATTTAAAT
67851 CTATTTAAAC AACTTCGGAG CAGTCGACAT ACCCACAATA AATGAGTACA
67901 TAATAGCTTT GCTCTTAAAT CATTTTAA GCTACTTTAA TATTTGTGAA
67951 GGTGTGTATC AGATTAACTC AAGATTGGTC TAATTAATAT GAAGTGAAA
68001 CAAAGCAAGT CTACATCTAT ACAAATTTT TTAATGAATC CAAACCCAGT
68051 ATTAAAGTGT GGATCTAAGT GCCTTAGAGG ATAAAACTA TAAAGATAT
68101 ACAAACCTGA AGGGTCTGCC CATGTTTGA CAGACTAAAA AATCCTATTT
68151 TTAACAAAAA CAAAAGACCT TGACTGAAGT ATGCCTGGCT GGTTCAGTGT

```

FIGURE 3

26/32

```

68201 GCTCATGCCT GTAATTCCAG CACTTTAGGA GGCCAAGGAT CACTTGAGTC
68251 CAGAAGTTCG AGACTAGCCA AAGCAACATA GCAAAACCCT ATCTCTATAA
68301 AAAATTAGCT GGGTGCAGCG GCATGCACCT GTAGTCCCAG CTACTTGGGA
68351 GGCTGAGGCG AGAGGCTCAC TTGAGCCCCA GAAATTCAAG GCTGCAGTGA
68401 GCTGTGATCG TACCACTGTA TACTCCAGCC TGGGCAACAG AAAGAGATCC
68451 CATCTCTTAA AAAAAAAAAA AAAAAAAAAA AAAAACATAA ATTATATAGA
68501 CTAGAACACA AGAAATCGGT CTGTTTTGTT CACTGAGGTA TTCCAAATAC
68551 CTAGAAATAGC ATCTGGTACA TAAGCAGGTA TTTAATATTT GTTAATTCCT
68601 TAAACTCAG AAGAGTTAGT GTTAAAAAGC AAGTCTTGG GCCAGGCACA
68651 GTGGCTCCCA CCTGTAATCC CAGCACTTTG GGAGGCCAAG GCAGGAGCAC
68701 TGTTTGAGAC CAGCCTGAGC AACATGATGA GGCCCATCT CTACAAATTT
68751 TTAAAAATTA GCCAGGTGTG GCGTGACCT GTAGTCCCAG CTAATTGGGG
68801 GGCTGAAGAG GATTGCTTGA GCCCAGGAGG CTGAGGCTGC AGTGAGCTGA
68851 GATTGAGCCA CTGCACCTCA GCCTGGGTGA CAGAGCTGTC AAAACAGAC
68901 CCTGCTCAA AACTAAAAA TTATAATAAA TAAGAACTAC AAGTCTTAT
68951 AAAATGGCAA TAAATCAATA CCACTTATTT ATATTTATTT TAAATGATTT
69001 AGATATATAC AGTGAAGGCT GTTTCAGTAT GTATTCTAC AACTTATGAG
69051 AATGAGAGAT CACAGAATAT TCTGTAATAG TTGAACATTT CCTTTGTTTT
69101 TAAATATGAC AGAGAAGCTG AGGCAATCC GATTAGCCCA AAAGTTTATC
69151 TCCTACTAGG ACGAGAGCAT TACTATAAAA AGTTAGTAAT TTAAAGATGT
69201 TACTGTCTGT AAAGAAGTAT GCTTCCAATT TTCAACTTT AAGGCAAAAT
69251 ATGTATAATA ATACTTTATT TCTTCATGAA ATTCAGTCTA AACTATTAGA
69301 GTGAGAATAA GTTCAGAAAT AATGAAGCCA AAAAGAACTT CAAACAAGTA
69351 TCTTGTTAAG AACTAAATT GGAACAAAAT TTATCCAGGG TTACCTTGTT
69401 TCTGCTACT TACAATTGC CAAGCTGCTT TCCTCTGCAT TCATCACTAA
69451 CAACAACATC TTCTACTCTT CCTCTCTGAA AATATTTACA ATGTTTAAAG
69501 GAGTAAGCAT TTACTTTTGT TTTTAGCTAA AACGAGTTGG TAAGAATTTA
69551 CTGATAATAA GTAGTATATT TTGTAACCTT GAACCTAACA GAAATCAAAT
69601 GCAAAAAATA TTATACAGTG AAGGCTGTTT CAGTATGTAT TTCTACAAC
69651 TATGAGAAGG AGAGATCATA GAATATTCTG TAATAGCTGA ACATTTCCCT
69701 TGTTTTTAAA TATGACAGAG AAGCTGGGGC AAATCTGATT AGCCCAAAAG
69751 TTTGTTTCCT ACTAGTATGA GAGTACTACT ATTAAGTGT AATAATTTAA
69801 AGATGTTTTT ACTTATTAGA GGAAATAGTA TGAGTCAAGT TGTGACCTAA
69851 ACTTGTTTTG GCTATGTCCC CAACCTTCCC ACCCATTGT CTTAAACAA
69901 ATATCAGGAT CAACATCACC AAAATGTAAC CTTTTCATGA ATATATCCAT
69951 CATCTACTC CTGCTTACT AGCAAGTTAT TTTAGATATC CAAATAAAAT
70001 TAATGTCTAG TACAGAAACC CCACCGAAAT TCCTAAGTGT GACAGAACAC
70051 ATCCCAAGTG TTCCTACCTT ATTCTCATTG AATTAAGGTT TTCTCTCCCT
70101 CTTTTTTTAT TTACTATTTT ATGTGAGTTA TTGAGGGATG AAAGGGCACT
70151 ACATGCATTA GATGTATCAT AATTAGAACG GAATAATCTG AACCCTTTAC
70201 CATGTGGAAG CAAATTTATG CTAACGTGGT ATATTCAGAG TTGTTTTTTT
70251 TAAAGAGTA ACATTAGGGA TTTTGTGCAT TACTGCTAAG TTGTTTGGTT
70301 TCTCTATGCC TATACCAAAT TGATCCACCT TACAGAACAA TTTTAGCATA
70351 CAATTCATAC TGTATACAT TTTCTTCTT AAAGCTCTCA GAACACACTG
70401 GGAAAGGGA TTTCTAAGAG GCACTGAAAA TCAATGAGAA AACAGATTTG
70451 TCTAATGGAA ACTCAAAGTC AGTTGTGCTA GAAAACAGCT GTCCATTTTA
70501 TTTATAAGCA GCACATACCT TAGCACAGGA ATGGATGAAT TTATGTTCTA
70551 TAATCAGAGT TGCCGTAGCA ACAATCTGTC CTAGAGTCAC ATCTTCTACA
70601 ACTGTAACAT AATAATCCCC AGATTCTTTC ATATGCTCAA AAGATTCTGT
70651 GGAAATTGGA TAACAAAGTG TTACATAGTA GACATTCAT TTTATGGGGA
70701 GCCAGAAAAA TATTAGGATT AGCTGACTTA ATTACTAAAT GTTTAAAGCT
70751 GTTTTACCAT AGTAATTTAC CTTCCATTTC TAAAGAAAAT ATTACCAAGT
70801 AGTTGAAATA TCAGCAATTA GTATCAATTG GAATATAACC TACACATTCA
70851 AAATATCTGC TAGCAAAATA AAGACTAATA TAGCTATTTT AGATGAACAA
70901 CACTTAAAAA ACAAGTAAAT GGCTGATGTT GCCACTTCCA TGACTAATGA
70951 AAACCTTCAAT TTCTTCATTT ACTTTAAATA GATCTCTTTA ACTTTTATAC
71001 TCAATAGATA TTCAAATATA ACCTTTGCAC ATTTTAAACA GAGCATGTTT
71051 ACATGGCTCA ATTCTAGAAT TTTTAGTCTT TTGCTTTCAA AATATTTTAA
71101 CAAAATATAT TTAAATTTTC CCTTTGTGAT GGAAAGTGTT TTGTGATAAC
71151 ATGACTTTGCT CTGTTTGCT TTGAGAGCAC CTTGCAAGGA AGTAAAAACA
71201 TATCTGTTTC CAAGTAACTT TTCCAAGTCA CATAGCAAAT AGGTGCAAG
71251 ATACTTCCCC TCAAATGGAT TTTCACTACT ATTGCTGAAA TAACATGGTT
71301 TCTCATCTAA TTCATGTGCA TGCAAGAAA AAATTCAGGA ATAAAAATTG
71351 AGGCTAATAG TCTCTCATAT TGGTAATTTT CTATGGGGCC TCATTCCAGA
71401 TAGAGATCTA AAATGGGAAA AAGAAATTCA GTGAATGAAA ATAAACAATG

```

FIGURE 3

27/32

```

71451 AGTAATCAGT AATGATGGTC CTCATTCTCA GGAGGGTCAA ATAGCAATTC
71501 AATACAAAAT TCCCTATTAT AAGGAAATGA AGAATTGTAA TTCCTCAGCT
71551 ATTAATATATT ACTAAATATT TAGTAATGAT AATAATACTT CATTTCCTTT
71601 ATAACAGGAA AAAGCAGTGG TAGAGCACTG GACAGAATTA AGGTTTTATT
71651 CCTCACCGTA GCAATAACTA CCTGTGATCT TGGGCAAGTC TTTGGATCTC
71701 TCTAAATTC TATTTTCTCC TATGTCTAAA AGAAGAGGGG CAGGGGACGG
71751 GTGGACTAAC TCTTAAGATG CCTGCTAACC TTAAACTTCA ATACAAATAA
71801 ACCCCAAAAT AAATTTAAAG CGTATAGTCT TGCTTTTTTG ATTTGGTAAT
71851 GAAATTTCTG TAAATAACCA CAGTAAGGGA AATACTACAA TAAAAAACG
71901 AAAAACCTCT AGAGCTAACA CCTAGGTCCT ATGGTACAAT AATTATCTAA
71951 TAAAGTAGTC AGATAGTTTG CAAAAACAAA GTTACTGGTA CATTGGGATT
72001 CTAGAACAAC TCAGCCACAT TAAACATTG TATAAACAG CTAATTTGTT
72051 CTTTGAATAA TTTCCAGCTA TTTGAACAAA AACAGAAGTG GGCAGTGAAC
72101 AGCTCTAAAC AAAAATGAAA TCATGTTTCC CTTTATTTCA GAAAAAGAG
72151 GTTATAGTAC TTACTCATAA ATTGTTTCTG GCTGACAACT CCAGTCTCTG
72201 TTAGCTGACC CAATACCTTA AAAAAACCTA GTTTTGAAAA ACAGATTTC
72251 AATTACGAGA ATAGCAAAAG GAAGACAGTA TGAAAAAAG CAATATATTA
72301 AGCAGGTGGG CTTACAGGCA ATTATTTTTT CAGAACTTTC TATAATCTTT
72351 TAATTATTAG AATAAAGTGA ACCCTATTCT TCTATAATCA CTACATATAA
72401 CAAAAATAAC AGGTTTTACC AGTGCTTCTG CCTGCATAAG ATGTTTTAAA
72451 TAGTGCTGAC CTTAATATCC AGTATTTATA GACCCAGAAC ATACATTCTT
72501 CAATGTATTA TATTTTACAT TAAGTTCAAT GCAAAGGGTG CCAGATTTTC
72551 CCAAATATGT GATTTGGTTT TACTTAAAGG TGCAACATGG CTAATAACAA
72601 TATTCCGTAAA TTAAAGTATA AGTAACACTG TTGAGATTAC ACTCTTTAAA
72651 ATTGTAATTT CTAGTGAATT TCATTAGTGT TACCGGAAAT TGATGTGAAC
72701 AGTGCACTG GAATTTTGAA AATCTTAACT TTCCTACACT CAATAATTAG
72751 GCCAAAATTA GGCCCTTCAG GCTGTCTAGC AAAGAGATAA TTGTGAAAAG
72801 GACAAAGTTG ACTTTTAATT ACCAAAGTTT AAGGAAGTTA ACTTGGAGAA
72851 TTTAGATGTT AAAAAAGAAA TAACTGTATA AAAACCCCTT CAAATTTATCC
72901 AAGGAAAATT ATTTCCACCT TCATTCCCCA ACCAGCTTCT TAAGATCCCT
72951 CCTTATGTGT CATCATACAT GATAATTTAA TTTTGTGTTA TGAGAAATCT
73001 TTTTGGCTTA ATTAGGAAGG AGTGATGTTG TATTTAAGTC ATTTTAAATA
73051 TTTTACAGTA ATATTTGGTC TTAGCCATGA CACACACTCA TTGGTATGTA
73101 GTGTCCATCA CTTTAAAAAC .TAAGTATTAT AAAAAAATA GTCCAAAAGT
73151 CAAATATTTA AAAAAAATTA TCTGCATCAT AATGTTTGA GAAAAATGGA
73201 AGGCTAACTC TAATTTTACA CAGGATTTTG TACATTACCT CTATTTAAGT
73251 CAGCAGTACA AAGAGGCCTC AAAACCAAGC CTTCTCCAGG ATGTGTTGGG
73301 GAAATGGCTG GAGAAAATGT AGCTGTATTC TGACTCCAGT CCACTTCTTT
73351 GAGTAGACTT GGGTCAACAA TAGGAGTTTC ATCAGGTTTC ATTTTCTAG
73401 TAAGGTCTAA AATAAAAAAT TGAATATTAA GTCACCTTAT TTAATAGAAG
73451 GAAAAATTATG ATTGTTGAGA AAGTTAATAT AAATTAATGC AATTAGAAGC
73501 ATTCTTTAGC ACATATGCGA GATATTTTAC TGCAACCCAG CCTGAATCTA
73551 ACATTAAATT CCACAACACT AGATAAATAG AAAAATCATG CCTACTATCA
73601 GATAAAAAAA TGGCTAAGTG ACTAAATTAG TAAGTTTTTA ACTATAAAAT
73651 CCCATTTATT ATCAAGTCTT TTTTTTTTTT TTTTTTTCAG ACAGTCTCAC
73701 TCTGTTGCC AGGCTGGAGT GCAGAGGCGT GATCCCGGCT CACTGCAACC
73751 TCTGCCTTCT GGGTTCAGT GATTCTCCTC TTTGAGCCTC CTGAGTATCT
73801 GGGATTATAG GCACGTGACA CCACGCCCGG CTAATTTTTT TGTATTTTAA
73851 ATAGAGACGG GATTTGCGCG TGTTAGCCAG GCTGGTCTCA AACTCCCGAC
73901 CTCAGGTGAT CTGCCCGCCT CGGCCTCCCA AAGTGCTGGG ATTACAGGCG
73951 TGAGCCACTG CGCCCGGCTA GTATCAGGTC TTTTAAACAA TGTTTTCTCT
74001 CTGGGTGGT GCTACTAAAT GAATAGCTGA CTTTTCATGG GCTCTTAAAT
74051 TTTTACATT ATGTTCTTGG ATTTTATTAT TGAGCCAAGA AGGCATCTGT
74101 TTTCAACAGGA AATTGCAAGG GGAAAAAAAT TTTTTTAA AAAGTAATCT
74151 CTTAGTCTTA CTTGCCAATA AAGAAACTT TCAGCTGTGC ACGGTGGCTC
74201 ACACCTGTAA TACCAACACT TTGGGAGGCC GAGGTGGGCA GATCACCTGA
74251 GGTCGGGAGT TCGAGACCAG CCTGACCAAC ATGGAGAAAC CCCCATCTCT
74301 ACTAAAAATA CAAATATTAG CCGGGCGTGG GGGTATACCG CGTGAAACT
74351 TATTTTCCAT CTATGATGAA AAGTTAAGAA TATTCTGCC TACAGCATAC
74401 TGTGACTTAT GAAATAAGGA ACAATTGGGG GTTAGGTTAT TGGGCAAAAT
74451 GGTCTCTCAT TAAATATGG TTTCTTAAAC TGATATAGA AATAAGTTGG
74501 GGACTGCTTT TTTTGGATCT CTAATCCAAA AATCCAAAAC ACTCCAAAAT
74551 TTTGAAACTT TATTGAGGG CCAACATGAT TGCCACAAGT GGAAAAATCC
74601 ACATCTGGTA TAATGGACAA AAACCTTTCC ATGCACAAA TTTATTTAAA
74651 ATATGGGGT AAAATATTTG GGCTATCTGG ATAAGATGTA TATGAAACAC

```

FIGURE 3

28/32

74701 AAATGGAATT TTGACTTTGG GTCCCATCCC CAAGATATTC TTCATTATGT  
 74751 ATATTGAAAA TATTCGCCAA ATCTGGAAT ATATCCTATT TTTGAAATAC  
 74801 ATTATGTGTT TCCAAAACCT TGAAACATT TTTGGGCCCA AACTTTTGGA  
 74851 TAAGGAATAC TCAACTTTTA ATTTGTTGGG AAGCTTTGTT TTTTAAACAT  
 74901 TTTGGGCTG GAAAAAGCC CCCTGGCCCC AAATTTATCC CTTTGAATGA  
 74951 ATTGTTTAT CC

## FEATURES:

Start: 19364

Exon: 19364-19420  
 Intron: 19421-34110  
 Exon: 34111-34143  
 Intron: 34144-35683  
 Exon: 35684-35737  
 Intron: 35738-39940  
 Exon: 39941-40038  
 Intron: 40039-45810  
 Exon: 45811-45871  
 Intron: 45872-46578  
 Exon: 46579-46615  
 Intron: 46616-47002  
 Exon: 47003-47042  
 Intron: 47043-47133  
 Exon: 47134-47184  
 Intron: 47185-48943  
 Exon: 48944-49016  
 Intron: 49017-57568  
 Exon: 57569-57602  
 Intron: 57603-57761  
 Exon: 57762-59835  
 Stop: 59833

## SNP's:

Position	MMajor	MMinor	Context
3114	G	A	AGGCTGTTTGTATATGGACCACCGTTGGTATTGAATTATTTCTACTCCACCAATAAG ATAAATGAATTAAGGAATTAAGGACAAATTTTATTTTATTTTATTTTGTAGA CACGGTCTCACTCTGTTGCCAGGCTGTAGTGCACTGGCACAATCTGGGCTAACTGCAAC CTCTGCCTTCCGGGCTCAAGTGATTCTCCACCTCAGTCTCCACGTAGCTGGGACTGCA GCGTGTCATCACCATGTCTGGTTAATTTTGTATGTTTGTAGAGAAGCAATTTTGCCAT [G,A] TTGCTCAGGCTATCTCAAACTCCTGGACTCAAGCGATCTGCCACCTTAGCCTCCCAAAA TGTGGGATTACAAGCATAAACCACTGCGCTGGCCATAAGGTGGAATTTGATGTGGGC AGTTCCAACTTCTCCTCTCTTCAGAGTGAGAATGAGATAGGATATTTATGCTACTGTTT TTTGAGGCATGCTTAGTGCAATTTGTGCTCACAGTACATTTATCTTAACAGGCCATGTGA TTCTAGTGCAACAGTCCCAAAATTTGGTTTACAGACCCAGAGGTGCTTTCATGGACTCT
4004	-	A	TCCAGCCTGGCTGACAGAGTGAGACTCCTTCTCAAAAAAAAAAAAAAAAAAAAAATTT TTTTATATAAAGCAATGTACCTATAGCATACTGCTTGACATATGTAGCCCCACAATGAC ACAAAACAAAAAACTAAATGTTGTTTGGCTCTTCCACTGTGTTGACATTTGTGCTGATG GTGCAAGAGCACCATGGGTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT GGCATGAACGGTGCTAGTTAGTAGCCATTGCGTTCTTGACTGCCACATACTTGCACTGT [-,A] AAAAAAAAAAAGTCAGTTTCACTATAAAGTCTTGGTGAAACAGTAAAAATTATTAAT TTTGTAAATCTTCATCTTTGGGTAATATTTTGTGTTCTTCATGATAAAGGGAAAAATAA ATATAAAGTACTGTGCAATTTGAATAAGATAGTTGTCTTTAGGAAAGCACTTGTGCAG TTATTTAAGTTGCCAGCTGAATTCATTGCTTTTATGGAATACTATTTTGTCTTGAATGG ACCATTTACAGATATGCTGTGATTATCAGACTGGTTATTGGTTATTAGTTATTGATTACT
4514	T	G	TTTTATGGAATACTATTTTGTCTTGAATGGACATTTACAGATATGCTGTGATTATCAG ACTGGTTATTGGTTATTAGTTATTGATTACTCAAGACTGGTTTTTGGTTATTTGGCGCAC ATTTTTCCAAAGCGAACAATTAAGCCTGTGATGTTAAACAACTGACACCATCTATTGC CATTGATAAAATATGAATGTCAAGTGAATTAAGAAATTTTAGAAACATATATCTGGCA CTATGTGGTTGAAGCTTTTCTTTTTTCTTTTCTTTTCTTTTTTTTTTTTGATAAGG [T,G] GTTACTCTGTTACCCAGGCTGGAGTGCACTGGCGTGATCATCTGGCTCGCTGCAACTTC TGCCCTCTTGGGCTCAGGTGATTCTTCCACCTCAGCCTCCTGAGTAGCTGGTACTACAGGT GTGTGCCACCATGCCAGGCTAATTTTGTGTTTTTAGTAGAGGCAGGGTTTGCCATGTT GCCAGGCTGGTCTTGAATTCCTGGGCTCAAGCAACCCGCCACCTCAGCTCCCAAGT GCTGGGATTACAGGCATGAGCCAAATGTCCAGCCACGGCAGCTTCTAATATATTAATA

FIGURE 3

29/32

Position	MMajor	MMinor	Context
7570	A	G	<p>TAAATGTAAAAGAACCTTTTCCCTCTCTTAATCTGTAATGTGACTTGTATGAAGTAGA TACCACAATGAATCAGATGTTAGTTTAAACCAATTTTAAATAAATACCTTTTCATGGCCGGG TGTGGTGGCTCATGCCTGTATCCAGCAGCTTTGAGAGGCCAAGGTGGGCAGATCACCAG GTCAGGAGATCGAGACCATCTGGCCAAACATGGTGAACCCCTGTCTCTACTAAAAATACAA AAATTAGCTGGATGTGGTGGCAGATGCCTGTATCCAGCTACTGAGGAGGCTGAGGCAC [A, G] AGAATCGCTTGAACCCAGGAGACGTAGGTTGCAGTGAGCCGAGATCACACCCTGCACTC CAGCCTGGCGACAGAGCGAGACTCCGCTCTCAATAAATAACCTTTCACTTTAAACAAATGA GAAATGTACACCAAAATCAAGTCTAACTTTGTCAGCATAATCTTGCTCTTTAATTTTC ATCTTAATGTTTTAAGCCACAGACTGTTATGTTCTGTTTTCTTAAATGATGGTTGTAGAG GAAAAGAGTAATGCATATAAATTTCCAAATCTACTATCTTAGGTGGTCTGCGGTTTTCTG</p>
11672	C	G	<p>CTGGAGGAAAGGCAGAGTACATAGATGCTTATGATGACAGGTTCTTAGATAGTGCAGGAA CTTGTGGAAGTGTTTTTCTGAATGCTTCTGTTTTCTCAGTGAAGTAGAATGCACGTTTC AGAATGAAGATAGGGAAGTGTCTTAGAGATTGAGGACAAAGGAGAAGGTATAAAGTCA TTATCTATGGAAGTGAGGGATTGGACTAGGGTGCAGGCCAGTAAACATGGCTTGTGAAC CAAATTCGCTGCGCTGTGTTTTGAAACACACAAAGTTTGTGTAAACCAAGCATG [C, G] TCATTTATCTGTGTCTATGGCTGCTTTCTCTACTGGAATAGCTGAGTTGAATAGTTACAA CAGAAACCATATGGCTTGCAAGCATACAGTATTACTCTCTGCGCCTTTACATAAAAG TTTGCTGACCTCCAGACTAGGGAATCTAGTATAATTTCCAGGCAGCCTTAAAACTCTT TAGAAGTTAATGGTCCAGAATAATGACAAATAGCTGATTGTTGAATTTCACTATCTTCAT TGCCCTTGTTAGAGAGTTTGAGCTGGAAAGACCGAAGTGAACAAAGGATGTCAATGTAT</p>
11897	A	C	<p>ACATGGCTTGTGAACCAATTCGCTGCGCTGTGTTTTGGAACACACAAAGTTTGT TGTAACCAAGCATGCTCATTATCTGTGTCTATGGCTGCTTTCCTACTGGAATAGCTG AGTTGAATAGTTACAACAGAAACCATATGGCTTGCAAGCATACAGTATTACTCTCTGG CCCTTTACATAAAAGTTTGTGACCTCCAGACTAGGGAATCTAGTATAATTTCCAGGC AGCCTTAAAACTCTTTAGAAGTTAATGGTCCAGAATAATGACAAATAGCTGATTGTTGA [A, C] TTTCACTATCTTATTGCCCTGTAGAGAGTTTGAAGCTGGAAAGACCGAAGTGAACAA AGGATGTCAATGTATAGGTTTCTCCACAAATAGCTGAGCTCTTGCTAGATGCCAGATCT GTGCTAGCCTTGGGAATCTTGCTCTCAGGAAGCTTACAATGAACCTAAACCTGATTAAA GACAATTCATGAATATATGTGTGATTCAAAATAGAAACGACATGCCCTATATTGCCCTGA CCAAACGGTGCATCATCAAAGTTATTCAAACGTAGTAGCCTGTGCTGTCTTACTTCTCT GATTAAATTTAGTGTCTTTTTTAACTAGGTGGGACATTACATCTGGAACATACCTGAA ATTTTTATCTTCTTTTAGACTTGAAGGCTTTTTGTTAACTTTTCGTAAGTTAAAT ACACTTGATTCAACTACAGTTGCCCTTCCGTTCAGGTCCCTGACATTATCTCTTTGGAT TATAATACATCTCTATTTTATTTTCTTTTGGACGGAGTCTCACTCTGGCCAGGCTG GAGTGCAGTGGCATGATCACTGCTCCCTGTAGCCAGACCTGATCATTCTCTCTTTATCT [T, C] CCAGTAGCTGGGACTATAGGCGTGCGCCACCACACCCAGCTAATTTTTGTATTTTTGTA GAGACGGGTTTCAACATGTTGTCCAGGCTGGTCTCAAATTCCTGGGCCCCGAGTAATCCAC CCACCTGGGCTCCCAAAATGCTGGGATTACAGGCACAGCTACCAGGCTGGCCAGGCA TCTCTTGTGCAGATTACTTATTCACTAAAGTGATTGGAAAAATAGCCATGTGTGCAAGG TTTACAAAAATAACTTACCTAGTTTCACTGTAGCTTTCTAAACAAGTTTGAACCTTTGT</p>
14523	T	C	<p>GATTAAATTTAGTGTCTTTTTTAACTAGGTGGGACATTACATCTGGAACATACCTGAA ATTTTTATCTTCTTTTAGACTTGAAGGCTTTTTGTTAACTTTTCGTAAGTTAAAT ACACTTGATTCAACTACAGTTGCCCTTCCGTTCAGGTCCCTGACATTATCTCTTTGGAT TATAATACATCTCTATTTTATTTTCTTTTGGACGGAGTCTCACTCTGGCCAGGCTG GAGTGCAGTGGCATGATCACTGCTCCCTGTAGCCAGACCTGATCATTCTCTCTTTATCT [T, C] CCAGTAGCTGGGACTATAGGCGTGCGCCACCACACCCAGCTAATTTTTGTATTTTTGTA GAGACGGGTTTCAACATGTTGTCCAGGCTGGTCTCAAATTCCTGGGCCCCGAGTAATCCAC CCACCTGGGCTCCCAAAATGCTGGGATTACAGGCACAGCTACCAGGCTGGCCAGGCA TCTCTTGTGCAGATTACTTATTCACTAAAGTGATTGGAAAAATAGCCATGTGTGCAAGG TTTACAAAAATAACTTACCTAGTTTCACTGTAGCTTTCTAAACAAGTTTGAACCTTTGT</p>
16586	C	T	<p>AGCTTCACATTTATTCCATAGAATTATATTGTTTTCTTATAATGAACATATAATTTCATA TGTGATATATAGCAGTCATGTTGTTTTATTCTCTACAGGTATGTTCCGAATTCGTGCTGA TCATGATTTTGTAGTACAGGAAGACTTCATGAAAGCAGTCAGAAAAGTGGCTGATTCTAA GAAGCTGGAGTCTAAATTGGACTACAAACCTGTGTAATTTACTGTAAGATTTTGTATGGC TGCAATGACAGATGTTGGCTTATTGTAATAAATAAGTTAAAGAAAAATATGTATGATTGG [C, T] AATGATGTCATTAAGATATATGAATAAATAATGAGTAACATCATAAAAATTAGTAATT CAACTTTTAAAGATACAGAAGAAATTTGTATGTTTGTAAAGTTGCATTTATTGCAGCAAG TTACAAGGGGAAGTGTGAAGCTTTTCATATTTGCTGCGTGAGCATTTTGTAAATATT GAAAGTGGTTTGAAGATAGTGGTATAAGAAAGCATTTCTTATGACTTATTTGTATCATT GTTTCTCTCATCTAAAGTTGAATAAATCTGTTGATTCAAGTCTCTACATATATAT TATGTGATATATAGCAGTCATGTTGTTTTATTCTCTACAGGTATGTTCCGAATTCGTGCT GATCATGATTTTGTAGTACAGGAAGACTTCATGAAAGCAGTCAGAAAAGTGGCTGATTCT AAGAAGCTGGAGTCTAAATTGGACTACAAACCTGTGTAATTTACTGTAAGATTTTGTATG GCTGCATGACAGATGTTGGCTTATTGTAATAAATAAGTTAAAGAAAAATATGTATGATT GGCAATGATGTCATTAAGATATATGAATAAATAATGAGTAACATCATAAAAATTAGTA [T, C, A] TTCAACTTTTAAAGATACAGAAGAAATTTGTATGTTTGTAAAGTTGCATTTATTGCAGCA AGTTACAAGGGGAAGTGTGAAGCTTTTCATATTTGCTGCGTGAGCATTTTGTAAATA TTGAAAGTGGTTTGAAGATAGTGGTATAAGAAAGCATTTCTTATGACTTATTTGTATCAT TTGTTTTCTCTATCTAAAGTTGAATAAATCTGTTGATTCAAGTCTCTCATATATAT ATTCTTGTCTTTTCTGAGTATATTTACTGTGGTCTTTAGGTTCTTTAGCAAGTAAACTA</p>
16644	T	C	<p>TATGTGATATATAGCAGTCATGTTGTTTTATTCTCTACAGGTATGTTCCGAATTCGTGCT GATCATGATTTTGTAGTACAGGAAGACTTCATGAAAGCAGTCAGAAAAGTGGCTGATTCT AAGAAGCTGGAGTCTAAATTGGACTACAAACCTGTGTAATTTACTGTAAGATTTTGTATG GCTGCATGACAGATGTTGGCTTATTGTAATAAATAAGTTAAAGAAAAATATGTATGATT GGCAATGATGTCATTAAGATATATGAATAAATAATGAGTAACATCATAAAAATTAGTA [T, C, A] TTCAACTTTTAAAGATACAGAAGAAATTTGTATGTTTGTAAAGTTGCATTTATTGCAGCA AGTTACAAGGGGAAGTGTGAAGCTTTTCATATTTGCTGCGTGAGCATTTTGTAAATA TTGAAAGTGGTTTGAAGATAGTGGTATAAGAAAGCATTTCTTATGACTTATTTGTATCAT TTGTTTTCTCTATCTAAAGTTGAATAAATCTGTTGATTCAAGTCTCTCATATATAT ATTCTTGTCTTTTCTGAGTATATTTACTGTGGTCTTTAGGTTCTTTAGCAAGTAAACTA</p>

FIGURE 3

30/32

Position	MMajor	MMinor	Context
17969	A	G	<p>AATAGAAAATGGAGTGGTCAAGTTAGCCATCTCATACTCAAATATTGTACAGTTCTAT  TTCTATGTGTGGCAGTGCAATTTATGTGACAAAAAGTAGAATGTAGGGGGAGGTTTAAAG  TCAAATATCTATGTGATCTTTTCACTTATAATTTGCATTTAGTTAAGGAGTGACTATCTT  GCCTTTTACCTTTGTGCTGGCGGTGGTTTTTAAAGAATCAATTTGGTGTACAAATCCTT  TCTTTCTTTTTTATTTTGTATTTTTTTGAGATGGAGTTTCGCTCTTGTGCCAGGCT  [A, G]  TAGTGCCATTGCACTATCTCAGCTCATTGCAACCTCCGCTCCCGGATTTAAGCGGTTCT  CCTGCCTCAGCCTTCTAAGTAGCTGCGATTACTGGCATGCGCCACCACACCCAGCTAATT  TTTGATTTTTTAGTAGAGACGGGGTTTTCCATGTTGGTCAGGCTGGTCTCAAACCTCCG  ACCTCAGGTGATCCACAGCCTCAGCCGCCAAAGTGTGGGATTACAGGCGTGAGCCTC  CGCGCCCGCCCAAATCTTTTACCATGGGTTTACAGGCATAACGCCACCACCCAGGG</p>
18117	C	T	<p>TAATTTGCATTTAGTTAAGGAGTGACTATCTTGCCTTTTACCTTTGTGCTGGCGGTGGTT  TTTTAAAGAATCAATTTGGTGTACAAATCCTTTCTTTTATTTTTGATTTTTTTT  TGAGATGGAGTTTCGCTCTTGTGCGCCAGGCTATAGTGCCATTGCACTATCTCAGCTCAT  TGCAACCTCCGCTCCCGGATTTAAGCGGTTCTCCTGCCTCAGCCTTCTAAGTAGCTGCG  ATTACTGGCATGCGCCACCACCCAGCTAATTTTGTATTTTAGTAGAGACGGGTTT  [C, T]  TCCATGTTGGTCAGGCTGGTCTCAAACCTCCCGACCTCAGGTGATCCACAGCCTCAGCCG  CCCAAAGTGTGGGATTACAGGCGTGAGCCTCCGCGCCCGGCCCAAATCTTTTACCATTG  GGTTTACAGGCATAACGCCACCACCCAGGGAATTTAAAATTGTTTTTAGAGAGGGG  GGTCTTACTATTTTGTCTCAGGCTGGCAAACCTCTTTTAAAGATATTGAAGCCATCTGG  TTTATATTTTTTTTCAAATATAATAATGAAGAAATTTTACAGTATTATATACAAT</p>
18518	C	A	<p>GCCCAAATCTTTTACCATTGGGTTTACAGGCATAACGCCACCACCCAGGGAATTTTAA  AATTGTTTTTGTAGAGAGGGGGCTTACTATTTTGTCTCAGGCTGGCAAACCTCTTTTAAA  AGATATTGAAGCCATCTGGTTTATTATTTTTTCAAATATAATAATGAAGAAATTT  TTACAGTATTATATACAATTTACTGAGTCAGCTATCAGTTCCCTTTTCTGATTTTTTCT  AGTTGCCATTCTGATATTTTCTAGGTAATCTAACTGAGTTGTATTTTCAAGTACTCTT  [C, A]  AAATACTTTAAAAATTTTAAATTGAGCCGTTTAAATCTTTGCTTAAAGGTGATGGGTAT  TTTATTTTCTGTATGGCACCACGTGATTTTAAATTGAACCTCTTCAATTATTAGTCATTTG  GTTATAAATCAGCATAGATTGCGCAGAAATTTTGTAGAGGGGAGAACTATAGCTTTCCCTT  TCGGATGCCACTGGTGGGTAGCCTGTTTGGCTGTTTGTCTTATGTTAAAGAGGGGCTC  TACGTCCTGTCTGGAAGGGGCGAGCTGGCTCGGACCGCCCACTGCCTTTCCAGGACC</p>
19882	G	A	<p>TGAGTTGCTCGTCTCTCCAGACCCCGCGGAGGGGAGCGCTGTTGTACTTTACATTGA  GAAGAGGAAAAGCAATCCCTTAGTCCCTAGGCTTGGCATCCAGGACTGACCTGGAGTAAG  GTTCTCTTTTATTGTCAAAGTAACAAGAGAGCGAAGTTGGTTTAGTCTCCTTTTGAGGA  ATATCTGTGGTGTAACGATTCTCTTGTGGGACACATGGCCCAACATGTGAATAGACTC  GGCGCCTGAAGTTTGAAGCGCGCTTCGAAAAGTTTCCCAAAGTTTTTGTGTGTTTTT  [G, A]  GACAAAGCTATGACCCGCACAACAAGTGTCTCAAAGCTAGTCTATCTTAATCTGAGAAC  TCTTAATCAGAAATCTTGACCTTTGGAGGAAAATTAATATTGAAAGTAAATACTATATA  CCTTTTCTCCTGGTTTCTAATTTGTGGCTATTTTACTCCACCTTAGATCCCTGCCTGCT  GTTTCTACTCGGATTTTTTTTCTCTGTGTAGTTTAACTTTTACGGCAATTCAGACT  ACTAAATAGAATTTTCTGGAGGCTAAATTAACAAGACGAAGATACTCAGCTATACCTTA</p>
20988	G	-	<p>TAAGAGTAGAGACTTTGTTTGTGACTATCACTGTTGCAAAATGTAGTGCACTGGTGTGAT  CTCGGTTCACTGCAGTCTCGAACTCCCATGCTCAAGCCATCCTTTCACTCAGCCTCTGG  AGTAGCTGGGACCATGCCGGCTAATTTTCTTTTTTTTTTTTTTTTGTAGCGATGGGTTTT  TTCTCCAGGCTGGTCTCGAACTCTTGGCTCAAGATCCTCCCGCCTTGCTCTCGAAAGT  GTTGGGATTACAGGTGTAGCCACTGCACCTGGCCCAAGAATATACTCATGGTTTTTTTG  [G, -, T]  TTTTTTTTTTTTTTTACACAGAGTTTCACTCTTGTGCCCCAGGCTGGAGTGCACTGGC  GCTGTCTCAGCCCAACCGCAGCCTCTGCCTCGGGTCCCGGTTCAAACAGTTCTCCTGCCTA  AGCCTCCTGAGTAGCTGGGGATTACAGGCGCGCACCGCCAGGCCAGCTTTTTTTTTTTT  TTTTTTTTTGTAGACAGAGTCTCACTCTGTGCGCCAGGCTGGAATGATCTTGCACTGGTGGC  ATCTGGGCTCACTGCAAGCTCTGCCCTCCCGTGTTCAGGCCATTCTCCCGCTCAGCCTCC</p>
20999	-	T	<p>ACTTTGTTTGTGACTATCACTGTTGCAAAATGTAGTGCACTGGTGTGATCTCGGTTCACT  GCAGTCTCGAACTCCCATGCTCAAGCATCCTTTCACTCAGCCTCTGGAGTAGCTGGGA  CCATGCCGGGCTAATTTTCTTTTTTTTTTTTTTTTGTAGCGATGGGTTTTTCTCCAGGCT  GGTCTCGAACTCTTGGCCTCAAGATCCTCCCGCCTTGCTCTCGAAAGTGTGGGATTAC  AGGTGTGAGCCACTGCACCTGGCCCAAGAATATACTCATGGTTTTTTTGTTTTTTTTTT  [-, T]  TTTTGACACAGAGTTTCACTCTTGTGCCCCAGGCTGGAGTGCACTGGCGCTGTCTCAGC  CCACCGCAGCCTCTGCCTCGGGTCCCGGTTCAAACAGTTCTCCTGCCTAAGCCTCCTGAG  TAGCTGGGGATTACAGGCGCGCACCGCCAGGCCAGCTTTTTTTTTTTTTTTTTTTTGTAG  ACAGAGTCTCACTCTGTGCGCCAGGCTGGAATGATCTTGCACTGGTGGCATGGGCTCA  CTGCAAGCTCTGCCTCCCGTGTTCAGGCCATTCTCCCGCTCAGCCTCCCGAGTAGCTGG</p>

FIGURE 3

31/32

[illegible]

FIGURE 3.



32/32

37703	A	G	CCATTATCTAAAAACAACAACAAAAATAATAATGGAGATAAACCTAAATGGATAAACTC CTTTTTAAACACTCATTACTGTTATTATTTTGTGGGAGAGGAGTGGGGTCTTGCTCTGT TACCCAGGCTGGAGTACAGTGGCGGCTCTCATAGCTCACTGTAACCTCAAACCTCTGGG CTCAAGCTGTCTTCCACCTTAGTCTCCCAAGTAGCCAGGACTACGGGCACACACCACCA TGCCTGGCTTAATCTCAAAGTTTTGTAGAGATGGAGTCTGGCTATGCTGGCCACATTT [A, G] CTTAAGTATATCTTTTTATTAAATTCAAATACAGTTTAAATAAAAAGGGACAAATTTAGGG CCTTTGTAATTAGTAACCGGTTTGTTTTGTAAAGTTTTTCTACTGTTTTTAAATGTGAG GTAAGGTCATAATTTGCTTCATATTAGGTTGGTGCAAAAGTAATTGCAGATCTGCCCTCTG AAAAGTACAAAATCTATTGCTGTTACGTTAGGGCTCTATTTTGATAGTTATTTTTATT TAGTAGTAGTCTATTGGGCTTCAAACCTTGTAAAGCATATTTATACATAATTATGTGC AACCTTATTATCTGGTAATTTCTAGAATTGTCATGTTAAATTGCTTAAAGTATGGAGCCAA AAGCACTACAGTTGAGTATCCCTAATCTGAAAAATCTGAAATGCTCCAAAGTGAACTT TTTGAGTGTGAGCATGACAGCACAAGTGAATTCACACCTGACCCCATGTAATGGGTCAC TGTCAAAATTTTGTTCATGCAACCAATGACTGTATGAAATTACGTTACAGAGTATATATG GTGTGTGTGAACATAAATGAATTTGTGTTTAAACTTGGATACCATCCCCAAGACATCT [C, G] AGTATGTATATGCAATATTTCAAATCTGAAATCTGAAACACTTCTGGTCCTACCTTGG GACCAGCATTTTAGATAAGGGTACTCAACCTGTATTGAATATAATAAGATGTCATTGAA GTTGCCATTTTAACTTCAGGAAAAATTTTAAATGGTAAAGGTTAATTAGATTCTGTGA AGTATGTAAATTAATCTGACTCTTAAAGTACTGGGAGAGGCAAGGAGTTGCTAGAG ATTTGGGTTCCAGTACTGCTGTTAACTAGGTCGGTGATGTCCAAGTATTGGTAATGTAA
39269	C	G	AACCTTATTATCTGGTAATTTCTAGAATTGTCATGTTAAATTGCTTAAAGTATGGAGCCAA AAGCACTACAGTTGAGTATCCCTAATCTGAAAAATCTGAAATGCTCCAAAGTGAACTT TTTGAGTGTGAGCATGACAGCACAAGTGAATTCACACCTGACCCCATGTAATGGGTCAC TGTCAAAATTTTGTTCATGCAACCAATGACTGTATGAAATTACGTTACAGAGTATATATG GTGTGTGTGAACATAAATGAATTTGTGTTTAAACTTGGATACCATCCCCAAGACATCT [C, G] AGTATGTATATGCAATATTTCAAATCTGAAATCTGAAACACTTCTGGTCCTACCTTGG GACCAGCATTTTAGATAAGGGTACTCAACCTGTATTGAATATAATAAGATGTCATTGAA GTTGCCATTTTAACTTCAGGAAAAATTTTAAATGGTAAAGGTTAATTAGATTCTGTGA AGTATGTAAATTAATCTGACTCTTAAAGTACTGGGAGAGGCAAGGAGTTGCTAGAG ATTTGGGTTCCAGTACTGCTGTTAACTAGGTCGGTGATGTCCAAGTATTGGTAATGTAA

POSITION	Allele 1	Allele 2	
3114	G	A	Beyond ORF (5')
4004	-	A	Beyond ORF (5')
4514	T	G	Beyond ORF (5')
7570	A	G	Beyond ORF (5')
11672	C	G	Beyond ORF (5')
11897	A	C	Beyond ORF (5')
14523	T	C	Beyond ORF (5')
16586	C	T	Beyond ORF (5')
16644	T	C	Beyond ORF (5')
17969	A	G	Beyond ORF (5')
18117	C	T	Beyond ORF (5')
18518	C	A	Beyond ORF (5')
19882	G	A	Intron
20988	G	-	Intron
20999	-	T	Intron
21465	A	G	Intron
21625	C	T	Intron
26291	C	T	Intron
28012	T	C	Intron
28030	T	G	Intron
33671	A	C	Intron
37703	A	G	Intron
39269	C	G	Intron

Map:

Bac accession number: AL139317.2

Human chromosome 14

FIGURE 3

## SEQUENCE LISTING

<110> Wei, Ming-Hui  
 Sanders, Robert D.  
 Gilbert, Dennis A.  
 Beasley, Ellen  
 Bonazzi, Vivien R.

<120> ISOLATED HUMAN PHOSPHATASE PROTEINS,  
 NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS,  
 AND USES THEREOF

<130> CL000871PCT

<140> US 09/685,853

<141> 2000-10-11

<150> 60/182,194

<151> 2000-02-14

<160> 3

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1218

<212> DNA

<213> HUMAN

<400> 1

```

aacaccacgc gtccggcagc ggcattggcgg ccgggtgttaa gacgcccgc cctcctcttc 60
cctgtcttcg ccgccgccgc tgctggagtc actgggaccc ttagtctctc gtgtgttagt 120
tgtaatcccg ccgccctcct gtcagccctc cgctccgccg gccctccttc cttccgccgc 180
cgcagccagc ccgaggggtcg gccggctgtg taacactctc ccaccccacc caccagcccg 240
cgggcagca ccatggagga cgtgaagctg gagttccctt cccttcacca gtgcaaggaa 300
gacgccgagg agtggaccta ccctatgaga cgagagatgc aggaaatatt acctggattg 360
ttcttaggcc catattcatc tgctatgaaa agcaagctac ctgtactaca gaaacatgga 420
ataaccata taatatgcat acgacaaaat attgaagcaa actttattaa accaaacttt 480
cagcagttat ttagatattt agtcctggat attgcagata atccagttga aaatataata 540
cgttttttcc ctatgactaa ggaatttatt gatgggagct taaaaatggg aggaaaagtt 600
cttggtgatg gaaatgcagg gatctccaga agtcagcct ttgttattgc atacattatg 660
gaaacatttg gaatgaagta cagagatgct tttgcttatg ttcaagaaag aagattttgt 720
attaatccta atgctggatt tgtccatcaa cttcaggaat atgaagccat ctacctagca 780
aaattaacaa tacagatgat gtcaccactc cagatagaaa ggtcattatc tgttcattct 840
ggtaccacag gcagtttgaa gagaacacat gaagaagagg atgatttttg aaccatgcaa 900
gtggcgactg cacagaatgg ctgacttgaa gagcaacatc atagagtgtg aatttctatt 960
tgggaaggag aaaatacaag agaaaattat aatgtaaaat ggtaaaaaca taagtagttt 1020
ttttttcaat tacatgttgc ttccagacat acttctctgc aacttggtga gcaacatttt 1080
aagatgttgg acttctgcaa tagatgacac tgatgttttt actccttttt tttaaaaaca 1140
catgcgcgcg cacacacaca tgctttacaa gttttattat aaaccaagaa ttttggactt 1200
gcaaaaaaaaa aaaaaaaaaa                                     1218

```

<210> 2

<211> 223

<212> PRT

<213> HUMAN

&lt;400&gt; 2

```

Met Glu Asp Val Lys Leu Glu Phe Pro Ser Leu Pro Gln Cys Lys Glu
 1              5              10              15
Asp Ala Glu Glu Trp Thr Tyr Pro Met Arg Arg Glu Met Gln Glu Ile
      20              25              30
Leu Pro Gly Leu Phe Leu Gly Pro Tyr Ser Ser Ala Met Lys Ser Lys
      35              40              45
Leu Pro Val Leu Gln Lys His Gly Ile Thr His Ile Ile Cys Ile Arg
      50              55              60
Gln Asn Ile Glu Ala Asn Phe Ile Lys Pro Asn Phe Gln Gln Leu Phe
      65              70              75              80
Arg Tyr Leu Val Leu Asp Ile Ala Asp Asn Pro Val Glu Asn Ile Ile
      85              90              95
Arg Phe Phe Pro Met Thr Lys Glu Phe Ile Asp Gly Ser Leu Gln Met
      100             105             110
Gly Gly Lys Val Leu Val His Gly Asn Ala Gly Ile Ser Arg Ser Ala
      115             120             125
Ala Phe Val Ile Ala Tyr Ile Met Glu Thr Phe Gly Met Lys Tyr Arg
      130             135             140
Asp Ala Phe Ala Tyr Val Gln Glu Arg Arg Phe Cys Ile Asn Pro Asn
      145             150             155             160
Ala Gly Phe Val His Gln Leu Gln Glu Tyr Glu Ala Ile Tyr Leu Ala
      165             170             175
Lys Leu Thr Ile Gln Met Met Ser Pro Leu Gln Ile Glu Arg Ser Leu
      180             185             190
Ser Val His Ser Gly Thr Thr Gly Ser Leu Lys Arg Thr His Glu Glu
      195             200             205
Glu Asp Asp Phe Gly Thr Met Gln Val Ala Thr Ala Gln Asn Gly
      210             215             220

```

&lt;210&gt; 3

&lt;211&gt; 74962

&lt;212&gt; DNA

&lt;213&gt; HUMAN

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(74962)

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 3

```

ttgaaatcca aaaatatctg aagctacatt tggacccctg taaataatgt aatgtataag 60
gattttttcca aaataagtct taatttcagt tttcatatat caacaaaaag gtactattag 120
gagtacatag ttgccacact tgagacatat tccaaatgca tacacctaac ggtactacta 180
ttacagaaca gcacattcta atccacatat acacgagttt taattaaatt tagcactatg 240
tctataatca gaatgaatac ctggaataca tgtttctagc aggaatatatt gttagcagct 300
ttaaggtagt tgaaatcacc ataatcattt ctatttttaa tttaaatttc actactgggg 360
taaattccat gagggaaggt tgtggctatg aatttttatt tattcttttt cttttgtggg 420
aaatatggag aacttaccaa atctcttata tagcctggct gtagatggca atgcgaggaa 480
agaaaaagga agcagaaaga aaaaaaaagg caatcagaaa aaatggcaac gaagcaaaga 540
aaaagttgcg gtcacctgca aacaaaaatt ccagccaaaa gtcatgcaaa aaactacttt 600
aggtagaac caagcaaagt aaatgcaaga atgaaaaatg aaaatgagga agcagcaatt 660
actttccatt tagaactctg agaaacactc cacattattt tagaatgtta aatgttgcta 720
aagaacctaa gggtagaaat ttgtagggag aagataaaaa gagcaaatat ttctttcccc 780
ctacatcgtg taccaggtta catcgtgtac ccagtttctc ccggttaagg taaagccaat 840
tatttttagta gcaaaataaa agtatccaaa agcctttaaa gtcttctcag atttagtcag 900
ataaatgatg ccatgcactg cttttcagaa ataagaattt gaaggcataa aataagtgca 960
gtgcccattc gttttttttt ttacacaaga aaagcaaacc cctcagttac catgtgtttt 1020
ttgcatcctt tttcctggaa gggaaaacaa agagatgccg tatactacat gaggaatttc 1080
ggctttatgg cattagtcac ttccatttag attaacataa atcaacatat agaataattc 1140

```

ttcaaaat	ttt	gagagtc	atatttat	aaaaata	acagcatgtt	1200
tagttaata	atatataa	gaagggaatt	aaagtaggtt	aaatacaaca	ggttattttg	1260
atagacccaa	aagaaaacta	cgagtctatg	cccaggtagg	gaagaatgtc	cttgtggcct	1320
gcacatcttc	ctacagcctc	cagaacgcaa	ctggatacag	cttaataatt	actgagcact	1380
atgtccagtg	tgactagtgt	ggtatctgac	acacagtagc	aactaaactt	ctgaatgtca	1440
ctacttacta	ggcaccaggg	caataacatc	atggctcgta	ttctctggaa	acaatttttt	1500
tttctgacac	ggagtttcac	tcttggtgcc	caggctggag	tgcaatggcg	ccatcttggc	1560
tcactgcaac	ctccacctcc	caggtagagg	tgattctcct	gcctcagcct	ccaagtagc	1620
tggcattata	ggcgtgcacc	accatgcctg	gctaattttt	gtagttttag	tagagatggg	1680
gtttcaccat	gttgccagg	ctggtctcga	actcctgacc	tcaggtgttc	cactcacctc	1740
ggcctcccta	agtgtggga	ttacaggtgt	gagccaccgc	acctagccca	acacaactat	1800
tcaatagaaa	tttctctctc	ggtcaggcat	ggtggctcac	gcctgtaatc	ccagcactct	1860
gggaggctga	ggtgggtgga	tcactcgagg	tcaggagttc	aagaccagcc	tgccaatata	1920
gtgaaacccc	atctcttcta	aaagtacaaa	aattagccag	gtgtggtggt	ggcgctgta	1980
gtcccagcta	ctcaggaggc	tgagacagga	gaatctcttg	taccgggag	gcagaggttg	2040
caatgagcca	agatcatgcc	attgcactcc	agcctgggca	acagactctg	tctcaaaaaa	2100
aaagaaat	ctctcttaag	ttactggtac	tataagtaat	ttaaattgga	ctttcagatc	2160
ttcaatttct	ctagtctcta	ctttctctcc	ttgaatcagt	cttgagagca	gaacatactg	2220
ttctttaaaa	gctgccgtgg	caaaatgcc	acagataaaa	attgtatata	ccttttctct	2280
tggtatgttg	tcaaatccat	ccccattttt	agaattat	tgtgttgtat	tttcaaatgc	2340
aaactagtat	agatcttttg	agttgtgttt	tttgtttata	tgttcatttg	acttaactga	2400
ttttttgtg	gtataat	tcattgaggt	ataattacat	taaaaaatg	tagattctta	2460
agtgtacatt	tcaaataatg	ttggacaagt	tatatatctg	tgttaaccatc	acccaatca	2520
agtgtgtggt	ttatttataa	aacattat	gaaatttttt	agatttaaga	gatcttaaat	2580
ctacctggag	caaaacctct	taataataat	ggttttacct	agcatggaag	tctaggtcta	2640
ttaagaatta	tgatgtgtac	acctaactaa	ggtgatattt	gacttagagt	atttgaaagt	2700
acattaaaaa	tcttgactaa	ctttttaaga	aagatttaac	ttcttttcta	ggtgatagaa	2760
ttactcttta	caaaaccaga	gttatttcag	cgtgtaggaa	taataacctcc	aaaaggctgt	2820
ttgttatatg	gaccaccagg	ttggtattga	attatttcta	ctccaccaat	aagataaatg	2880
aattaaggaa	ttaaaaaaa	aaagacaatt	tttttat	tatttttttg	agacacggtc	2940
tcactctgtt	gccaggtg	tagtgcagtg	gcacaatctg	ggctaactgc	aacctctgcc	3000
ttccgggctc	aagtgttct	cccacctcag	tctccacgt	agctgggact	gcaggcggtc	3060
atcaccatgt	ctgggttaatt	ttgtatgtt	ttgtagagaa	gcaattttgc	catgttgctc	3120
aggctatctc	aaactcctgg	actcaagcga	tctgccacc	ttagcctccc	aaaatgttgg	3180
gattacaagc	ataaacctact	gcgcctggcc	ataagtgga	aatttgatgt	gggcagttcc	3240
aaactctcct	ctcttcagag	tgagaatgag	ataggatatt	tatgtctact	gttctttgag	3300
gcatgcttag	tgcatttgtg	cctcacagta	catttatctt	aacaggccat	gtgattctag	3360
tgcaacagtc	ctcaaattgt	ggttcacaga	cccagaggtg	cttcatgga	ctctgtaagg	3420
tcaaaactac	tttataatac	tgaaatgtta	agccaggcgc	agtggctcac	acctgtaatc	3480
ccagcacttc	gggaggccga	ggcaggcaga	tcaccagagg	tcaggagttt	gagagcagcc	3540
tgggcaacca	acagatgaa	accctgtctc	tactaaaaat	acaaaaatga	gccaggcggtg	3600
gtggcgtgca	cctgtaatcc	cagctactcg	ggaagctgag	gcaggagaat	tgcttgaacc	3660
tgaggagcag	aggttgagc	gagccgagat	tgccccactg	cactccagcc	tggttgacag	3720
agtgagactc	cttctcaaaa	aaaaaaaaaa	aaaaaaaaaa	attttttata	taaagcaaat	3780
gtacctatag	catactgctt	gacatatgta	gccccacaat	gacacaaaac	aaaaaactaa	3840
aatgttggtt	ggctcttcca	ctgtgttgac	atgtgtgctg	atggtgcaag	agcaccatgg	3900
gtaaaattaa	attacttgca	ctgtagtgtg	aatcagcatt	agtggcatga	aacggtgcta	3960
gttagtagcc	attgcgttct	tgactgccac	atacttgca	tgtaaaaaaa	aaaaaaagtc	4020
agtttacta	taaagtcctt	ggtgaaacag	taaaaattat	taattttgtt	aaatcttcat	4080
ctttgggtaa	tattttgtgt	tcttcatgat	aaaaggga	ataaatataa	agtactgctg	4140
catattgaat	aagatagttg	tctttaggaa	aagcacttgt	gcagttat	aagttgccag	4200
ctgaattcat	tgctttttat	ggaatactat	ttttgcttga	atggaccatt	tacagatatg	4260
ctgtgattat	cagactgggt	attggttatt	agttattgat	tactcaagac	tggttttttg	4320
ttatttggcg	cacatttttt	ccaaagcgaa	caaattaagc	ctgtcatggt	aaacaactga	4380
caccatctat	tgccattgat	aaaatatgaa	atgtcaagtg	aaaattagaa	tttttagaaa	4440
catatatctg	gcactatgtg	gttgaagc	tttctttttt	tcttttcttt	tctttttttt	4500
ttttttgata	aggtgttact	ctgttacc	ggctggagtg	cagtggcg	atcatcctgg	4560
ctcgctgcaa	cttctgcctc	ttgggctcag	gtgattcttc	cacctcagcc	tctgagtag	4620
ctggtactac	aggtgtgtgc	caccatgcc	ggctaatttt	tgtgttttta	gtagaggcag	4680
ggttttgcca	tggtgccag	gctggtcttg	aattcctggg	ctcaagcaac	ccgccacct	4740
cagcctccca	aagtgtctggg	attacaggca	tgagccacaa	tgtccagcca	cggcagcttt	4800

ctaataatatt	aatacttaaa	gacttttctg	atgagataag	tgggtgagaat	aacaaaaatt	4860
ttttataatg	tgtggtggaa	aatgtcaaca	tttgaagat	ttgcataact	caaccagtag	4920
tttccaaata	atcaatgctt	gatattaaaa	tattcataag	taaaagatcc	agtcagtgc	4980
caggatagac	caatgtattt	taatgtaaca	gaagtttctg	tcatagtcca	tgttgtaagt	5040
agatagctat	tataaaaaag	acaaaagtgt	ttgcaagatg	tagagaaaag	agaaaagaacc	5100
cttgtagact	actggtggga	atgtaaatta	gcacagccat	ttttgaaaac	atggagggttc	5160
ctcaaaaaac	taaaaaataga	attaccatat	gattcagcaa	tcccacttct	gggtttatat	5220
ctaaaggaat	tgaatcagat	gtgtcagaga	tagctgcact	cccatgatta	tttcacaata	5280
gccaagatat	agaaacagcc	taaaaattgc	ccatcaatgg	atgaatggat	aaagaaaatg	5340
tggtagccgg	gtgcagtggc	tcataacctgt	agtccaaca	ctttgggagg	ccgaggcggg	5400
cggatcacct	gaggtcggga	gttcgagacc	agcctgacca	acatggagaa	accccgcttc	5460
tgctgaaaat	acaaaattag	ctgggtgtag	tagttcatgc	ctgtaatccc	agctactcgg	5520
gaggcagagg	caggagaatc	acttgaacct	gggaggcaga	ggttgacagt	agctgagatc	5580
atgccattgc	actccagcct	gggcaacaag	agtgaacctc	catctcaaaa	aaaaaagaaa	5640
aagaaatgtg	gtaaattcac	acattggaat	actattcagc	cttaaaaaag	gaaactctgt	5700
catttgtgac	aatatggatg	aatctagagg	atgttatact	aagtgaata	agccagacac	5760
agaagacag	ttaccacata	atctcatttt	catgtggaat	cttaaaaaat	tgaactcgta	5820
gaaaccaaga	gtagaatggt	ggttaccaga	agttgtggtg	gtgtatgggg	ataggggaga	5880
tgttggtcaa	aggatataaa	gttcaacttag	acaggaggaa	taagttctag	gtgacatatt	5940
gcatagcatg	gtgacataaa	ttaataatgt	attagctatt	tcaaaattgc	taaaagttaga	6000
ttttaaatgt	tctaaccaca	aagtaatgct	aagcatgtga	ggcgatggat	atgttgattt	6060
gcctgattta	atcattcttc	aatatataca	tgtatcataa	tttaacccat	aatatataca	6120
tttatttgtc	aatttataaa	agatttttaa	aattataaca	ttttgattaa	aatttttaag	6180
ttgacagcag	aagtactttg	gaattttttt	tttttttttt	ttttttgaga	cagagctctg	6240
ctctgtcacc	caggctggag	tgcaagtggc	agattataag	ctcactgcaa	ccccacctc	6300
ccggattcaa	gcatctctcc	tgccctcagc	tcccagtag	gtgggactac	aggcatgtgc	6360
caccacgctc	agctaatttt	ttgtattttt	agtagagacg	gggtttcact	gtgtttcgt	6420
ctcctgacct	tgtgatctgc	ccgcctcagc	ctcccaaagt	gctgggatta	cagggtgtgag	6480
ccaccacacc	tggccaagta	ctttggaatt	ttaaatgaaa	attctattta	ggatttagct	6540
ttcatttttg	aaaatttact	tgccaacga	ttatattctt	aaaaggattt	taaaaatttg	6600
tttcacatag	gccgggtgcg	gtgggttctg	cctgtaatcc	cagcactttg	ggaggctgaa	6660
gtggcaggat	cacctgagcc	caagagttca	agaccagcat	gcgccaacac	agagagacc	6720
cgtctctgaa	aaacaacag	acaaacaaaa	aacttagctg	tgctgatgg	cacatgcctg	6780
tcatcccagc	tacttgggag	gctgaggtgg	gaaaatcgct	taggtctggg	aggccaaggt	6840
tgcaagtgac	tgtgatctcg	ccacactccc	agcctagggt	acagagtgt	tgccctgtctc	6900
aaaacaaatt	tttttctacc	ttaccatcta	attaagactt	cttttgtcat	tcttaggtac	6960
gggaaaaaca	ctcttggcac	gagccgttgc	tagccagctg	gactgcaatt	tcttaaaggt	7020
aaagggaaga	ttattttgta	cttattgaaa	tttaatttta	ctggaattat	cttatattta	7080
cottactgtt	tttcctttaa	tcagggttga	tctagtctta	ttgtagacaa	gtacattggt	7140
gaaagtgtc	gtttgatcag	agaaatgttt	aattatgcta	gagatcatca	accatgcac	7200
atttttatgg	attgaaataga	tgctattggt	aagaataaca	cccttggtga	aagttttagg	7260
actttttttt	aaatgtaaaa	gaaccttttt	ccctctctta	atctgtaatt	gtgacttgta	7320
tgaagtagat	accacaatga	atcagatgtt	agtttaacca	attttaataa	ataacctttc	7380
atggccgggt	gtggtggctc	atgcctgtaa	tcccagcact	ttgagaggcc	aaggtgggca	7440
gatcaccagg	tcaggagatc	gagaccatct	ggccaacatg	gtgaaaccct	gtctctacta	7500
aaaatacaaa	aattagctgg	atgtggtggc	acatgcctgt	aatcccagct	actgaggagg	7560
ctgaggcacg	agaatcgctt	gaaccagga	gacgtaggtt	gcagtgagcc	gagatcacac	7620
cactgcactc	cagcctggcg	acagagcgag	actccgtctc	aataaataac	ctttcacttt	7680
aacaaaatga	gaaatgttac	accaaaatca	agtctaactt	tgtagcata	attcttgctc	7740
tttaattttc	atcttaattg	tttaagccac	agactgttat	gttctgtttt	cttaaatgat	7800
ggttgtagag	gaaaagagta	atgcatataa	atttccaaat	ctactatctt	aggtggtcgt	7860
cggttttctg	agggtacttc	agctgacaga	gagattcaga	gaacgttaat	ggaggttaata	7920
tttggttaaag	ggggtttata	aagaaaccaa	tgtttattaa	atgaagaact	gaacattgca	7980
tatttgatag	tcaaaatata	tagaacattt	taaatgaaat	atgaaatttg	aaaatattgt	8040
caggaacaaa	catgtttctc	tatcacaaac	tctaagcaaa	atgactactg	gaaaataagg	8100
ctatctgcca	aattccattt	ggtatacacc	tgtactattc	tgtgtttttt	tgagtagatc	8160
agtcattcat	atattttaa	tcttatgaat	gtgatcttgc	ggtagtttta	tgaagacatt	8220
ttttgtaatg	gtcatattaa	gactgttggc	aataaatgag	ctataattat	gtatgaagct	8280
gctctaaaaa	ttattttttt	ctctcacttt	attgctgaga	ctgaggcaac	taaaaatagtt	8340
ttgataattg	aagaggatag	atgacagaat	gaaagaatgc	acataaagcc	ttcctccagt	8400
tttacctttc	cccactccaa	attctgtgaa	agtgatatca	agagtccaaa	tacattttcc	8460

acttcaaata gaaactaggt agcatgggta atgcagtgtc aaattctttc tccttagaag 8520  
 tatttgaaaa atcttttttc ataaattata cagatccgct cagaagataa catagcattt 8580  
 ggaaattata aaatctctta gaaaccttaa attgagatat ttttaataa cacaataact 8640  
 catttttatt caagtaacta atatatcatc aactaacaca ttgtcaggac tagctatatt 8700  
 tttagagagg tttgtttaa gtagtaaaagg tttttcattt attcaagaaa acttttagaaa 8760  
 ttgaggacaa ttttttttat gtcttttagt atttctgtgt acagtagaat tatttgaaaa 8820  
 aataggccag gcatgggtgc ttctgcctgt aatcccagca ctttgggagg cccagctggg 8880  
 cagatcatga ggtctga gca ttgagaccag cctgaccaac gtagcgaaac accatctcta 8940  
 gtaagatac aaaaattagc tggcggtggt ggcgtgtgcc tgtaatccca gttactcagg 9000  
 aggctgaggc aggagaattg cttgaaccca ggagggtagg ttgcagtgagg ctgagatcgc 9060  
 cccattgcac tccagcctgg gtgacagagc gagagtctgt ctccaaaaaa aaaaaaaaaa 9120  
 aaaagcagtc ccagctactc aggaggttga ggtgggaggga ctggtcgagc ccaggagggtg 9180  
 aaggttgtag tgagcgatga tcaggccaca gtactccagc ctgggtgaca gagtgaact 9240  
 ctgtctcaaa aaaaaaaga ctatcaaata tgcaatgttc attatcagtt tattatcaaa 9300  
 tttgtagaaa aatctttgta tccatttatc tcaatataaa tgttatgtct gacatatcta 9360  
 aagcacttta tatattgga tttattatta gcttttcctt taaaaataa ttgatgaaat 9420  
 tttggacatt ggaaattaga tccacatagt ttaatttcat aattcttgac atgatggaag 9480  
 ccttcagatt tattaaaact acctggtagc tatagaaaga tacatagcta ttaaaaggta 9540  
 cataatctag cttagaactt tgaggctaga aagtatatcc ctttatataa gagagagaaa 9600  
 aagaattcta tcaaatgacc attctgaaga tagaacatat ctatctgtag acaatacatt 9660  
 tcatggcatt agacataata aaggtgtgtg ctattttttt taatggttag aatttttcta 9720  
 aaatctgatt cttaatattc ttagttagt aatcaaatgg atggatttga tactctgcat 9780  
 agagttaaaa tgatcatggc tacaacacaga ccagatacac tggatcctgc tttgtcgtgt 9840  
 ccaggaagat tagatagaaa aatacgtgag ttaagattct ttacctactg tccatttccc 9900  
 tttgtgcccc tttctttttc catacttcac ttcaccttcc actgtatttt aaaaaagata 9960  
 aaactggact ataaaaataa tttttatttt cagatattga tttgccaaat gaacaagcaa 10020  
 gattagacat actgaaaatc catgcaggtc ccattacaaa gcatgggtgaa ataggtaagg 10080  
 aagtcacata ttttatatgt atttacattt ggtaaatgaa gaaaaatact tttagaatt 10140  
 actgatagtt tcctaaatct ggttttaaat tcagcaaatg tgggtggttt aaattcagca 10200  
 aatagttatt gagcatctac tataagctag gaaccattgt aagtgttttg taagggtcta 10260  
 caatatagca aggaacaaaa cagacaaatt tctgccatta gagaacttat attcttgta 10320  
 ggaaaaaaca gataaagtta gtaaaacaaa gtataataga tgatgataag tgctatggag 10380  
 aaaaataaag caagaaagtg gggggcgggc atggtggtc actcctgtaa tcctaatggt 10440  
 tttggaggcc gaggcagaag gaccgcttga ggccaggagt ttgaggttgc agggagctat 10500  
 gatcatgtga ctgcactcca gtttggcaag acgctgtttc aggggaaaaa aaaagaaaag 10560  
 ggggatagga aattaggga gtgccaggac caggcatgag gatattgttt taaatgacag 10620  
 ggaggattag cacagggaag gccttaccaa gaaggtaat ttttttttag agacagggtc 10680  
 tcaactctgc ccaggctgga gtgcaatggt gtgatccag ctactgcaa cttctgcctc 10740  
 ccaagttcaa atgatcctca cacctcagcc tcctgattag ctgggactac aggcacacac 10800  
 caccaacctt ggcttgtttt tttgtaggga tggggtttca ccatgttgcc caggctgatc 10860  
 ttgaactact gggctcaag atactgccc cctcgccac ccaaagttct gggataacag 10920  
 gcgtgtgcca ctgcaccgg cctggttgtt tgtttgtttg ttttttaaat tgattcctgt 10980  
 taaatgctga caataggtca gataaagagt tctcagagta gacctttgga ttttaactata 11040  
 tggagggtcat tggtaatctt gtcaaaagta gcttcttggg agtgggtggag gtgaaagcct 11100  
 atttcagatg ggtttcagag agattgggag gagaggcatt gaggtttagac atttctttta 11160  
 agagttctac agagggggca gaagaagtag aaggggaatg ccgatgagga gttggcagag 11220  
 ttttctataa gatggaagag tttatgacct cctgcccctt tttttttttt ttttaataat 11280  
 gctactggga atgacctagg agaaagagaa atttgcaatg ttctttcctt gaagagggat 11340  
 tggccctata tatatgtgta cttttatgag actggaggaa aggcagagta catagatgct 11400  
 tatgatgaca ggttcttaga tagtgaggga acttgtggaa gtgttttttt ctgaatgctt 11460  
 ctgttttctc agtgaagtag aatgcacgtt cagaatgaag atagggaagt gttcttagag 11520  
 atttgaggac aaaggagaag gtataaagtc attatctatg gaagtgaggg attggactag 11580  
 ggtgcaggcc agtaaaacat ggcttgtgaa ccaaattctg cctgccctgt gtttttgaa 11640  
 acacaacaa gttttgtgta acccaagcat gctcatttat ctgttgtcta tggctgcttt 11700  
 cctactggaa tagctgagtt gaatagttac aacagaaacc atatggcttg caaagcatac 11760  
 agtatttact ctctggccct ttacataaaa agtttctgta cctccagact agggaaatct 11820  
 agtataattt ccaggcagcc ttaaaaactc tttagaagtt aatggtccag aataatgaca 11880  
 aatagctgat tgttgaaatt cactatcttc attgcccctg ttagagagtt ttgagctgga 11940  
 aagaccgaac tgaacaaagg atgtcaatgt ataggtttct tccacaaata ctgagctctt 12000  
 gctagatgcc agatactgtg ctagccttgg gaattcttgc tctcaggaaag cttacaatga 12060  
 acttaaacct gattaaagac aattcatgaa tatatgtgtg atttcaaata gagaacgaca 12120

tgccctatat	tgccctgacca	aacgggtgcat	catcaaagtt	attcaaactg	tagtagcctg	12180
tgctgtctta	cttctcttcc	tattctgtat	cagatccatt	gttgctaccc	caatcctata	12240
gctctttgat	tcatgtctgt	tatgtgggtg	gatggagaac	tcactttatt	actgctacca	12300
tagatctgat	acttcaccac	ttgaatcttg	cacagaaacc	agagaagcta	gctaattgcat	12360
gctgtagcat	ttaaaaattc	catgtgatac	aattatgtat	gattacattt	cagttttgct	12420
atactttata	tttggtctgt	atgattaaag	taaacaaagt	aaattccatt	gttataaattg	12480
gttttgagtg	ttataggttt	attcaaatcc	aagatttgat	tacagttttg	ataagagtca	12540
cagcttaaca	ggatctgga	gttcacatgt	gcatagctat	ttcactgtat	aaaaatagat	12600
taagatattt	tgagattttg	gtgatatttc	ctgtttttta	agtttcaggg	gtgtgtctaa	12660
ttcttcttgg	tgctggttta	tttaacagaa	gtcttagttt	ttggatatta	atattgttga	12720
aagttaacag	agctgatgtc	tagctgatca	aactcaaagt	aagctcttca	gtttaaattt	12780
tcgatgtggg	cataaatcaa	gtaaaggtct	aattttttaa	actaatttcc	agtatttttt	12840
ctaaacagat	tatgaagcaa	ttgtgaagct	ttcggatgpc	tttaattggag	cagatctgag	12900
aaatgtttgt	actgaagcag	gtaagggttt	aaagtacagt	tttactattg	attttgattt	12960
ttaaaatttg	ctgaaactgt	tttgagttta	tctgaaagcg	gagcatagac	tttgcaagga	13020
tttggtttca	tgctgttctt	ttaggaaatcg	attccaggaa	ataggagaag	cagggcaagt	13080
gagatggaaa	gagggaaagc	taatatgagg	gtgcaccatt	gaggtaggtg	ctgtaggaaa	13140
gggaggttag	atctcagaga	agcatacaga	atgccttcca	ggatcaccca	gctgaaagtt	13200
gggagactag	aacattgatt	taccagtact	catcccccat	tggatgagat	ttgtccttgg	13260
tagtgttgac	tcctttgcac	ttctacctgc	cttagggcag	aatgtggaaag	gagaggcatg	13320
taatagaaca	ctggccccct	aaagtaagtc	tgaggtgcta	cagaattgcc	taccacacct	13380
gtggctggaa	ttagaatggg	ccagcaccag	aggtatctgc	tgcaaaatga	attgtgtatg	13440
ttgtctaata	ctagtctgtg	agcagtgttt	tgaaagattg	atttatgaat	tatgtgatca	13500
tgccatttgt	gtaaaatgta	gtatttaaat	ataattctct	gtggattgtg	tgatactatt	13560
tttttcactt	ctacatggta	tgtaaaaatt	gtgtgatgct	atttttattt	ccagtaccaa	13620
gtagctttta	taccctacct	agaatcattt	agtttttgtc	ttccatacag	aatcttttaa	13680
tagaaaaaat	aaacttctac	agtatagtta	ctgactttat	aggttataga	ttttcttaag	13740
tattagaata	tgtgatttcc	tcttgctttt	catatcatgt	ttagccttag	taaattcaac	13800
acagtgttta	aagtggctgc	tcagggaggg	cttctcagta	caggtatctt	catgggtatt	13860
gggtatgctg	tgagtcagta	tctgcatcag	atatgcagg	cagatacttc	tgttcacgtc	13920
tagaaatgct	gtcaatgcaa	attagggtaa	atcatgctca	cagagcggtta	tcaataaact	13980
aaactatttta	gaggtaaact	gtcataatagc	tgaacaagt	tagagtaatt	tatgacattc	14040
tctttccaaa	atgtaaacca	gaccaaatta	ttatcagaag	attgcttttg	ttagattgta	14100
atccaaatgc	aagctgtgca	gtgaacctaa	aggctgttgc	tatcaaaaata	tacgcttttt	14160
ttcctttacat	attctttaca	atttaccttt	agttattgca	aatgagctat	aacttctgtg	14220
tggtattaaa	ttgtagttct	tttttaacta	gggtgggacat	tcacatctgg	aaacatactg	14280
aaatttttat	cttcttttta	gacttgaagg	cttttttgtt	aacatttttc	gtaagttaaa	14340
atacacttga	ttcaactaca	gttgcccttc	ctgttcagg	cctgacatta	tctcttttgg	14400
attataatac	atctctattt	tattttttct	tttgagacgg	agtctcactc	tggcccaggc	14460
tggagtgcag	tggcatgatc	actgtccctt	gtagccacga	cctgatcatt	tctcctttat	14520
ctcccagtag	ctgggactat	aggcgtgcgc	caccacaccc	agctaatttt	tgtatttttt	14580
gtagagacgg	gtttcaccat	gttgtccagg	ctgtgtcaca	attcctgggc	ccgagtaatc	14640
caccacacctg	ggcctcccaa	aatgctggga	ttacaggcac	aagctaccag	gcctggccag	14700
gcatctcttg	tgcatattta	cttattcact	aaagtatttt	ggaaaatagc	catgtgtgca	14760
aggtttacaa	aaataactta	cctagtttca	ctgtagcttt	ctaaacaagt	tttgaaactt	14820
tgttattttt	taaaaatcag	tcattttccat	tcacccggtt	tctaggacaa	catagattgt	14880
ttccttatgt	agaaatctag	aaaggaagta	atccttgaaa	tcttctatat	taactccctc	14940
attttatgta	agtgaataat	caatacaggc	agatcctcag	tggaaatttt	agaattcatt	15000
taattagtag	atagcaataa	acttacctgc	tttagtttat	catgagttag	gattatctca	15060
aaatctggga	cccatatcca	taacacaact	aatgttttaa	aaactgcata	caaggaaact	15120
tttacccttt	tgtcaaatac	tgtttgagaa	ggtacttgtc	aaaaagttga	aggaaaaaat	15180
tgagttgtga	tactcaaata	tgaatcaaatt	aaaaatacca	atttgtacat	aaattaggta	15240
aatttttaaca	catgaataat	gactccgagt	tttgctaaaa	cccgtgtgtg	gctttctata	15300
tgattcccta	ttctcaacgt	ttttgattat	taacaaagaa	tggctatcaa	acttactcaa	15360
gatttttttt	ccccataaaa	tgtgtgcctt	ccagcaaat	gcttctgtc	aagtttaagtt	15420
acgcttaaaa	tgtgtatgtg	ttggtagttt	tgattgtctc	ggttttttat	gcttgttttt	15480
attaagagct	acaatcagat	acagggacca	tttaagcctg	attttatttt	attttatttt	15540
tttgagacag	agcctcactc	tgtcacccag	actggagtgc	agtgggtcga	tcttggctca	15600
ctgcaacctc	tgcctcccgg	gttcaagcga	ttctctgcc	tcagcctccc	aagtagctgg	15660
ggttacagat	gcccactact	acgcccagct	aatttttgtg	tttttagtag	aaacggggtt	15720
ttaccatggt	ggctagagctg	gtctcgaact	cccgaaccca	ggtaatccgt	ccaccttggc	15780

```

ctcccaaagt gttgggatta cagggtgtgag ccaccgtgcc cagccttgaa ccggatgtta 15840
aatattcata taatggcat acctgttttt gttttagaac ataatacaca caccgctatg 15900
gatttttttt tttttttttt ttttgagatg ggggtctcgct ctgttgccag gctggagtgc 15960
agtgccacta tctcagctca ctgcaacctc cgcctcctgg gttcaagcca ttctcctgcc 16020
ttagcctccc gagtagctgg gactacaggc gcgcgccacc atgccagct aatttttttt 16080
tttttttgta ttttttagtag agatggggtt tcaccgtgtt ggccaggatg gtcttaatct 16140
cttgacattg caatctgccc atcttgccct cctaaagtgt tgggattaca ggcgtgagcc 16200
accgcacccg gcctgtggat ttttaattgaa aaaagatagt ggttttttagc aaattacaac 16260
tactggctca gaagtaataa atctaagctt cacatttatt ccatagaatt atattgtttt 16320
tcttataatg aacatataat tcatatgtga tatatagcag tcatgttgtt ttattctcta 16380
caggatgtgt cgcaattcgt gctgatcatg atttttagt acaggaagac ttcatgaaag 16440
cagtcagaaa agtggctgat tctaagaagc tggagtctaa attggactac aaacctgtgt 16500
aattttactgt aagatttttg atggctgcat gacagatgtt ggcttattgt aaaaataaag 16560
ttaaagaaaa taatgtatgt attggcaatg atgtcattaa aagtatatga ataaaaatat 16620
gagtaacatc ataaaaatta gtaattcaac ttttaagata cagaagaaat ttgtatgttt 16680
gttaaagttg cattttattgc agcaagttac aaagggaaag tgttgaagct tttcataattt 16740
gctgcgtgag cattttgtaa aatattgaaa gtgggttgag atagtgggtat aagaaagcat 16800
ttcttatgac ttattttgta tcattttgtt tctcatcta aaaagttgaa taaaatctgt 16860
ttgattcagt tctcctacat atatatctt gtcttttctg agtatattta ctgtggctcct 16920
ttaggttctt tagcaagtaa actatttgat aaccagatg gattgtggat ttttgaatat 16980
tatttttaaaa tagtacacat acttaatgtt cataagatca tcttcttaaa taaaacatgg 17040
atgtgtgggt atgtctgtac tctcctttc agaaagtgtt tacatattct tcatctactg 17100
tgattaagct cattgttgtt taattgaaaa tatacatgca catccataac tttttaaaga 17160
gtatgattca acgtaatat tgctaatatg tgactgggtt ttcttggttt atgtaagacg 17220
ataggctcct gttgaggatg tgaaaggtctg gaccctctc caggaaaaat tctaacatac 17280
aattttgcgt atactataat ttcaggaaat ttattgtttc ccaagctcat ccaaggattc 17340
ttaggtatg taatggatacc tggctaagag tgtatgatgt aggggatgta ggagtgtcag 17400
aaatgttcaa aacatgattt ctgttaccta tacatgattc ttatatcatc tggcaataaa 17460
agctataaca aagtacacaa aggaatcatc attgggcatc aataattatt aaagatgctg 17520
gtgaaaagaa aagacaactt cagtttcata aacactaaag aaccaaaaaat acatgaccta 17580
gctaattata caataattct tcaaattaaa aacttcctag caggatatta tgtgcctttt 17640
tataattttt agaaagatga acagttaaaa tagaaaatgg agtgggtcaag tttagccatct 17700
catactcaaa attattgtac agttctattt ctatgtgttg gcagtgcatt ttatgtgaca 17760
aaaagttaga tgtaggggga ggtttadgtc aaatatctat gtgatctttt cacttataat 17820
ttgcathtag ttaaggagtg actatcttgc cttttacctt tgtgctggcg gtgggttttt 17880
aaagaatcaa tttggtgtac aaatcctttc tttctttttt tatttttgat tttttttgag 17940
atggagtttc gctcttgttg cccaggctat agtgccattg cactatctca gctcattgca 18000
acctccgcct cccggtttta agcgggtctc ctgcctcagc ctctaaagta gctgcgatta 18060
ctggcatgcg ccaccacacc cagctaattt ttgtattttt agtagagacg gggtttttcc 18120
atgttgttca ggtgtgtct aaactcccga cctcagtgta tccacacgcc tcagccgccc 18180
aaagtgcgtg gattacaggc gtgagcctcc gcgcccggcc caaatctttt caccatgggt 18240
ttacaggcat aacgccacca caccaggga attttaaaat tgttttttag agaggggggt 18300
cttactatth tgcctaggct ggcaactcc ttttaaaaga tattgaaagc catctgggtt 18360
attattttta tttcaaaaata taataatgga agaaatttta cagtattata tacaatttac 18420
tgagtcagct atcagttcct tttctgtatt tttttctagt tgccattctt gatattttct 18480
aggtaatcta aactgagttg tattttcaag tactcttcaa atactttaaa aaattttaaa 18540
ttgagccggt taattctttg cttaaagggt atgggtattt tattttctgt atggcaccac 18600
gtgattttta attgaactct tcatttatta gtcatttgggt tataaactca gcatagattg 18660
cgcagaatth tgagagggga gaaactatag ctttcccttc ggatgccact ggtgggtagc 18720
ctgttttgcc tgtttgttct tatgttaaag aagggtcta cgtcctgtct ggaaagggcg 18780
gagctggctc ggaccgcccc actgcctttc ccaggacctt cactcgtcct gtcccaccgc 18840
agccccgcct cctccacgcc ggggtgagctg tggcctagca gcacccgagg ctccgcccc 18900
cccaccccc agcgtctgcg ctctagcgaa gggcgcgagc agggcggttg cgcgctgaca 18960
cctgcccgcg gcggaggcgc ggcaagagc gagcgtgggc tgggattggc tgaggcgacg 19020
cgggtggagg gggcggaag gagcgggga gacgggtgt cggcgtggtt cctgtgctgg 19080
atcctgggag gcctgagggg tacggagact ctgggggagg gagacggcag cggcattggc 19140
gccgggtgta agacgcccga ccctcctctt ccctgtcttc gccgcgccc ctgctggagt 19200
cactgggacc ctctagtctg cgtgtgttag ttgtaatccc gccgccctcc tgtcagccct 19260
ccgtccgcc ggcctcctt cctccgccg ccgcagccag cccgagggtc ggccggctgt 19320
gtaacactct cccacccac ccaccagccc gcgggcccag accatggagg acgtgaagct 19380
ggagtccctt tccctccac agtgcaagga agacgccgag gtgagtcgct cccgtggctg 19440

```



tccttttgggt	acttaggcgt	ggaaagttag	ggttttccct	tcaagttagt	tctgggaagt	23160
cggggtgaaa	cagccttaga	ttccctgcct	ccagacccta	ttcacctgcc	tcactagcac	23220
ctccagtggt	ttcatccaga	agctcaacaa	atcttattca	acggttttta	tagaacttca	23280
tctccatccc	ctcccataga	ggtgtgtgtg	tgtgtgaggc	tgagagttca	accctcttgt	23340
cacatgggtct	ttctggtgac	tggccccacc	ctaaatcact	tcatttagcat	aatcaggttt	23400
gatcaaaaat	agtggctcat	aaataaccaa	agacactcct	attagaaaat	tccaagagtt	23460
ttaggaggac	tgtgacagga	actggagaga	aagaccatgt	atttcatatt	atatcacagg	23520
gacagaggta	atggttaaag	ctagtggata	atgatgcaag	tattgtctgc	tgaaagccaa	23580
ttcgttccgt	atttcttaat	attgcatggt	tggatatctt	tgggtgcaag	caacaaaaac	23640
gaatttaaga	aaaagaagaa	gtaattaaat	ccggccgggc	gcggtggctc	acgcctgtaa	23700
tcccagcact	gtgggaggcc	gaggcggacg	gatcacgagg	tcaggagatc	aagaccatcc	23760
tggctaacac	ggtaaaaccc	cgtctctact	taaaaaaaa	ttagctaggt	atggtggcgg	23820
gcgcctgtag	tcccagctac	ttgggaggct	gaggcaggag	aatggcatga	acccgggagg	23880
cggagcttgc	agtgaagcga	gatctagcca	ctgcactcca	gcctgggaga	cagagcgaga	23940
ctccatctca	aaaaaaaaaa	aagtaattaa	atccagaagg	gtagtgggtg	agctagtttc	24000
aaggatttga	ccaaacccag	gtattataaa	gcatacgaac	tgcctttgtc	tctcatgagt	24060
tcttatctct	actttctctc	agagtctctg	ctttctctct	ggcttctcca	agatgtgaag	24120
cttggccatc	tggggtcaca	cctttatgag	cttgggtatt	gaggaataaa	actgaacact	24180
tccagcttct	gtgtttgaaa	tctagaggaa	ttgcccatt	taattcatgt	tcccacactt	24240
tggatcagtc	actgtagcca	ggaaagggca	gatacaatga	ggggcccat	ctaggtcata	24300
tccctaattc	cttggctaga	ggagtgaagt	ttattgttgg	tagccctccc	accaaaccac	24360
taggaacatt	tccacaggtg	gagggtactt	tctgggctga	taaaaactata	cataggggcc	24420
acataaataa	actattaaat	aggagcatat	agttattcat	aataaaactga	ctaataagca	24480
ctgttaattt	tctaactctc	agtgaataa	tgtaaagtgt	caaatggtct	taagtagtta	24540
gagtgatcag	ccagcattgt	ttctttgaca	caggagcac	tacctggaaa	tccaaattac	24600
agaccaaaat	taataaaaaa	ggaattcaag	cagagagttc	aggggaatgct	tttaatgtta	24660
atgtgatcaa	gctatgatag	gttgatgatt	ctgtcacctc	tacaagaata	ttactttcac	24720
gtttcttgaa	atatgtgtat	tctttgtata	ggacagtgtc	aacaaaaatt	tagatcagtc	24780
agtttgtgaa	aagattgtta	ctttttttgt	ttaaaacttt	ttcatgaatt	tccattgttt	24840
tgaagatgaa	atttaaacc	ttgacattat	ttccagggtc	ctgtatggtc	tgacatctgc	24900
atacctctct	aacctcatta	tgagctactc	ttcttgctcc	tttctctgta	agccctagcc	24960
atatttatct	tctctcagtt	cctggaatgc	tttaatttcc	accccccgcc	ttcagagcct	25020
ttatgtttgc	tattttccccc	tgccttggct	gccagcacct	tccttaccct	cacctaatca	25080
actgcttacc	cttgggttag	atccpacttt	agggcaacatt	tcttcagaga	agcttttctc	25140
gtttgcccagt	ttctctaaact	cctttcctca	tctcttagac	tggttcaatt	ccccagctac	25200
tatggcactt	ggtactttaa	tacttacctt	tgtaacattt	aacaattttt	ggtcattgtc	25260
tattttccat	ttagactgaa	cctttcataa	gagagcttag	atattaggaa	gaaggagtag	25320
ctgatagtac	caatttttaa	gcaaattggt	tgtagctggg	gctattgggt	ttataattta	25380
aaagttaatg	ttttatcttc	tcttctgaca	gaaagtga	tatttatctc	cattgcagtt	25440
tagcaacttt	ccatgtttcc	ctttccattt	ttcttgtgaa	tcccgtagta	caggatcaaa	25500
gataggaatt	atttaacata	catggctgag	gattcccttt	ctagctcctt	tatttagaat	25560
ggtgcttttt	aacccttact	ctagagtaag	gaatttttta	aaaatactga	tgcctggacc	25620
ctaccagcac	ctattgtagt	ttaatttatc	tgaatgaagc	tagatgattc	taatgttcag	25680
tcagggttaa	aaattgctgg	tttagaaaat	atcttgagta	ctctctgcc	cctccagtc	25740
ctgcccacct	tctcttttta	tttgagtga	acattttctt	ttctcctttg	atttaagcaa	25800
agctcaagct	tgggtgtgga	atgaaaggaa	aaggactttg	gagggattta	cctatttttt	25860
ctaggagaga	aagtgaata	ctaacttttc	tgttttggg	aatgtcccag	tgcaagtcta	25920
gtattctgat	gttttttttc	ttcccaaac	tgttgccccc	cacctccagc	ctatgtacaa	25980
tttgtgtttt	atttttagtat	tgtgtatata	ggattcagca	ctatcctcaa	atgtatgaac	26040
atatccctg	tggataagg	gggactactg	tatttgtaaa	agttcatatt	tcatatttca	26100
atgcatataa	gaattatttt	atctaattgt	tacagtctat	atccttcatt	gatgtgttta	26160
tttgagggtc	tttgaacatt	tttgaactt	ttctctatcc	aaatgcagtt	ttatagatca	26220
tttttatgga	aaggaaggag	ataattcgga	aggatgtttt	aacatgtggg	actttctacc	26280
tcatgttgat	cgaaagattt	tcaacttgta	attaatgtgt	ctcagaatca	tgggtgttca	26340
caatagagg	ttattttggg	ttatctggct	tgccttgggt	tggttaatgt	gggtgaactg	26400
cttggctact	cataaagttt	gggaaattga	tttctactaa	tttaattaca	tagtaactta	26460
aaatagatca	ttgctggtga	tatggagatg	cctccattaa	taccacgggt	tctaaaatga	26520
tagatttcag	gagtagtgtg	agcaggctga	gattaagaat	taagtgtgat	agtggaaga	26580
cttgggtatt	agacgtgtgt	tcagacggat	gtgtggtaga	agaagactat	gagcattcag	26640
acttaaaatc	ttggttagta	agatccatag	acaggcaggg	ttttttgtt	tgtttgtttg	26700
ttttaacagg	ttggagtga	gtggcaggat	ctcaactcac	tgcaagctcc	gcctccggg	26760

ttcacgccat	tctctgcct	cagcctccc	agtagctggg	actacaggcg	cccgccacca	26820
tgcccggcta	atTTTTtga	TTTTtggtag	agacggggg	tcaaccatgt	tagccaggat	26880
ggtctcgatc	tcttgacct	gtgatccacc	ctccttggcc	tcccaaagt	ctgggattac	26940
aggcgtgagc	cactgtgccc	ggccaacagg	caggtttaag	gtttgttctg	taggtggtaa	27000
tctgggttag	ggcagcaaa	aaggtggatt	ctgagatcag	catctgatga	taacaccagg	27060
aatagttcca	aatgaacttt	tctgtgagag	aaagctttct	aggtttcaaa	ggatccatac	27120
ctattgcagt	aattactaat	gttctctgaa	gaaggcttct	tatctgtcct	gtgactagga	27180
ataatTTTt	attccctcct	actatacaac	ttgcttttcc	ctcttataat	atcttccata	27240
tatatatata	tctcaagaga	gtctttcatg	ttgtattaca	tataacctta	tggaaagctc	27300
aaaagtTctt	tgaagcctct	tgTTTTgcta	aaaggttcag	gtaaatTTtg	cattctatcc	27360
catatgtgcc	tgTTtgtttt	aatataaaaa	ttgtttaaat	tagtaaccag	tgaaaatact	27420
gtttctccct	aaagaatTTt	tttgataaaa	ttgatacttc	agtggctttg	agtgtctttt	27480
ggcatattgc	caaataaggg	tgTTgaggaa	atgccactcc	aaaatatgac	accttgatat	27540
attgattact	ttaagttgga	aacacttgca	aagtagcaaa	tgcaaaagaa	cactttctct	27600
gaactcctgt	tacctaccta	aggacagatc	ctccaaaaga	agctcaattt	gctcctagg	27660
agtttgatca	accaggaag	attgtctctt	atcactggag	aggagagtaa	aagtcagcac	27720
cacacccaga	caaactgaca	caaagtatca	tctattatta	ttctaagggc	ccatttatct	27780
ttctccagaa	ttgttcttct	aaattgcctg	tatacctcta	ccccatgct	atataaagg	27840
tataaaact	cctaaatata	actTTTTttt	TTTTtgata	cacgtttctt	tcctgtgata	27900
cccccatgca	cataatgaat	ctgtatacct	tttctccgtt	tagtttattt	catagactgg	27960
tttgaaatat	cacggatttt	gtttgttttt	ggtatacact	ttttaaaaa	atcacttttt	28020
tttttttgg	atacactttt	ctttcctgtg	atactcccat	acacataata	aatttgtata	28080
cattttctcc	atttagttta	tttcatagac	tgttatcgaa	tcctgatgg	agagggaag	28140
tcttccctgc	cttacacaag	tatttccag	aatataTTta	caccattcct	tgatatgtgt	28200
tgccctgttt	TTTTttctt	aattacacaa	aatttagtga	tttcacttta	gataaattca	28260
aaagtacgca	tttctttaat	tgattttctt	ctttatcaca	gctctgacaa	gttgcttcag	28320
gaagataagg	ctggctgtta	gactacttga	gaatctTTta	aaaagaaaa	agtcaataac	28380
atttagtgca	gtagatctct	gaaatgcata	tattttgtgc	ttattctgtg	tcaggcactg	28440
tgcttatcat	taggggtacc	atgactaaaa	agagtatttg	gcctaaagtc	tttaaaaact	28500
gttttctttt	tcctttcttt	cttttttttt	TTTTttttt	tttcgttgag	atagggtctg	28560
tctctgttgc	ccaggctgga	gtgcaatggc	accatgatga	ctcactgcag	cctcgacctc	28620
ccaagcccga	gtgatcttcc	tgccctagcc	tcccaagtag	ctaggacctc	agtcatgcac	28680
caccaccgca	cctggctaat	TTTTtaattt	ttgtagagat	gaggtctccc	tatattgccc	28740
aggctggtct	tgaactcggg	ctcaagctat	cctcctgccc	cagccttcca	aagggtctgg	28800
attgcagggt	tgagctacca	tacctggcta	aaaaactcat	atataaaaa	attaccataa	28860
cacattggta	agttaaagaa	tctaggctgg	gcgcggtggc	tcatgcctgt	aatcccagca	28920
ctttgagagg	ccgaggcagg	tgatcatga	ggtcaggagt	tcaagaccaa	cctggccaag	28980
atggtgaaac	cccatctcta	ctaaaaatac	aaaaattagc	caggtttggt	ggtgggcgct	29040
tgtaatccca	gctactcagg	aggctgaggc	agataattgc	ttgaacctgg	gaagcggagg	29100
ttgcagtga	ctgagatcgt	gccactgcac	tgcactccag	cctaggcgac	agagcgagac	29160
tccgtctcaa	aaagaaaaaa	aaagtatcta	gtaaacaaat	acatttccct	cattgtctgg	29220
ttagaaatta	catgctttat	ttctattctg	TTaatatcca	taaatagtc	attattttat	29280
gcagccaata	tttgtttaat	tgtaactgta	tgTTtgccgt	aaagttcatt	cttacattga	29340
aagactgtat	agtatatTga	ttcagagaat	gaactctggg	ttcagactat	ctggatccaa	29400
aatcaagtta	cttaggttct	ctatgactaa	aatagacagt	gatagtatcc	cttcttcaaa	29460
gaacatttta	actTTTTttc	TTtaaagata	TTTTtccgag	catatattct	taattaacag	29520
ttgttttTgt	cctgccacta	tgaatgaatt	tattgtgtcc	tctggcttct	gttcatgcaa	29580
ttgagaagtc	atgtgtccatc	tgattgtcct	tcctttgtgt	gtaactctgc	ttttgtctag	29640
ttgatctttt	TTaataaagg	Taaaatttat	atagtgtaat	gtacaaatag	taagtgtgca	29700
gttcattgag	ttttgatgaa	catacactaa	tccaccccat	caagatacaa	gaacattcta	29760
ttagcataga	aggttacatc	tatttccagg	catttccctc	cccatccac	aataggaaac	29820
cagatttcta	tcaacataga	ttagttttcc	ttgctcttga	acttgataca	aatggaatca	29880
tgcaaatgga	ctcttttTgt	tgTggctttc	ttcactgagc	ataatgtcaa	tgaaattcat	29940
ccatgttTgt	gtgtttatga	gtacttcgta	gacttttatc	cctgagtact	actattcctt	30000
tgatTgaaga	gaccatagac	atttgagttc	tttgagacta	caataaataa	agctgtctata	30060
aatattcatg	tataagtctt	tgtgtggata	tatgttttta	tatatatata	tatatttttt	30120
TTTTttttTg	Taaagcctag	gagtggaaatg	gctagatatt	ataatagggt	agggtgatgt	30180
Ttaccatttc	attttacatt	cccaccagca	atgtgtgaga	gtcccagttg	ctccacatca	30240
Tcaccagcat	ttggtgtTgt	caattTTTTt	aactttaacc	attctaattg	taggtaatga	30300
TatctttTga	ttttactttt	gagtttctgt	tgTgtgtgta	Tgagagatgg	agtctcactc	30360
Tgtcaccag	gctggagTgc	agtggTgcaa	Tctcggtcca	ctgcagcttc	cacctccag	30420

```

attcaagcaa ctctcctgcc tcagcctccc gggtagctgg gactacaggc gtgccacctc 30480
catgcctggc taatTTTTat atttttagta gagacagggt ttcaccatgt tgcccaagct 30540
ggtaaaacttc tgagctcaag tgatccgcct acctcagtct cccaaagtac ttggtaattt 30600
acaggtgtaa gccaccgcac ctggcctatt cactgatttt taatttcaat tatacttctt 30660
atttctacat attctgtgtt tttaaaaate aatttcttag tctggtcata ttttgatact 30720
ctaatttctt taaatttttt atatttttctg ttattgctta taatatctgc agttttgtaa 30780
gtgtaactca gttgtttctg cttcctgtgg ttggtcattt cctgttttta aattagtttt 30840
tgattgtgag cttgttgga ctttatctgt gtgaattatt tctgatctag gtttaaggtg 30900
tgtttttcta gagaatatgc atttgcttct tccaggaatc cagggatgca atctaccag 30960
gaccacttac attaaattct cacttggcct caaaaagta actgaattct aaccccaaac 31020
ttgagtggat gccagattgt ggtaggaag accccactcc accactacca atacctacc 31080
agagccaaag ctaggaaagga caagagtact cacttctgtg ggatgagttg agtttttgtt 31140
tttctttctt tccctagttt atctttcact gaggatgttg cctttgggag ttctagcttt 31200
ttggtcttga tctgagttcg actttgagca gatcatagac tttgtcttat gtttacaagt 31260
acgtttccac ttaaaataag gccgtagtga agatgtagaa caactagaag tcccatacat 31320
tgctgggtgg agtgtacagt ggttttacia aacttttggc agtatctagt aaagccaaac 31380
ataggcctac cctgtgtcaa aagacaaaat tacaacaaat ttagcttaaa aatctaactc 31440
acttttatta gtggttcatg aatcaggcag tgtgtcatca aaagatttag aaaaggcatt 31500
tcagtgtgct gagcagagga agttgaattt ataggcaaaa tctagctaaa taaagcagaa 31560
atgaaacaaa aatgtgattg gtcatttcaa agttagtttc tttatagtat taaaacacag 31620
gggacttctc tatgtggct caggataact ggcctccttc tgattgattg ctatgaatct 31680
tttgattttt tttttttttt tgagatggag ttctactgat gttgcctagg cctggagtgc 31740
aatgccacga tctcatctca ctgcaacctc cgcttccagg catcaaggga tccctcctgc 31800
tcacctctcc acgcagctgg gattacaggc tccctccacc atgcctggct agtttttcta 31860
tctttaatct agaaggaccc ccacctgca gccaggcgca cagactgata cccaccta 31920
agagatccac ccgcctcatc ctcccaattt gccagggggc agactgcatt ccaccggtcc 31980
ctgatttggg tgcttaaaac tcagaatttt cttggggatt ttggtctccg acgtttatcg 32040
ggaaaactgt ttttaacctt ttattttgaa acaattttag gatctttgaa aagttgcaa 32100
aatcctccat ggaattccat ttaccctctc cccagtttt ttcttagnnn nnnnnnnnnn 32160
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnngc tcccgcccca tgcttgcta 32220
atttttgtat ttttagtaga gatggagttt caccatgttg gccaggctgg tctcaaattc 32280
ctaacctcag gtgatccacc cgctcagcc tcccaaagtg ctgggattac aggtgtgagc 32340
caccgcgccc ggctttttga tttttttaaa ctgtcattac tcggggttta tagtctacta 32400
ctatattgct gagaacagtt ttcaagatta aaaataaaaa tgttttctgt ttctcttagt 32460
taaaaaaaaa aacctgtctc tcattgtagg attattatc tctcttttca ttatagatgt 32520
atactatttc taccttctgt gttaaaaata cttttctggg ccgggggcag tagctactc 32580
ccgaaatccc agcactttgg gagccgagg cgggcagatc acgaggtcag gagatcaaga 32640
ccatcttggc taacacggtg aaaccccgct tctactaaaa gcacacaaaa aaattatggc 32700
gtggtggtgg gtgectgtag tcccagctac tcgggaggct gaggcaggag aatggtgtga 32760
acccgggaga cggagcttgc attgagccga gatcgcccca ctgcactcca acctggatga 32820
caggttaaga ctcggtctca aaaaataaaa aatacttttc tgacttagag 32880
aatctgggtg aagggtaaat ggaattcctt gtactatttt tgcaactttt ctataatcct 32940
aaaattgttt caaaataaaa ggttaaaaaa atattttcca gactacttca gaaacctaat 33000
tactaataat aattctgagt ttttagcaac caacttagaa acttttgaa tgcagtcaac 33060
ccactgacaa atgaggacta tctgtactat agtatttttt tagacggggt ctcagtctgt 33120
caccctagct ggagtgtgg ggtgatctca gctcattgca acctctgect cccaggctca 33180
agcgattctc ccacctcagc ctctgtgta gatgggatta caggcaggct ccacctgcc 33240
caacgaattt ttttgtattt ttagtagaga aggggtttca ccctgtttcc caggctggtc 33300
tcaaactcct gagctcaagc aatctgcctg cctcggcac ccaaagtgtc gggattacag 33360
acatgagcca cagagcctgg ccttttagtc tatttcgatt cttcatttca attcactata 33420
ctttttttct aagtttttaa atatttttta tcttttacca ttgacatttt gtgtgtttt 33480
acagcttctt tatattggtc tgcattccaa agacaaaatg aagtctotta tgttttgtga 33540
tatgtgttaa aataattgaa ctagacaaga atgttaggcc caagtgagat gaaggaaagg 33600
ctctttgata agcatttggc atttttagatc agagatggca agtacgtatg acatagcatt 33660
cttcttttat acatttcaga tattatttgt tgatcagaca ctcttcttcc tgtcttgac 33720
cacacagtgt tttaggtatc tgctgtcagt tgatcagagt tggcatgaga aacaaaaaaa 33780
atctattggc atctctgact tagaagatca gttttgggag aatcttctgg aatatctatt 33840
ctattcttaa gtttaatgag taatttcac ctttttatga agtaacataa caattctgga 33900
agcctagtta tttaaagaat gctttaagct ttgtttcttg tcacttcaat tttcagatgt 33960
ttgtgaaacc aagctctgta ttttaataaa atgttcttaa agtataatgt aactttaaaa 34020
aatctacata cttgtgtgtc acatctttag cctttaattg ggtgactttt taaatgttat 34080

```

ctactttttat tcttatgttt tccttcccag gagtggacct accctatgag acgagagatg 34140  
 caggatattggc aaccttttct ttgttcaaac caacctatgt tattatcata ataagaacct 34200  
 tagttttatag gatttgagac ctgctgattt catgatctgt aggttcatca ttatgtattt 34260  
 taaataatta ttttaaatat ttaagggttaa tcttgatct taaaacgatg ggaaattaga 34320  
 aagaggaacg tagtaatagg tgtatgtgct taatgagtca ctttctcttg gttttttttt 34380  
 tgtttttttt tttttgaaac agagtttcgc tcttgttgcc caggctagag tgcaatggca 34440  
 cgatctcggc tcaccgcaac gtccacctcc cgggttcaag tgattctcct gcctcagcct 34500  
 cccgagtagc tgggattaca ggcattgccc accacacca gctaattttg tatttttagt 34560  
 agagacaggg tttctccttg ttcaggcttg tctcacactc ctgacctcag gtgatccagt 34620  
 gacctcaggt gatccacca ccttgccctc ccaaagtgtt gggattacag gcatgagcca 34680  
 ccgtgcctgg ccaatgagtc actttctttt tctcactgtg aaaaattgga tactttcttt 34740  
 gtattccttt tgaaagcagt ttgctttctc tgtttgtcta gataagttag ggagagtgt 34800  
 ctgtacaaca aataagcatt gttcattttt tgtccgattt ttaatacaact tccacaatta 34860  
 agtcttctag aagatcaaat tgaatacttt cagtttgga tgaattaaac gatagctaac 34920  
 cctcatagca gttcattttc ttttgcaatt catacattt accgtcaagt ctgtttgccc 34980  
 caggattaag cagtatcttg ttcctgggaa tcccatgact tctaaaaatc tgttactttt 35040  
 ctctcttaat gaaagttcac tttgaaaaaa taggtgagta cctatgaggc attttacttg 35100  
 gtgttaggag gaatgcaaaag atgactaaat gtaatttctg cccacaaaag cctgggtggaa 35160  
 gaaatcagtt ttatatacaa ataattatga cttatagaac tgaactataa agttactgtt 35220  
 agtatctagg gtatgatata tccagactga aagctttctg tattgaattt acataaaata 35280  
 aatttgaatt caacatctgg aaggtacata cttgttgaaa ttttgtcaac tggcaaatat 35340  
 ttgaatttgg aatttttatg ttacagtaat aatttgcttc tattaactat agataatagt 35400  
 tttaggctcag gcacaggagt tcatgtctgt aattccagcc gtttgggagg ctgaggcaga 35460  
 aggatcacta gagcccagga gttccttacc agcctgggca acatagttag acttcgtctc 35520  
 tattttttta agaaaaaaa aaagattaaa aaaatagata atagttccaa tcttgttgta 35580  
 tcttgtgctg cttttgattt ggccaaataa ggttgtctt atttatatag ctttatagat 35640  
 ttaaattgct gatggtaaat acctcaaatt tttttttt taggaaattt tacctggatt 35700  
 gttcttaggc ccatattcat ctgctatgaa aagcaaggta tgaactttgt tagattcatc 35760  
 aagagagact tttattaacc aacttttctt gggttaagtt tttagtaata aagagtttta 35820  
 ttttagggag catccacaaa tactgtctgt taacagtaat tgtcactctg gattaccttc 35880  
 ctctttccct attttactag accagtagtt ctcaagtgtt tcaccacaaa tcagagtttt 35940  
 tgttttttcc tcatgaaatt tgtatgtttg aaagatttac caaataactg acctttaata 36000  
 acttatttac tctctaaaac actagacatc tgaattgct aatcatagct tcagaacaat 36060  
 atgagatgta gttaaagccc aaaataagga atttcaatgt ttagttaaac cttccttacc 36120  
 aagggtaaga ctgtgtgtgt taattgaaag tcattcacct tagttctgtt ttgccagcca 36180  
 gacttttagag agctagttgg tatccccgct ctgaaatttg aaactttttg agcaccagta 36240  
 tgtcactga aggaaatcct cactggagta tttcggattt cggatttttg gattagggat 36300  
 gctcaattat aagtataatg caaataggca aaacaacaa atccaaactc tgaaatattt 36360  
 ctgggtccctg gcatttttaa taagggatat tcaatccgta tagatattct acatagtcaa 36420  
 actttaatgg acttactcag ttgcagttaa aataggtaga tctcatttta ataaatatag 36480  
 caatgttctt gccacttcta aaagattcaa tgctactaat tctctttgag ttacaacgtg 36540  
 gaacatatca cagatgtctt tccccaatat tttgcctatt cagaagtcag tatactttaa 36600  
 ttgtgtttga tatatccata atttaatttg atgttcttag gaatttaacc ggttttaaaa 36660  
 ggtcattgat tttgaaactg gaagattttt ttgacagttg agacatggct aagagtaaac 36720  
 ctggctcatct tgatgatttt tgcttagttg gaaagatagg gagttagtaa aaataagtac 36780  
 tagggaaagg atagggcagg taactataga catagccgta atttattttg taaaagacag 36840  
 atgtaaaciaa ggttattgtc catataattt gctattcacc aagtactagt cttccagatg 36900  
 gttttagata atttacattt ttgaaattcc cactgtactt tataaatata catacagtat 36960  
 ttatcacatt aaattaaagt atttgtttta aggtctatct cctcaatggg aggttgaggc 37020  
 aggcggatta catgaggcca ggagttcgag accagcctgg ccaacatggc aaaaccccg 37080  
 ctctactaaa aatacaaaaa tttagctggtt atgggtgtac acacctgtaa tcccagctac 37140  
 tcacgaggct gaggcgcgag aattgcttga atctgggagg tagaagttgc agtgagccaa 37200  
 catggcacca ctgtactcca gcctgggtga cagagtgaga ctttgtctca aaatgaaaca 37260  
 aaaacacgca caaaaaagg tctagtctt caaaacttct tttcttgaaa tgtcaccatg 37320  
 gtcttattag acagggaaaag cctctgtggc agtttatttc ccaccctagg taaccataat 37380  
 atagcccata tttcttttca taccattatc taaaaacaac aacaaaaaat aataatggag 37440  
 ataaacctaa atggataaac tcttttttaa aactcattt actgttatta ttttgtggga 37500  
 gaggagtggg gtcttgcctc gttaccagg ctggagtaca gtggcgcgct ctcatagctc 37560  
 actgtaacct caaactcctg ggctcaagct gtcttccac cttagtctcc caagtagcca 37620  
 ggactacggg cacacaccac catgcctggc ttaattctca aagtttttgt agagatggag 37680  
 tctggctatg ctggccacat ttacttaagt atatctttt attaaattca aatacagttt 37740

aaataaaagg	gacaaaattta	gggcctttgt	aattagtaaa	cggtttggtt	ttgtaaagtt	37800
tttctactgt	ttttaaatgt	gaggtaaggt	cataatttgc	ttcatattag	gttggtgcaa	37860
aagtaattgc	agatctgcct	ctgaaaagta	caaaatctat	tcgctgttac	gttagggctc	37920
tatttttgata	gtttatTTTT	atttagtagt	agtctattgg	gccttcaaaa	cttgtttaag	37980
catatttata	cataattatg	tgcatcgtct	tgtgctttct	cacattcata	aagtagatag	38040
gaaaactcca	taggcatcaa	gtgtaaacga	aggacttaat	gttgaatttg	ttgtggaat	38100
tggcacaaat	ctcaatatag	aacattgggt	aattattaat	cttaccaaat	gcttatctca	38160
ctttccctaa	ctcaagttat	actcaagaaa	tacaaagata	attgaattct	aatctatgct	38220
gacataaaac	ttgctgcaga	aattaacact	taaaacttgc	aaattatatt	gtcttagccc	38280
aggctgctca	aacaaaatac	catagacagg	gtggcttaaa	caacagacga	ttatttgagt	38340
tctggaggct	ggcaagtcca	cagtcatggt	ccggctctgg	tgaggaccct	cttgctggct	38400
cgcagatccc	tcccttcttg	ctgtatcctc	acacggccaa	gagaacgagt	tcttgctctc	38460
tcttacaagg	gtacaatcct	gtcatggagg	tttctaccct	catgacctca	atctaaaact	38520
gattatcttc	cagagactcc	accatcacat	cttgggggta	aggatttcaa	cataagaatt	38580
tgagggtgat	caaacattta	gttcataaca	catataaatt	attttttttt	actttgctca	38640
tgaattatta	gtgctactgt	tttgactat	ttaaaatgca	gaaaatggga	attaaatata	38700
taggatttaa	aacaatgtgt	caagaaattc	aaggttatct	gattctcatg	ccatcgtgac	38760
ttgttagttc	atttattgaa	caggtaatta	ttgaacaact	taactagtta	tacatacttg	38820
atacttaagt	gaattgtatt	atacatttta	cacatactat	gtatcagtga	acaaaataaaa	38880
atcttttctg	tcattggaact	taatgctcta	ggtaataaaa	taacatctat	aaactcactt	38940
aaacttatca	ctagcaaatg	aaaacttatt	atctggtaat	ttctagaatt	gtcatgttaa	39000
attgcttttaa	gtatggagcc	aaaagcacta	caggttgagt	atccctaate	tgaaaaatct	39060
gaaatgctcc	aaagtgaac	tttttgagt	tcagcatgac	agcacaagt	aattccacac	39120
ctgaccccat	gtaatgggtc	actgtcaaaa	ttttgtttca	tgaccaaact	gactgtatga	39180
aattacgttc	agagtatata	tggtgtgtgt	gaaacataaa	tgaattttgt	gtttaaactt	39240
ggataccatc	cccaagacat	ctgagtatgt	atatgcaaat	atttcaaaat	ctgaaatctg	39300
aaacacttct	ggctctacct	tgggaccagc	attttagata	agggatactc	aacctgtatt	39360
gaataataata	ataggtcatt	gaagttgcc	tttttaactt	caggaaaatt	tttaaatggg	39420
aaaagggttaa	ttagattctg	tgaagtatgt	aaattaattc	tgactcttaa	agtatactgg	39480
gagaggcaag	gagttgtcta	gagatttggg	ttccagtact	gctgttaact	aggctcgtga	39540
tgccaagta	tttggtaatg	taactgtttt	atgtcttagt	ggttctctct	aaacaataaa	39600
gattgcagtc	aataatattt	aactaccatt	tattaaacac	ttgctgtgtg	tcccagggtc	39660
tatgccaaac	atcttacata	aaggttccat	caagctctaa	aattgtaggt	atgaaatata	39720
ccgtgttaact	ttttgaggac	attaatgtat	taactctgaa	tcattgaaat	atcttgctgc	39780
ccacttcagg	tattattata	aattagcttt	aatccctgg	acttaagcag	agatgtgggt	39840
tctgtgtatt	ttcaaacatc	tgtgttatat	agtaagatga	tgtttgatat	tttaaaatat	39900
ttatcttccc	tgtctctccc	ctgctttttt	ttttatacag	ctacctgtac	tacagaaca	39960
tggaaataacc	catataatat	gcatacgaca	aaatattgaa	gcaaacttta	ttaaaccaaa	40020
ctttcagcag	ttatttaggt	aagaattatt	gctatgattt	gtaaaacact	taatgaagtt	40080
tcattttcagg	ttttgtacca	tcagttgttt	ctgtacatat	ctagtttgta	aaaatgggtc	40140
atatagtaca	tagtttttta	aaataaattt	tacttaaaat	acttaaatga	attatgccca	40200
taatgcagaa	ttctaaaggt	tcaaaagagt	gtatattgtc	aagaagtttc	tgggaaagta	40260
aaaataaaaa	agaattttaa	aataatgtat	actgaaaaat	aggttttagt	gtacattatt	40320
ttatctcttg	agggataaag	gaattgagta	tctaggggat	aggtttagg	aaacagcatc	40380
tactgttacc	tctttattgg	gtagtttttg	agtgttaggt	taaaatttat	agcatagtct	40440
tatagataaaa	ttttttttta	cattggcttt	cttttttact	ttatattttt	tggagattgg	40500
tttatatcgg	tatgtatatc	aaactgctta	ttctttttta	gttgcatgtg	aatccattgt	40560
atggctatac	taaaatttat	tcaattagtc	tgttagatat	ttagattgtt	tctggccttg	40620
tactaatatg	tatagcatat	agtgaactat	attgtacata	ttactcaatt	tatatgtgag	40680
catattgata	gggcttattt	gcagaattgc	tggatataag	agtatgaaca	ttttaaattt	40740
tgatagatgt	tgcagattgt	tttccagtgc	gttgatcag	tgtacattcc	cattatcaag	40800
tatgtgagag	tgactcttcc	cttagtatct	ctccaagacg	gaattgtgaa	acatttttaa	40860
tttctcaagg	tctaattggg	taaaaatggg	atctcatttg	atgttcttat	ttatcttgta	40920
agttcagttg	agcatgtaat	ggtttttaat	gttctttatt	ttacttcat	ttttaaaaata	40980
gagtatatta	gcgatgttac	aaaagtga	ggatatgtaa	acatatataa	tgaaagtaac	41040
tctacttttt	ctcttaaccc	aagccacctt	gtccttatcc	tgggaggcag	cttcttcctt	41100
caatatctat	gtaaaagtat	atatgttaaa	aatatttttag	gccagcacgg	tggctcacgc	41160
ctgtaatccc	agcatttttg	gaggccgagg	tgggcagatc	acctgagggtc	aggagttcga	41220
gaccagcctg	gccaacatgg	caaaacccca	tctctactaa	aacaaaaatt	acctgagcgt	41280
ggtggcacat	gcctgtaatc	ccagcagctc	aggagactga	ggcaggagaa	ttgcttgaa	41340
ccagaaggca	gaggttacag	tgagccgaga	tcacaccact	gcactocagc	ctgggcaaca	41400

gagcaagaca	ccgtctcaaa	aacaaaaaaa	aacaaaaaaa	aaaaaaaaca	gtgctgtggc	41460
ttacacctat	aatcccagta	ctttgggagg	ctgaggaggg	tggatcacga	ggtcgagatt	41520
gagactgtcc	tggccaacac	agttagagccc	cgtctctact	aaaaatacaa	aaattatctg	41580
ggcgtggtgg	cacatgcctg	tagtcccagc	tactcaggag	gctgaggcag	gagaatcact	41640
tgaacctggg	aggcagagggt	ttcagtgagc	caagattgcc	ccactgcact	ccagcctggc	41700
gacagagcaa	gactctgtct	caaaaaataa	aaaaaaaatt	taatgctctg	ctttattttt	41760
acaatgaaac	caatctataa	atatctgtaa	atacaagata	catactctaa	aatacattgt	41820
gtgaacatat	aatagaatac	tatgtaacca	tgaaaaagaa	tgaatatata	gtatgtgttt	41880
ggatttgga	tgatctccaa	gataatgcat	tacatgaata	aagcagggtg	tggaaacaatg	41940
tatatatttg	caatgtgttg	agtaaataa	tataactac	attccatata	tttattctta	42000
atatatgcat	agaaaatttc	tggaccaaga	ggctagaaac	ttcatagtga	ttgcttctaa	42060
gaaggaaaat	tcagggcctg	tgatggtaga	gggacgtatt	tttctttcgt	ttttaatttt	42120
gttttttttt	gttggtgttg	tttttttttt	ttttttgaga	tggagtctca	ctctgtcacc	42180
caggctggag	gcagtggtg	tgatcttgcc	tcactgcaac	ctctgcctcc	tgggttcaa	42240
cgattctcct	ggcctcagcct	cctgagtagc	tgggattaca	ggcatgtgcc	accacacca	42300
gctaattttt	tttttttttt	tttttttga	cagagtttcg	ctctgttgcc	caggctggag	42360
tgcagtggca	tgatctcggc	tcactgcac	ctccgcctcc	caggtttaag	caattctctg	42420
cgtagcctt	ctaagtagct	gagattacag	gtgcccacca	ccactcccag	ataatttttt	42480
ttgtattttt	agtagagacg	gggtttcagc	atcttgccca	ggctgatctt	gaactcctga	42540
cctcttgatc	cacctgcctc	agcctcccaa	agcactggga	ttacagggtg	gagccaccgc	42600
acctggccta	ttttttgtat	tttttagtaca	gacggggttt	caccatgttg	gccaggctgg	42660
tctcgaactc	ctgacctcgt	gatctgcccc	cctcgccctc	ccaaagcact	gggatttaca	42720
ggcgtgaagcc	actacgctca	gccgagggac	ataattttca	tggtagcctt	gatatccatg	42780
ggggattggc	tccaggaacc	cccatgaata	acaaaatcct	cagatgctca	agtcccttat	42840
ataaactggg	gtaatatattg	catataacct	gtgcacattc	tctcatatac	attaaatcat	42900
ctctagatta	cttctaatac	ttagtacagt	gtaagtgtctg	tgtgaatagt	attggatttt	42960
attttttatta	tttttagtgt	tgtattttac	cttatttttt	gttaatgttt	tttattgttg	43020
tcggttgaat	ccacagggtat	gaaattcctg	gatattggagg	gctgactctt	tacttttgta	43080
gtgttttttt	tttacacccat	atttagttta	ttaaaactag	ttattaaaaa	ggaatatccc	43140
aaaacactga	tttttttttt	tttttttttt	tttttttgag	acagagtctc	gctctgtcat	43200
ccaggctaga	atgcagggct	cactgcaacc	tctgcctccc	aagttcaggc	aattcttctg	43260
cctcagcctc	ctgagtagca	gagattacag	gcatgtgcca	ccacgcctgg	ctaatttttg	43320
tatttttagt	agagacgggg	tttccacatg	ttggtcaggc	tggctctcaa	ctcctgacct	43380
cgtgatccgc	ctgccttggc	ctcccacagt	gctgggatta	caggcgtgag	ccactgcgcc	43440
cggcctgaat	tttttataat	tatgaaagaa	atactttttt	ttttttcaaa	gataggatct	43500
ttctctgctg	cccagcctgg	attgcattgg	catgattttt	gttcatttga	gccttgacct	43560
cccaggctca	agcaatcttc	ctgcctcagc	cttccaagta	gctgggacta	cagggtgcacc	43620
accggatcgg	gctaattttt	tttttttttt	tctagagatg	gggttttgct	gtgttgcccc	43680
ggctgttctt	gaactcctga	gcttaagcga	tctaccacc	tcagcctccc	aaagtgtctg	43740
ggttacaggc	atgagccacc	acacctggcc	atgaaacact	tattctttat	aagtacttctg	43800
gaaggtatag	aatgacacca	agaaaaatat	ttaaatcatc	tacagttcca	caattcagag	43860
aaaacacttt	tgttaacatt	tggaaatatt	ccttttaaat	cgttctctgt	tgtgtatgtg	43920
tatttacgta	tatatgcata	gaattattaa	agaaaatgag	aatgttgtat	tttaaaatat	43980
caaactatat	aaggtgaaac	taatcttaag	aaaaaacaaa	aaagccaaaa	aatcatacta	44040
ttcatttcta	atgtgtacag	actttttgtt	ttaaattata	atgttgtttg	tgcaggttct	44100
ttatccta	ggaagaacca	ttctcctta	aacttttaca	atactagctt	cttagagatt	44160
gatagttcta	ctagcagtg	ttgacactga	aaatgttatg	cgttaaaata	tttaatttca	44220
ttctgagtta	acatttttcc	cctgaagcat	tattttatgt	aactggaata	cccagtcact	44280
tcaggatata	gtcattgtcg	aaatccttgt	agggttaaata	ttggattttc	ctcagatcct	44340
gaggttcagc	ttctgtgttt	ttttttgttt	gtttttttgt	tttttttttt	ttgtttttga	44400
aacagagtct	tgctgtttca	cccaggctgg	agtgcagtgg	cacaattttg	gcccactgca	44460
acctctgcct	cccgggttta	agtgtattct	ctgcctcagc	ctcctgagta	gctgggatta	44520
caggtgtgca	ccaccatgcc	tggctaattt	ttatattttt	agtagagatg	gggtttcacc	44580
atgttggcca	ggatggtctt	gaactcctga	cctcaggcaa	tccacctgcc	tcggcttccc	44640
caagtgtctg	gattacaagc	atgagccacc	atgctcagcc	tcagcttctc	tgtattaaag	44700
tcctgaattc	tttgaagttg	ttaccaccta	aatgatcatt	gaaaaactgt	attttttagt	44760
gcaaaattgt	tcttaaaact	aatttaataa	cttagcta	tgcttatagt	tgtgttaata	44820
aacagtggtc	ttagaacacg	ttagaatagg	aagtttttta	caaaaataag	ctaacaatatt	44880
taaaatgcct	tttaagtatt	ttgtaaagtg	taaaattcag	tacaggtgct	ctctcagcta	44940
gttttttttt	tttttttttt	ttccctttta	ctaaagatga	gttcaaacag	tgaatgtttg	45000
actcctggtt	ccatagacca	taccttccgt	ttttatttgt	tcgttctctt	agactttgga	45060

cttcctctga	aatgtcctct	gtaggttcat	gagcaggagt	cacaggacca	cttagagaac	45120
aatcttctgg	tcttagagaa	attggttagaa	ataaaagaat	aacataacga	ttacagggtac	45180
ttttgtcttt	atttctaggt	ccactctaata	ctagaggaat	gtatcttcct	gcttgtgatt	45240
tttctatttt	aaccagatgg	ttcattatat	gcaaataaaa	tatgtattta	tttttgagat	45300
aagaatcttg	ctctgttacc	caggctggag	tgagtgggcc	caatcacagc	ttactatata	45360
cttgacttcc	aggctcacac	agttctacct	cagccccctt	agtagctggg	actataagtg	45420
cacaccacga	caccagcta	atTTTTtaat	attctgtaga	gatggagtct	ccctctgttg	45480
ctcaggctgg	tctcgaatcc	ctgggctcaa	gtgactcctc	caccttggcc	tcccaaaaga	45540
gtttcttttt	gctgggatta	taggcataag	cccattgtgc	ccagcctgat	ggatttttta	45600
aatacttaaa	tatcagagat	gttaacatgg	tgtttcagg	tttaatgcct	tcaagcaatg	45660
taaaatctac	cacacagttc	ttgggaatat	gatactttga	aagttgtttt	gcattcttgc	45720
catggttaac	aagaaataat	gagttatttt	tttaaagtac	cttaagtgtt	ttacttaaag	45780
tgtgcttata	acaaaataact	ctattttcag	atattttagtc	ctggatattg	cagataatcc	45840
agttgaaaat	ataatacgtt	ttttccctat	ggtaggtacc	agtatttttt	aaatatcatt	45900
taaaatttat	ttatgatttg	acttcttagt	tggtcttttt	tttttttttt	tttttttttt	45960
tttgagacaa	gagttttact	cttgttggcc	aggctggagt	gcaatggcgc	aatcttggct	46020
caccacaacc	tctgcttccc	gggttcaagt	gatttttctg	cctcagcctc	ccaagtggct	46080
gggattacag	gcatgagccg	ccatgccag	ctaattttgt	atTTTTtagta	gagacggggg	46140
ttctccatgt	tgatcaggct	ggtctcaaat	tctcgacctc	aggtgatctg	cctgcctcag	46200
cctcccaaag	tgctggcatt	acaggcgtga	gccacogtgc	ccagccccct	taattgtgct	46260
tgtaaagctt	gctactttta	ctttgctatg	actgaaaatt	atgtgattgt	gtttttaaaa	46320
gaattatttg	tagaaaaattt	tttatgatct	ccagaaattt	gaggaatcat	attgtgaatg	46380
tattggactt	aaattaaatt	ttggcttctt	taattttttt	ggacttgtaa	tagttctatt	46440
tatagcattt	tgaaaatttg	tgaatcaaaa	taatttttat	acataataat	taggaaattg	46500
ttttcaatag	gtttcatttt	gtttcattat	atgcatttat	tttatgctta	cattaatcca	46560
catgtctttt	gcctccagac	taaggaaattt	attgatggga	gcttacaatt	gggaggtaaa	46620
taacatttcc	tttccctaac	taatgtttat	atTTTTgatta	tttgtttaatt	ttttagtttg	46680
tatttgcctt	aaatgcagga	tatggaagtt	acaattatat	gtagtagctt	actcccaaat	46740
ttgtattttc	ccaattactt	gtttcatttg	gataggcttt	ctggagtatc	cctgtagact	46800
gttttcaaat	tctctgtgag	ctttcagttt	ctttaataag	agtctgctat	attctctaca	46860
cagttgataa	taacaaattg	taaagatttg	aagatatcca	agtgattata	gtatataagg	46920
agttacttta	ctgtggtttc	aatgtagttc	agctactgac	tcagggtgtt	ttctattaga	46980
ataatgaatt	catgtttttc	aggaaaagtt	cttgtgcatg	gaaatgcagg	gatctccaga	47040
aggtatgaag	ttagaaataa	tctttctttc	tataacattt	aattaatggg	ctgtattttc	47100
tggttgtttt	taaaattatt	ttccctctt	cagtgacgcc	tttgttattg	catacattat	47160
ggaaacattt	ggaattgaag	acaggtaaga	aaatacccta	aaacctagcc	acagtttaaa	47220
ttctcattaa	aatgaaactt	aatgggaata	gtttggaagt	ttgaagtctt	tattcccctg	47280
attatttttc	atgtagtcat	gtttgattag	gcaggccctt	attccatgat	tagtcttaac	47340
ctaatttata	tacttgata	gatatgcata	ggctaataatg	gaaatccctat	ggaaaactac	47400
ttacctacca	caagggaatt	ggttggtatg	agtataaaaa	ctcgtgacca	caaatgttag	47460
tgttgcctt	atttaaagg	ctaatttatc	atgttctcct	ttacaataag	ttggatgaaa	47520
aattacctag	gaattgtttg	cagcatctat	ttacaattca	gagtagtctt	tcttatcaaa	47580
aatcatcttt	tccaagcatt	ctgtatagat	tttttaaaag	atagggggtg	gtaatgagct	47640
tcttgcccc	aagacaaagc	aaaagcctgg	gccagtgtac	agtatttcct	ttctcagctt	47700
ttcttgttct	acaaattaga	aatcttatag	taatcattga	cacatctttc	tatttcagtc	47760
cccttttata	tctaaattag	aatggataac	tttgcttaaa	aatatctatt	cttaaaggaa	47820
tattatttga	atacaaatat	ttatttattt	atTTTTgaga	cggcgtcttg	ctctattggc	47880
aggctggagt	gcagtgggtc	gatctcagct	cactgcaacc	cccgcctccc	agattcaagc	47940
aattctcctg	cctcagcctc	cctagtagct	gtgcacacca	ccacgcctgg	ccacgcctgg	48000
ctaatttttg	tatttttatt	agagatgggg	tttcaccatg	ttggccagga	tggtctcgat	48060
ttcttgacct	tgatgccac	ctgcctcggc	ctcccaaggt	gctgggtatta	caggggtgag	48120
ccactgcacc	cagccagaat	acaaatattt	aattgaaaaa	agattaaaca	tgtattgatg	48180
gactttatgt	tttatatatt	gtttttatta	tttcgaattt	tgtcagacca	ttaatgttgg	48240
aaataacttg	tatttatttg	gtctctgcta	tgagctcagt	actattatag	gcactttaag	48300
cctcataaca	aaagtaaata	aacctcttta	accagtata	gtattttgag	cttgaacttg	48360
tactatatgc	acaaaatgct	tacattttat	atattttatt	tagagacagg	gtcttccttt	48420
gtttctcagg	ctggagtgtg	gtggcacaa	catagctcac	tgtagtctca	gacttgagga	48480
ctcaagtaat	cctccacact	cagcctctca	agaagctggg	actataccac	atcactgtgc	48540
ctggctaatt	tttaagtttt	ttgtagagat	ggggtcttac	tacattgccc	aggctggctt	48600
caaagtcctg	gcttcaagca	gtcctcctgt	gttgccctct	caaaggattg	gggttacagg	48660
caagagccac	tgacactggc	cactttacac	ttacctcta	ttcatagtag	ttccccaagg	48720



taggtgttat	tagactcttc	attttaccaa	tggacaaaat	agagcttaga	gaagttgagc	48780
aagctgacgt	aagcatatag	ctggtgagaa	aaggaaattgt	gatattttaat	ctcatcatgc	48840
tttttccatt	acaactcatt	accctctct	attgctaagt	tgtatgatta	tgattaattc	48900
attaaataat	gctatcacat	taacactctt	tttctgtttt	cagagatgct	tttgcttatg	48960
ttcaagaaag	aagattttgt	attaatccta	atgctggatt	tgtccatcaa	cttcaggtaa	49020
cttttcttcc	tctttaaggc	aatcagaagt	aagatataaa	atcttttata	catgtaattt	49080
aggtgtacaa	tttactttgt	gaatacttaa	aattgccata	atctgactac	tttgatgctt	49140
tattcaagtt	tatatctcta	tttagaagta	ttttcttggc	tgggtgtggt	ggcttatacc	49200
tataatcaca	gcactttggg	agaacaaggc	atttggattg	cttgaggcca	gaagtatgag	49260
atcagcctga	gcaacaaagt	gagacccaat	ctctaaaaaa	taaaaaatta	aaaaaaaatt	49320
agccagtcac	ggtggtgcat	ggctgtggtc	ccagctactc	aggaggctga	gatgggagga	49380
ttgcttgagc	ccaggagttt	gaggctacag	tgaacagtgt	gtctttgcac	tccagcctgg	49440
cccacagagt	gagaccccat	ccctaaaaaa	ttaaaaaac	tttttttct	taagggtctg	49500
cattaccaag	aaaaagggt	taaagacaca	ttatcaaata	taaaagtaaa	taattgctgt	49560
tagaaatgtc	tgattttttt	ttgttgttca	ttttgatcac	acagagcata	agacagtttt	49620
gattctaagt	atactaacta	taacagcttt	ttctattcta	tgtttatctt	ttccatgttg	49680
tttcataatt	tgttgatgcc	tggcagatgc	actgacaaag	atgataagtc	tatgaattaa	49740
cctaattaga	ccacgttgct	cagtttatte	caagaggcaa	aatcataggc	tgagaatgt	49800
gctctggcta	attacatcca	attatgtagg	aataaagctc	atgtttcaac	atcaagaata	49860
tttattacaa	aatatattgt	tatagttacc	aaggtttaaa	ttttatttta	atatttaatt	49920
tacttttaat	ttttactaca	ttcaaaaagag	aaacagtgtc	atctgtgttc	agcctgttca	49980
tgtaaaatgt	ttgtcttcta	actttgttaag	tttctttgcc	ttttaccatg	ttgtagaaaa	50040
cattgttttt	tttcatTTTT	tttaaaactat	tttttaagct	tttctttttt	ttgtggatac	50100
atagtaggtt	aggtattttg	atacaggcat	gcaatgtgta	ataatcacat	catgaaaaaa	50160
tagagtatcc	atcccatcaa	tcattttatcc	tttgtgxxxx	xxxxxxxxxxx	xxxxxxxxxxx	50220
xxxxxxxxxxx	xxxctccca	agtagctggg	attacaggca	cgtgccacca	cgccaggta	50280
atttttgtat	ttttaataga	gatgggatgg	ccgggtgtgg	tggctcacgc	ctgtaatccc	50340
aacactttg	gaggctgagg	tgggtggatc	acctgagatc	aggagtgtga	gaccagcctg	50400
gccaacatcg	tgaaaccctg	tctctactaa	aattacaaaa	attagccagg	cgtggtggca	50460
ggtgctgtga	atcccagcta	acnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	50520
nnnnnnnnnn	ntgctggaa	agggatcacc	tgagtatcag	gagtttgaga	ccagcctggc	50580
caacatcgtg	aaaccctgtc	tctactaaaa	ttacaaaaat	tagccaggcg	tggtggcagg	50640
tgctgtaat	cccagctact	tgggaggctg	aggcaggaga	attgcttgaa	ctcgggaggc	50700
ggagggtgca	gtgagccgag	atggpatcat	tgactccag	cctgcggaac	aagagcaaga	50760
cttcgtcaca	aaagaaaaaa	aaaaatagag	atagggtttt	gccatgttgc	ccaggatggt	50820
cttgaactcc	tgacctcagg	tgatccaccc	accttggcct	ctcaaaagtgc	tggaaattaca	50880
ggcgtgagcc	accactcctg	gccccaaaaa	gttttatcag	atttttgtga	tcatttgttg	50940
gtgttcctct	caccggtttg	taagagctct	ttttatatta	tggaaatcta	tttatagcct	51000
accgatttga	aatatcattt	ttattttata	ccaaattctg	atatgtcctt	tagaagtttg	51060
aagttttctt	ttttaagggtg	cttatggaat	ggctagtctt	agtttttgaa	ccgttaatat	51120
ggtgacttga	gttactggat	cacattagat	tggatttctt	aatattgaat	catccttttg	51180
gtccagcaat	ggatccact	tgggttatgat	agactgttct	gttaatgtat	tgctggattg	51240
tatttgctaa	tctttttgtt	caggattttg	gaatcagtta	aatagtaaat	tggtttgtct	51300
ttcttttttt	tttctgtact	atccttttct	ggttttacta	tctctgtcac	agtgttctca	51360
tttttttagtg	gaagctttcc	atttctcttt	gtgccatgga	tcaatttaaa	ttagattgga	51420
gttactttgc	tcttaatgca	ttagtatatg	gcacctgtga	aatatctgac	cataatgttt	51480
tatctaattc	agttattcat	tatttcattc	attcatatat	tttgacaata	gaccagttct	51540
cagacaacat	tcttcatttg	gtgtatcggg	ttgatttttt	cttttcttct	tttctttctt	51600
tctttttttt	tttttttttt	ttttttttga	ggcagagtct	tctgctctgt	tgcccaggct	51660
ggactgcagt	ggtgcaatct	caactcactg	caacctctgc	cacctgggtt	caagtgatte	51720
tgctgcctca	gcctccaaaa	tagctgggat	ttacagggtc	ctgccaccac	aactggctaa	51780
ttttgtattt	tcagtagaga	cgaggtttca	ccacattggc	caggctggtc	tcaaactcct	51840
aacctctggt	gatccgcccc	cctcgccccc	cagagtgtct	gggttacaga	tgtgagccac	51900
tgtcctggc	ctggtttgat	tttctgatac	ccttcaggte	actttggatg	tatttatgat	51960
cttctgtgta	atcattgatt	tcataagagt	tctacataga	attaaggaaa	ataatatctt	52020
gtactttaat	atcttttggg	tctattattt	tttttcttca	tctggttagt	ccatgttgtt	52080
tttctgtatt	ctaatttctg	cttcttggg	actttgcttt	agtgttgttt	gctgctgctg	52140
ttgtgaattt	cctgagttga	aaacttggtt	tctttttatt	ctttcaaaaa	ttcaaggcta	52200
ttaattatcc	tctttgcatt	gtgttagtcg	catgctgcag	attctcatct	gcattatttt	52260
tatgttatag	cttgatattc	tgtgatttca	gttttggttt	cattttttat	ctaatatgtg	52320
ttgagatttt	ttttattgta	taggtgactg	ggttttaaat	tttttatttt	tgttcatatt	52380



tagttttatt	acattgtaat	cacagaatgt	ttttagtagac	ttgtattttt	tgatgttttc	52440
tttgtggttt	aatatgtagt	tgttttcatg	aattttatgg	gcatttgaaa	agaagatgca	52500
ttctgttttc	aggggataaa	gttaaagtga	tttgtccact	tgatctgtct	tgggctgaaa	52560
tcagtgaatt	gaaatctttt	actatatgtt	gtttattttt	tctttatttc	cccttttttg	52620
gttctgcaag	tttttttctg	tacttaacta	tttggtagat	aaaaattcaa	gttaggtttt	52680
tatttttagtt	gtaccctggt	taaatttcag	ggttttttgt	tgttgttgtt	gagacagagt	52740
cttgctctgt	ggcccaggct	ggagtgcagt	ggtgcgatct	cggctcactg	caacctctgc	52800
ctcctgggtt	caagtgattc	tcctgcctca	gcctcccaag	tagctgggat	tacaggcatg	52860
catcaccacg	cccggctaatt	ttttgtattt	ttagtagaga	cgggggtttca	ccatgttggc	52920
caggctggtc	tcgaactcct	gacctcatga	tcctcccacc	tcggcctccc	aaagtgcctg	52980
gattacaggt	gtgagccact	gtgcctggac	aaatttcggt	tattttacct	tgcaagttaac	53040
ctcgtttaat	attgtgaatc	ctactctttc	tgttcgcttg	ctaccttttg	agttttccca	53100
ttccttttcc	ttcaagcttt	ctaaatcact	tgattttaga	tgcttttctt	cagtgtagtc	53160
taggattgag	tttggctatt	agatttggtg	tcattgtttc	ctaataggtg	aatttaaccc	53220
acttttcattt	actgaaaatg	acagatacaa	tcttatctat	tattatttca	tattatgctt	53280
tctgttttaa	atgaatcctt	tttttaacct	tctgctatag	tttaaaattt	tttgggtgtg	53340
ttatgtttgt	tacatatttt	ttaaggtttt	atttattttac	ttttcctttt	tttttttttt	53400
ttttttgagt	tagagtctca	cactcttgcc	caggctggag	tacagtgggtg	tgatctcggc	53460
tcactgcaac	ctttgcctcc	tgggttcaag	cgattcacac	acctcagcct	cccagtagtc	53520
tgggattaca	gacatatgtc	accacatcca	gctaattttt	gtatttttgg	tagagacggg	53580
gtttttgcat	gtttggccagg	atggtctcga	attcctgaga	tcattgtgatc	caccgcctcc	53640
agcatcccga	agtgtcggga	ttacgggcgt	gagccacggc	gccagccccc	ttaatcctac	53700
atttaaatag	ggattcagcc	caatcctatt	acctgtttcc	aggggtcttt	attaaactct	53760
tggactttat	taagaatagt	ttcatggaaa	ctatatcccc	agggaaaact	atccctttgc	53820
atattggaaa	aatatttttc	tttttgccct	tatatattgaa	tgacagtggc	tagatataaa	53880
ataggtattt	aatacttttt	ccctagtgtg	tttgtacaca	gacctgatat	taaatatttt	53940
ttgtttgttt	tttttttttt	ggagatggag	tctcactctg	tcgccaggcg	tggaatgagt	54000
gcagtgggtac	attctaggct	cactgcaatc	tccacctccc	gagttcaagt	gattctccgc	54060
ttcagcctcc	tgattagctg	ggattacagg	cacatgccac	cacacccagc	taattttata	54120
tttttagaag	agatggaatt	tcaccatggt	agctaggctg	gtctcaaact	tccgacctca	54180
ggtgatctgc	cctcctcggc	ctcccaaagt	gttgggatta	cagggtgtgag	ccaccgtgcc	54240
tggcctaaat	attgttttag	agaagtttga	aggcagacca	attttaagat	tcccccttta	54300
ggtgaattga	tttgtatcag	gagaagggtg	tctagatcag	cagtctccaa	cctttttcac	54360
accaaggacc	agtttcatga	aagaçaattt	ttccacggat	ggggtggcgg	gggagatggg	54420
ttcaggacaa	aactgttcta	tatcagatca	tcaggcatta	gttaaggagt	gtgcaacctc	54480
gatccctcgc	ataccatagg	gagggatagg	tttaccatag	ggtttgcgct	cctgtgagac	54540
tctaagtctg	ctgttgatct	gagaggaggt	ggtgctcaga	tggtaatgct	ccctggagtg	54600
ccactcacct	cctgctgtgt	ggcctggttc	ctgacaggcg	atggaccgat	tctgggggtct	54660
gcagtccagg	ggtggggacc	ctcatctaga	tgaccataag	atgctttatc	aaggtgtatc	54720
ctggtttttt	atgtttttgt	tttttgaggg	ggtctcgcac	tgtcaccagc	gctacagtgc	54780
agtggcgcg	tcattggttca	ctgtagcctt	gacctcctgg	gctcaagtga	tcttccacc	54840
ctagcttctt	aagttagctg	gacctagggt	gcacactatc	acacctggct	aagttttttg	54900
tttgttgttg	tttgagacaa	agtctcactc	tgttgcccaa	gttagagtgc	aatggggcaa	54960
tcttggtctc	ctgcaacctc	tgctcctcgg	gttaaagcga	ttcttctgcc	tcagtctccc	55020
aagttgccag	gattacaggc	atgtgccacc	aaactcagct	aatttttgta	ttttttgtag	55080
agagacaggg	tttcaccatg	taagccaggc	tggtctggaa	ctgctgacct	caggtgatct	55140
gcctgcctcg	gcctcccaaa	gtgctgggat	tacgacgtga	gaccacacac	ctggcttagt	55200
tttttaaat	atttttggta	gagatgggg	tttgccatat	tttccagggt	ggtctcaaac	55260
tcctgggctc	aagcgatcct	cccaccttgg	cctcacaagg	tgctgggatt	acaggcatga	55320
gccactatat	ccggccaaga	tgtatcttgt	tgattgctct	acatcagttt	ttttctgagt	55380
cacagtgtgc	ccttaccact	tgcaaatcca	agccttccct	gatttcagga	aagttgtctt	55440
ctattgtgta	tttacccttt	tggttggtct	gtttcttttt	cttttttagta	taccctttac	55500
cccggtatag	tttatgttcc	cttttttctt	tgttatttgc	tattttctct	gtaattattt	55560
gcagctttgt	tctttttttt	ttttocactt	gatttttctc	acgttttggtt	tccatgtccc	55620
atgctgcatt	gtttcattaa	atatattattt	ggcattgttt	tagttaggca	ctgacagtaa	55680
agcagagaa	aaaacagaca	ataatccttg	acctcacgaa	acttatttag	tgggagaatc	55740
agacaacaaa	caaaatgtag	taggccagaa	gtaatgaatc	caagaaaaat	aaggccatgt	55800
aaggaagggtg	ggacgagaat	tgtattttta	gaagggtggg	cagaaatggg	cttactgaaa	55860
agtgatattt	gagcaaagac	ctaaagagat	gcacgtattt	ggggaaaagc	atttgaggta	55920
gaggaataag	tgtaagtggg	ttgaggtggg	agcatagttc	ttagaaggat	actcatttca	55980
tcataggggc	agtcctctca	tgacctcatc	ccaacttaat	cacctgccaa	agtccccaca	56040

ttaagtgttt	ggacttcaac	atatgaatta	tgaggggaat	gcaaacattc	aatcccataa	56100
ctgccatatt	ttcttttgatt	aatttgttca	tagttttcat	ctgcttcatg	gtataagttt	56160
tatggcattt	tctttatgac	attttggttat	actottgctt	ttctgttttt	gttttgtttt	56220
gttttgtttt	ttcttgcaaa	atctttgagt	aagacctaac	tggttccttc	ttgattattg	56280
gtcatctttg	aactggaggt	attcgtctta	gatcagctat	ttacccaaga	ataaaattgt	56340
gggaaagggg	ccagaggagt	ggttggggaa	ggctgacagc	ttgaattttc	ccaggttcct	56400
ttggtggcat	gaatcagtga	gtaagaagca	gagctcctta	tatcacaggt	ttattttgtt	56460
taaattgata	aacactgatt	catattagaa	tcacctgggg	aatccttacc	catgccaatg	56520
aaatcaaaa	ctgtgagagt	ggggcctagg	tatataggtt	ttaaagtgcc	tcagggtgatt	56580
ctcatgtata	tccaggctag	aattgctgat	ttagccttta	cttttagcta	tccaagatca	56640
actgatgctt	ggctacatgc	aaccaaattt	cacttccgcc	ttaccatact	taaacagcct	56700
gctgcttgca	aaaaatggca	ggtgtagggtg	ttcacatttt	ccttaatatg	tcccaccttc	56760
tcccataggg	cactcatatt	tcctgacttt	gtcataccat	gcaagggctt	gttggtttta	56820
ttttagggtca	ccttttttag	cgagctatga	actgtaccta	ctctggccca	cagaggagtt	56880
atctgctatg	cctagcttag	gatggttcta	ttttttttga	aaattttatt	gtgaaattat	56940
aatatagaaa	atgcataaaa	tgtaataaaa	cccatgta	actattgccg	aagtatggaa	57000
acagaatggt	taccaggaca	ccaaaagcct	ttttcatgcc	gcttctcagg	cacaaatctg	57060
tttctccctc	tgtaaagtaa	ccactatcct	gacgtagctg	gtaatcaatt	ccttttcccc	57120
tcattcttct	cattttcagg	gtaatggatg	tttcttagtt	tcatacaatg	tttctctgt	57180
tttcagaaaa	gagagaaaaa	aaaatgcctt	tattcttcta	tctataactg	gaagcagagg	57240
actattgaga	ttgccaat	aagtttttgg	tgttttttgg	ggttttttta	aacagatgaa	57300
gtcagagatc	attatagcta	atgccatact	gactggcagt	tcagcatgca	gtaccctagc	57360
acaaactatt	agccgggctt	gatttatagt	tatcagtagt	tctgaattta	tgagacagga	57420
attttaaaact	tccatttctc	ttcaaaacaat	atggcactag	atttttcaat	acagatgaa	57480
aataccaaca	gtgtatacat	taatcactat	tttgggtatc	caagaatgta	aatatataat	57540
taagttaatt	aacttatttt	ttttttagga	atatgaagcc	atctacctag	caaaattaac	57600
aatacagatg	atgtcaccac	tccagataga	aaggctatta	tctgttcatt	ctggtaccac	57660
aggtaaggat	ttttttcttt	ttggagaaat	ttgggaagaa	agataatgaa	aggtggagaa	57720
cttgctacaa	gttacactga	acaatttaaa	ttgttttagaa	aacttgtaa	actattgagc	57780
taattccaga	aggattcatt	ttataatgaa	taaatgtgta	ctataataag	cttaagtctt	57840
tcaagtagta	gtacatccgt	gttgtaaaga	ttaaaataat	acgaatctgg	agaagggggc	57900
ctaaacacgc	ttaggtgatc	ttattaaaag	tagagggcgg	ttaatacagc	gtgtagcatg	57960
gctaagtgtg	gcttctttct	cttgccatca	atatttccat	cctttcctcc	ctctgttgct	58020
atttcagaag	taccctaagc	cccttatttt	caaagttaat	ccaagcatgc	tcttaaaatc	58080
ttcctttccc	aagaccttgc	tacctgtgtt	tatcaccttt	gtttctctcc	caacaaagca	58140
cacaaggcat	ttttacttta	tttcagtttt	ttcctaccct	gcagttcact	tcaatctttg	58200
aaccaacagt	tataaaggt	agtaagaaca	gcttatatac	ttagcactga	cctggaaatt	58260
gaggacaggt	gatctgatcc	acaagtatag	aactctttgc	actctactgc	actgcccata	58320
gtgagtaata	tgactgtata	ttcatcccca	aggctcaact	tcctaattgt	cattgacttt	58380
ttcatttctc	ttgccacatc	tgtctaataa	ttgctctcca	catcctatag	ggtccgtttt	58440
gtcagtagtg	ttaacattcc	ttcctttttt	taatagtgtg	cttaatctag	ttcagggtccg	58500
gatttgcctc	ctttccaaac	tcttgttatt	tggtctgttc	tgtacattgt	ggccagactt	58560
atttccatga	aagatatttc	taataattgat	attttctctt	tgccaaagcc	tcctttggct	58620
tcatttctac	aaaagtttat	agaatgccat	atgcccttct	gattttttgg	tttctttctc	58680
tcattgttct	tctttatgtc	tgcatctcag	aaaacaactg	ctgatgggtt	cctgtgtgtg	58740
tcttcttttc	cccacctaaa	atgcatacaca	tttagtctcc	ctattcttgg	ttcatatgtc	58800
atctcctcag	gaagacatga	tgattaatgc	actcttctct	taacccttag	tcatttggag	58860
ttcccataga	agcacagcac	ttcatctgaa	acttaatcac	agtatctggg	tttagcctga	58920
gggctaggat	attttatctc	attcaattgt	attgatacta	tattttttatc	tttatgaatt	58980
ttatagttaa	acattcttca	attagaatat	gccctctgaa	ttacatttat	tattaccatg	59040
atataacagt	cctgtagggg	ataagtttaa	ggctatgcca	ttgttaggca	aaaaacacag	59100
cagaccctct	gctgggttaa	ctgttcccta	aagttttcct	ccattgagag	tctaatttct	59160
tgattataac	ttttggggat	acagagatag	ctttgattct	atgtgggaga	tttctgtact	59220
agcagatgct	ggtatgaaga	atagataaaa	gaaaatctct	ttatatgcta	catgccttcc	59280
tttctcccaa	cctagacttc	gatagcttga	gtggaaaaat	attttcagct	gctcttcata	59340
acagcctctg	tgaagcaaaa	aagattatct	acaaaaaatt	atacaaatat	aagatttaatt	59400
tcctaaattt	tatgccctaa	gtcacatggt	tatgggtgcct	aaaaaacaat	taacttgata	59460
actaaacatt	tatgtattat	ctcttgaaaa	ggtctatttt	cacactattt	caaaaattat	59520
ttattttata	tgcaatacct	aagacataat	acttgagaag	gaaaatatat	cctgtcatga	59580
agattaaaaa	gttataatat	ttaggttaatt	tatcacaaag	gaatttacta	aattttgcta	59640
tatcagttgt	ggaattttca	tagtgtatgc	atgatcactt	aataacaaaa	ttttacttgc	59700

tgtaaccttt	taacatgaat	ttatttttagt	gcccttttaa	tcttcatgca	ataactttta	59760
ggcagtttga	agagaacaca	tgaagaagag	gatgattttg	gaacctatgca	agtggcgact	59820
gcacagaatg	gctgacttga	agagcaacat	catagagtgt	gaatttctat	ttgggaagga	59880
gaaaatacaa	gagaaaatta	taatgtaaaa	tggtaaaaac	ataagtagtt	tttttttcaa	59940
ttacatgttg	cttccagaca	tacttctctg	caacttggtg	agcaacattt	taagatgttg	60000
gacttctgca	atagatgaca	ctgatggttt	tactcctttt	tttaaaaaa	catgcgcgcg	60060
cacacacaca	tgcttttaca	gtttttattat	aaaccaagaa	ttttggactt	gcaaagaggt	60120
attattgcaa	taatgcactt	ttcatacttg	aaattttattt	gtatgatata	aagttattac	60180
tttaaacaaa	atgcaagtat	ggggggattg	tttataaagt	ttgggttaatt	tataacaaaa	60240
tttgctaagg	tttgctaaaa	attcattttt	ctgttctata	tattacattt	ttaacataat	60300
tttacagttc	aattttatga	tggagcctct	tacagaaaac	ttacaaaaat	gcaggaatct	60360
gccacatttc	tttttttagta	taacttaata	gcttaattac	cattttattt	tttatacttc	60420
ttccattatt	aatctttaaa	tcatgatcct	aattagctgt	ccttacttta	acttgatcta	60480
attattgctt	ccttttcttat	tactttccta	atttttctat	attttaaaaa	ctacagtttc	60540
catgataaaa	tgaaaaacgtt	ttgatttata	gtaccaagtg	cttaaacaca	aggatagtgt	60600
tagattttcg	agtgactttc	ctttttgcat	tttttggcag	taaaagccaa	acgttggtatt	60660
tgttcttttc	agagttgtcc	agcccttttt	tcctttgtcc	aaaaatgattc	taaatagzat	60720
ctaataaacc	aatgtagcat	tatttttttc	taaatgaagc	cccaaaaaag	aaaagtgcct	60780
tgcatcattt	aaaaaaaaata	attaaatcct	catggcctct	aaattagtat	gtagaacact	60840
gaaaagttct	taacattttt	gtgtaatttc	ctttcttttt	aaaccataaa	ttagttttaa	60900
ctgaaagtac	gaggctggaa	gaaatattag	taaattattt	ggaatataga	atgtttactc	60960
tttcttttta	tgttgtctta	atgattctgt	gagattgttc	cggctcaaac	agaagctttt	61020
ctttggggaa	ggtgatttgt	gggagactct	agtgtatttt	aaattagcat	tttaatccat	61080
tcttgacatt	cagttagtcc	agatctgccc	cataatttgc	tttagtaaag	tcactttatg	61140
gatttttggc	tatgttttag	tttgtgtgta	taaaagttct	aagaaaacat	ttttgctatt	61200
ttaagtatgt	aagggaagag	aggagtgttt	tttaactttt	atagttgatg	acttttagggg	61260
tagcacaaac	aaaactcctt	tgtatctaac	ttttctcaat	cctctcttga	ggtgctttac	61320
taatgggaat	gtttctgtga	tgttcccttg	gtaccaaga	ggtactatgc	aaagtaacct	61380
attacaccaa	gttacttgct	ttgctttcct	ctctatgatg	tgataataca	gtaaaagctt	61440
tcttaccag	catagtggga	gagtggagat	taattaaaat	tgtaatttaa	gagtttaattc	61500
ctattgaccc	aggtgatatt	tctcttctga	tttccctccc	cttcccttct	cttatcttac	61560
cactgtgaaa	acagcatatt	gttaatctcg	ttgtcgtcca	gtattctgct	ttgtgattag	61620
gtcttttgat	gtacagtggg	ctagtggagt	caagattcgc	attgggtttt	ctaaaattcc	61680
agttgataaa	agttccagat	aacapagctt	tcctgtatat	agatcactat	tgggcaggtc	61740
agcaaaagac	tcttaccagt	taataataat	ctatgatgct	tcatttagca	gaaactctgc	61800
ttaaaagaat	cttcataata	gtaagtttag	gttttaaaaa	cttgtttcat	aaatatacat	61860
atatcctctc	tagtagtctg	gccaaaagaa	cagattttgt	tattgataat	ttgtagctgg	61920
taattttcca	catttttctat	ccactgtaat	ttttatgttg	tcactgaagt	gcctgccag	61980
tactgtatat	tacagtctct	cacaaacact	gggaaaagg	actgtcatca	tcttgagtac	62040
tctgtgtgta	tatatatata	tatagataga	tagatttttt	tttttttttt	gagacagagt	62100
ctctaagtgc	accaggctg	gagtacagt	gcacaactct	ggctcactgc	aacctccacc	62160
tcctgggttc	aagtgatttt	cctgcctcag	ctccccaagt	agctgggggt	agaggcacat	62220
gccaccatgc	ctggctaatt	ttttagtatt	tagtagagat	ggggtttcac	catgttggcc	62280
aggctggctc	caaactcctg	acctcaagt	atccaccac	ctcggcctcc	caaagtgcctg	62340
ggattacagg	cgtgagccac	tgcgcctggc	tgagtacaat	attaatgtag	acaaaccatg	62400
aagtttatta	tttcatataa	gaacattaca	ggtttgtttt	ttcttgcatt	tctgtccacc	62460
taatgtttaa	gtagttctgg	tagctcttcc	tattctttat	tctatttgat	tccatttctg	62520
tgattctttt	attaccactg	atgttttgg	atagtttaact	atgataaatt	taactgatca	62580
tgatttatct	tctagagtat	ttaaataatg	tatgagtac	caccaatttc	caacattaaa	62640
agtgtaatct	gggcccataa	tttatagtga	aattgtatca	aaacatagg	aaactgtatt	62700
actgtccatt	ttgaaaatat	gaaacttgag	tattgaaaat	attcaaacat	ggaatggcag	62760
tattctaatt	tcagttagtt	ggttcattgt	aatttcttac	ctgttagatg	tttaaaactgc	62820
agtgaacctt	acttgtatct	actctgtggt	ggaaatgtta	aacctatgata	gcttttgcta	62880
ccaactcaac	cacttaactt	ttagagcagt	tttggggaga	gtttatgctt	catctgagtt	62940
tagaagtaat	gtcagaaaaat	gttaagcatg	tctgtattaa	gaaaatataa	ggtttctaatt	63000
tgtcttatta	atatggtaat	tcaagtgaat	tagaaatatt	taactgcaat	cttgaattat	63060
aaagttgaga	tatatatata	tatgtatcaa	gatctcaact	tgatgtaaag	taaatgagca	63120
gttacctggc	ggattttttt	ttttttaaat	aactgattta	atccataatc	ccataacaaa	63180
catagcttca	cctcagtatt	ttctttcttt	ctttgttcaa	cagtgtcccg	ataagggaaat	63240
gctagaaaaa	agatgagaag	tactgaaaga	cctttttttt	taattgatta	gaaaagtaag	63300
tctctagggt	ctttgaaatgc	tggaattttt	tttttttttt	ttgtctttcc	catctgtggc	63360

agctaaaaca aaaatcactc aaaatattca ggtttacatg ttagctctct ctcataggga 63420  
 gctgccatac ctcacagttc aaagtgtatt ctatagatca gtaacattat actgacatgt 63480  
 aattgcaatt tactatgcag caaaaatgat tcaagaagaa aaataaccta cagtgtctgt 63540  
 atacctttgt atacacaatt gcttaagtta ctctgctttt aacatttgta cttggataaa 63600  
 atgcttatgt ctgtatagga atgtcacagt gcaagatgct gctagcccag gcacaaagta 63660  
 ttaaaattat tttgtgaaga ttggtggttg tattaaaact gctgtgccat tatacctcca 63720  
 aaatattgaa aagctcattc atactgctgc ttatacctca aaacttcttt acttagattg 63780  
 ttatctgctg ggtaaaagta acccaaattt actctgagtt aagaagagtg gatgaacatt 63840  
 gaatgttgag aagcacttaa gagtatactc taaaacactg tggttacaca cacacacaaa 63900  
 attatggtct gtagtccagg caagcctcaa attccagctc aagtttattt ttaaggatta 63960  
 gttgagcaag tttgaggttg gaagtggagag aatcgtgttt aaaggaaagg gtaggtcatc 64020  
 cacagaacag ctttcagtca ttacaaaaaa aaaatacttc ttgcttttat attaccatct 64080  
 tccccatta ggcctacctg catactgtgc ttcatcaaat ctaagatcac ctcacaacta 64140  
 taccattatt ttaggcacca ctaaaagaca gtgtattgct aacaaaacta tgataaacca 64200  
 ttgataatat atccagattt cagagatggt acagtgcac ttagttgatg aaacaaaaat 64260  
 atacaaaaca tgagacacag taaaaatgat aggtaccacc tcattatacc ttttcacaag 64320  
 caaatagtg ccaaaagatg gaacggccag acacggtagc cgacatatgt aatcccagat 64380  
 actctggagg cttaggcaga ggcactcttg agctcaggag tttgagaccg gcttgggcaa 64440  
 tatagtaaga cccacacaga aaatgtaaag ccagggtgta tggcacacac ctgtagttcc 64500  
 agctactggg gaggtgagg caggagggat ggcttgaacc caggaaactg aggatgcagt 64560  
 gagctatgat cacaccactg gactccagcc tgggtgatgg agtgggacag tgtctcttta 64620  
 aaaaatgtgg gccagggtga gtggctcgca cctgtcatcc aagcactttg ggaggctgag 64680  
 gtgggaggat cacttgagcc taggagttaa gagaccagcc tgggcaacat agactccaca 64740  
 caaaaaattt ttttaattag ctgggtgtgg tggcatgcac ctatagtccc agccacatgg 64800  
 gaggtgagg tggaaggatc atttgagccc aggagattga agcggcagtg tgtggtgatt 64860  
 gtgcccctgc gctctagcct gggcaacagc gagacctgt ctcaacaaca acaacaacaa 64920  
 aaggctatct attgtgggta cactgcctat ggggtagtc tgctccacaa ggagcagttt 64980  
 ttaaaaaaaa aaagttaag aagtgtttta tgtagcactt ttttcatatt tacatttact 65040  
 caccatattg cttcaaaaaa cataaacata ctcaactaaa attacagatc accattgtcc 65100  
 tcaatgacac aatttttgta tgggtgtac taccgttaat tctatttcct atgggaggat 65160  
 ttaagagata tcttaggaac actatttaaa gggatttact gaagtgccaa ccttgtgaat 65220  
 gattttacct caaattgttc agtggttaaga aaggttaata agcatttagt tgtgccttta 65280  
 agtaggctaa tttttttgt tttgtttga gatggagtct ctctctgtcg ccaggctgga 65340  
 gtgcagtggt gtgatctcag ctcactgcaa cctttgcctc ccgggttcaa gcgattctct 65400  
 cgctcagct tcctgagtag ctgggattac aggcgcagtc caccacgtct ggctaatttt 65460  
 tctttttttt agtagagaca gggtttcacc atttttgtca ggctggtctc aaactcctga 65520  
 cctgtgtatc tgcccacctc agcctcccaa agtgctggga ttacaggcgt gagccactgc 65580  
 acccgccctt accaggctaa tttttaaaaa catgctgttt taattaccag gatttacctg 65640  
 ataaaactac tctttgtcaa ggtgttagga cttctgaaaa gacagaacta gctttgttgc 65700  
 gtttcacgaa ggacagatca gttcgtctgt ataggctata agcaggtaag tagtgactc 65760  
 tattggtgaa ggatttctgt tgttttgaa agccaactat agctggctgc atggagggaa 65820  
 atccaaaatc cagatgacgt ggtgtgagtc aatgggatga gaaacactgg tattttcttt 65880  
 acaatttcat tttaaaaaga gcacattaaa ctaaaatttt atgaattatg acttaactca 65940  
 atagtccaac agcagactca agaaaagcac agatgtgatt ctaacagaag actactcata 66000  
 taaacaggtt taatgcaaca tggaaatgcaa aagattagaa ccattaaaat atttaattct 66060  
 tcaactttta aaaattaaat aaaatcaaaa taggataatg accagaatag tgccattata 66120  
 atcacatcaa aaagcttcca ttaacatttt atgaatttgg caatctagta caatacatta 66180  
 agtatttgtt ttcactcaat tttgtgatac tccatttttg aaaaaactta gaggttcag 66240  
 ataccatga aaagaaaaaa atcagggtag aaacacatag gctgagggtt gctaattcac 66300  
 tgtttacaga tgccttaga tgtccacta taattgtct taggtatttt taacaaatga 66360  
 atagtataaa ttacacagaa agacaagtg tactttttat ctacatagac tatactatat 66420  
 aaactttcag taaaacattt aaattgtttt acttttaatc ttgtcaagta attttcattt 66480  
 cttctacttc aaaagggtga ccagggtgtt tgctgtatt gggatcaacg aatgttgagc 66540  
 tatactatgt ttagttataa taactaattt atccaccctg acttaatatg tgggaaacaa 66600  
 tacacccta agtgattga gatgtttctt tgaacaaaa atatttaatt ttatgcatgt 66660  
 gataaacagc cttattcaat gtatactttt ttaaatgag caacacagat agcagacata 66720  
 taactcctta ttaccctac tcttgactac caagaaagga agccaaactt ttagaaaaat 66780  
 acaatgcaag aaaagattca agttaaaaa atattccttt ggtaaaaaat catccccttt 66840  
 ataattttca tttgtaattt aaattcacag catgtccac cagcccaaag taactttcta 66900  
 aatgtcatta tactttagt attacaatgt tttttcagtc cagtatttat ggaggctact 66960  
 cggctgcagc aacaaaatat ttcaactcta ggaagagtgt agcctttagc cattagcccc 67020

tttgacaatt	ttcttacaag	atcttttactt	tagaaacctc	cgacacatgt	agtttttcttc	67080
agatacagta	tatccaaact	ttttatagaa	accaacattt	tgtggtagac	attcaagggg	67140
aatcttghta	cagttcagtt	tcttgcttag	caaagtaagg	gttgataata	acctgaaatt	67200
taaaaagggg	gtagggtgag	gagatagcat	ttattaataa	aaattgattc	tagtaacaat	67260
atgaattaat	gttataaaac	ttaagtttcc	ttagaaacag	gttttagatta	tggcttttcc	67320
cactgcattc	atgtaagttg	ataagcattt	aaatcaccaa	agcattttta	cttagagtca	67380
aatatacttt	tatctagtaa	tctccagctc	actaataaac	aggacaaata	caaaactcac	67440
ccttagccct	ctttaaaaat	gaaatttaag	gctaggtgca	gtgactcata	cctgtaatcc	67500
tagcactctg	ggaagccgag	gcaggcgatc	gctagagccc	aggggtttga	caccagcctg	67560
ggaaacacgg	caaaacccca	tctctacaaa	atataaaaat	tagtagggca	tgatggcaca	67620
tgctctaaagt	cgcagctact	ccagaggctg	aggggggaag	atcacctgag	cccagagagg	67680
tcaaggctgc	ggtgagtagt	gattgtgcca	ctgcaactca	gcctgggcaa	cagagtgaat	67740
ctctgtcttg	aaaaagaaaa	acgaatttta	agatgcatgt	taacactaaa	aactcaacct	67800
ttaaaaaaa	aatgaccaaa	aattattttg	taaaaaattc	ttatttaaat	ctatttaaac	67860
aacttcggag	cagtcgacat	accacataaa	aatgagtaca	taatagcttt	gctctttaat	67920
catcttt:aaa	gctactttta	tatttgtgaa	ggtgtgtatc	agattaaact	aagatttgct	67980
taattlaatat	gaagtggaaa	caaagcaagt	ctacatctat	acaaaatttc	ttaatgaatc	68040
caaaccagct	attaaagtgt	ggatctaaat	gccttagagg	ataaaaaacta	taaaagatat	68100
acaaacttga	aggggtctgcc	catgtttgaa	cagactaaaa	aatcctattt	ttaaaaaaa	68160
caaaagacct	tgactgaaat	atgcctggct	ggttgacgtg	gctcatgcct	gtaattccag	68220
cacttttagga	ggccaaggat	cacttgagtc	cagaagttcg	agactagcca	aagcaacata	68280
gcaaaacctt	atctctataa	aaaattagct	gggtgcagcg	gcatgcacct	gtagtcccg	68340
ctacttggga	ggctgaggcg	agaggctcac	ttgagcccca	gaaattcaag	gctgcagtga	68400
gctgtgatcg	taccactgta	tactccagcc	tgggcaacag	aaagagatcc	catctcttaa	68460
aaaaaaaaaa	aaaaaaaaaa	aaaaacataa	attatataga	ctagaacaca	agaaatcggg	68520
ctgttttggt	cactgaggta	ttccaaatac	ctagaatagc	atctggtaca	taagcaggta	68580
tttaatatatt	gttaattcct	taaaactcag	aagagttagt	gttaaaaagc	aagttcttgg	68640
gccaggcaca	gtggctccca	cctgtaatcc	cagcactttg	ggaggccaag	gcaggagcac	68700
tgtttgagac	cagctctgag	aacatgatga	ggcccatct	ctacaaattt	ttaaaaata	68760
gccagggtgtg	gcgtgtacct	gtagtcccag	ctaattgggg	ggctgaagag	gattgcttga	68820
gccaggagg	ctgaggctgc	agtgaagctg	gattgagcca	ctgcacctca	gcctgggtga	68880
cagagctgtc	aaaaacagac	cctgtctcaa	aaactaaaa	ttataataaa	taagaactac	68940
aagtctttat	aaaatggcaa	taaatcaata	ccacttattt	atattttatt	taaatgattt	69000
agatatatac	agtgaaggct	gtttcagtat	gtattttctac	aaacttatgag	aatgagagat	69060
cacagaatat	tctgtaatat	ttgaacattt	cctttgtttt	taaatatgac	agagaagctg	69120
aggcaaatcc	gattagccca	aaagtttatc	tctacttagg	acgagagcat	tactataaaa	69180
agttagtaat	ttaaagatgt	tactgtctgt	aaagaagtat	gcttccaatt	ttcaaaacttt	69240
aaggcaaaat	atgtataata	atactttatt	tcttcatgaa	attcagctca	aactattaga	69300
gtgagaataa	gttcagaatt	aatgaagcca	aaaagaactt	caaacaagta	tcttggttaag	69360
aaactaaatt	ggaacaaaat	ttatccaggg	ttaccttggt	tctgcctact	tacaatttgc	69420
caagctgctt	tcctctgcat	tcatacactaa	caacaacatc	ttctactctt	cctctctgaa	69480
aatattttaca	atgttttaaag	gagtaagcat	ttacttttgt	ttttagctaa	aacgagttgg	69540
taagaatttta	ctgataataa	gtagtataat	ttgtaaactt	gaacttaaca	gaaatcaaat	69600
gcaaaaaata	ttatacagtg	aaggctgttt	cagtatgtat	ttctacaact	tatgagaagg	69660
agagatcata	gaatattctg	taatagctga	acatttcctt	tgttttttaa	tatgacagag	69720
aagctggggc	aaatctgatt	agcccaaaaag	tttggtttcct	actagtatga	gagtactact	69780
attaaaagtt	aataatttta	agatgttttt	acttattaga	ggaaatagta	tgagtcaagt	69840
tgtgacctaa	acttggtttg	gctatgtccc	caaccttccc	acccatttgt	ctttaaacaa	69900
atatcaggat	caacatcacc	aaaatgtaac	cttttcatga	atatatccat	cattctactc	69960
cttgcttact	agcaagttat	tttagatata	caaataaaaat	taatgtctag	tacagaaacc	70020
ccaccgaaat	tcctaagtgt	gacagaacac	atcccaagtg	ttcctacctt	attctcattg	70080
aattaagggt	ttctctccct	ctttttttat	ttactatttt	atgtgagtta	ttgagggatg	70140
aaagggcact	acatgcatta	gatgtatcat	aattagaacg	gaataatctg	aaccttttac	70200
catgtggaaa	caaatttatg	ctaactgtgt	atattcagag	ttgttttttt	taaaagagta	70260
acattaggga	ttttgtgcat	tactgctaag	ttgtttgggt	tctctatgcc	tataccaaat	70320
tgatccacct	tacagaacaa	ttttagcata	caattcatac	tgttatacat	tttctttctt	70380
aaagctctca	gaacacactg	ggaaaaggga	tttctaagag	gcactgaaaa	tcaatgagaa	70440
aacagatttg	tctaattggaa	actcaaagtc	agttgtgcta	gaaaacagct	gtccatttta	70500
tttataagca	gcacatacct	tagcacagga	atggatgaat	ttatgttcta	taatcagagt	70560
tgccgtagca	acaatctgtc	ctagagtcac	atcttctaca	actgtaacat	aataatcccc	70620
agattttcttc	atatgctcaa	aagatttctgt	ggaaattgga	taacaaagtg	ttacatagta	70680

gacattcaat	tttatgggga	gccagaaaaa	tattaggatt	agctgactta	attactaaat	70740
gtttaaagct	gttttaccat	agtaattttac	cttccatttc	taaagaaaat	attaccaagt	70800
agttgaaata	tcagcaatta	gtatcaattg	gaatataacc	tacacattca	aaatatctgc	70860
tagcaaaaata	aagactaata	tagctatttt	agatgaacaa	cacttaaaat	acaagtaaat	70920
ggctgatgtt	gccacttcca	tgactaatga	aaacttcaat	ttcttcattt	actttaaata	70980
gatctcttta	actttttatac	tcaatagata	ttcaaataata	acctttgcac	attttaacaa	71040
gagcatgttt	acatgggtca	attctagaat	ttttagtctt	ttgctttcaa	aatattttta	71100
caaaatatat	tttaattttc	cctttgtgat	ggaaagtgtt	ttgtgataac	atgacttgct	71160
cttgtttgtc	ttgagagcac	cttgcaagga	agtaaaaaaca	tatctgtttc	caagtaactt	71220
ttcgaagtca	catagcaaat	agggtgcaaag	atacttcccc	tcaaatggat	tttcagtact	71280
attgctgaaa	taacatgggt	tctcatctaa	ttcatgtgca	tgcaaaagaaa	aaattcagga	71340
ataaaaaattg	aggctaatag	tctctcatat	tggttaatttc	ctatggggcc	tcattccaga	71400
tagagatcta	aaatgggaaa	aagaaattca	gtgaatgaaa	ataaacaatg	agtaatcagt	71460
aatgatggtc	ctcattctca	ggagggtcaa	atagcaattc	aatacaaaat	tccttattat	71520
aaggaaatga	agaattgtaa	ttcctcagct	attaaatatt	actaaatatt	tagtaatgat	71580
aataataactt	catttccttt	ataacaggaa	aaagcagtgg	tagagcactg	gacagaatta	71640
aggtttttatt	cctcaccgta	gcaataacta	cctgtgatct	tgggcaagtc	tttggtatctc	71700
tctaaattcc	tattttctcc	tatgtctaaa	agaagagggg	caggggacgg	gtggactaac	71760
tcttaagatg	cctgctaacc	ttaaacttca	atacaataaa	accccaaaat	aaatttaaaag	71820
cgtatagtct	tgcttttttg	atttggtaat	gaaatttctg	taaataacca	cagtaaggga	71880
aatactacaa	taaaaaaacg	aaaaaacctct	agagctaaca	cctaggtcct	atggtacaat	71940
aattatctaa	taaagtagtc	agatagtttg	caaaaaacaa	gttactggta	catttggtatt	72000
ctagaacaac	tcagccacat	taaacatttg	tataaaacag	ctaatttgtt	ctttgaataa	72060
tttccagcta	tttgaacaaa	aacagaagtg	ggcactgaac	agctctaaac	aaaaatgaaa	72120
tcatgtttcc	ctttattttca	ggaaaaagag	gttatagtag	ttactcataa	attgttcagg	72180
gctgacaact	ccagtctctg	ttagctgacc	caatacctta	aaaaaaccta	gttttgaaaa	72240
acagattttca	aattacgaga	atagcaaaaag	gaagacagta	tgaaaataag	caatatatta	72300
agcagggtgg	cttacaggca	attatttttt	cagaactttc	tataatcttt	taattattag	72360
aataaaagtga	accctattct	tctataatca	ctacatatata	caaaaaataac	aggttttacc	72420
agtgcttctg	cctgcataag	atgtttttaa	tagtgctgac	cttaatatcc	agtattttata	72480
gacccagaac	atacattctt	caatgtatta	tattttacat	taagtccaat	gcaaagggtg	72540
ccagattttc	ccaaatatgt	gatttggttt	tacttaaagg	tgcaacatgg	ctaaatacaa	72600
tattcgtaaa	ttaaagtata	agtaacactg	ttgagattac	actctttaaa	attgtaattt	72660
ctagtgaatt	tcatttagtg	taccggaaat	tgatgtgaac	agtgcacctg	gaattttgaa	72720
aatcttaact	ttcctacact	caataattag	gccaaaatta	ggcccttcag	gctgtctagc	72780
aagagataaa	ttgtgaaaaag	gacaaagtgg	acttttaatt	accaaagtgt	aaggaagtta	72840
acttgtagaa	tttagatgtt	aaaaaagaaa	taactgtata	aaaacccttt	caatttatcc	72900
aaggaaaatt	atttccacct	tcattcccca	accagcttct	taagatccct	ccttatgtgt	72960
catcatacat	gataatttaa	tttttgttta	tgagaaatct	ttttggctta	attaggaagg	73020
agtgatgttg	tatttaagtc	attttaaata	tttcacagta	atatttggtc	ttagccatga	73080
cacacactca	ttggtattga	gtgtccatca	ctttaaaaac	taagtattat	acaaaaata	73140
gtccaaaagt	caaataattta	aaaaaaatta	tctgcatcat	aatgtttaga	gaaaaatgga	73200
aggctaactc	taattttaca	caggattttg	tacattacct	ctatttaagt	cagcagtaca	73260
aagaggcctc	aaaaccaagc	cttctccagg	atgtgttggtg	gaaatggctg	gagaaaaatgt	73320
agctgtattc	tgactccagt	ccacttcttt	gagtagactt	gggtcaaaca	taggagtttc	73380
atcagggtttc	atttttctag	taaggtctaa	aataaaaaatt	tgaatattaa	gtcactttat	73440
ttaatagaag	gaaaattatg	attgttgaga	aagttaatat	aaattaatgc	aattagaagc	73500
attcttttagc	acatatgcga	gatattttac	tgcaaccacag	cctgaatcta	acattaaatt	73560
ccacaactac	agataaaatag	aaaaatcatg	cctactatca	gataaaaaaa	tggctaagtg	73620
actaaattag	taagtttttaa	actataaaat	cccatattat	atcaagtctt	tttttttttt	73680
tttttttcag	acagtctcac	tctgttgccc	aggctggagt	gcagaggcgt	gatcccggct	73740
cactgcaacc	tctgccttct	gggttcaagt	gatttctctc	tttcagcctc	ctgagtatct	73800
gggatttatag	gcacgtgaca	ccacgcccg	ctaatttttt	tgtattttta	atagagacgg	73860
gatttcgcgg	tgtagccag	gctggtctca	aactcccgac	ctcagggtgat	ctgcccgcct	73920
cggcctccca	aagtgtctgg	attacaggcg	tgagccactg	cgcccggtca	gtatcagggtc	73980
ttttaaaaca	tgtttttcct	ctgggttggt	gctactaaat	gaatagctga	cttttcatgg	74040
gctcttaaat	tttttacatt	atgttcttgg	attttattat	tgagccaaga	aggcatctgt	74100
ttcaacagga	aattgcaagg	ggaaaaaaat	tttttttaaa	aaagtaatct	cttagtctta	74160
cttgccaata	aagaaaactt	tcagctgtgc	acgggtggctc	acacctgtaa	taccaacact	74220
ttgggaggcc	gagggtggca	gatcacctga	ggtcgggagt	tcgagaccag	cctgaccac	74280
atggagaaac	ccccatctct	actaaaaata	caaaattagt	ccgggcgtgg	gggtataccg	74340

```
cgtgtaaaact tattttccat ctatgatgaa aagttaagaa tattctgccc tacagcatac 74400
tgtgacttat gaaataagga acaattgggg gttaggttat tgggcaaatt ggtctctcat 74460
taaaatatgg tttctttaac tggatataga aataagttgg ggactgcttt ttttggatct 74520
ctaataccaaa aatccaaaac actccaaaat tttgaaactt tattgagggg ccaacatgat 74580
tgccacaagt ggaaaattcc acatctggta taatggacaa aaacttttcc atgcacaaaa 74640
ttattttaaa atattgggggt aaaatatttg ggctatctgg ataagatgta tatgaaacac 74700
aaatggaatt ttgactttgg gtcccatccc caagatattc ttcattatgt atattgaaaa 74760
tattcccaa atctggaaat atatcctatt ttgaaatac attatgtgtt tccaaaacct 74820
tgaaacattt tttgggccca aacttttgga taaggaatac tcaactttta atttggtggg 74880
aagctttggt ttttaaacat ttttgggctg gaaaaaagcc ccctggcccc aaatttatcc 74940
ctttgaatga attggtttat cc 74962
```